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Abstract
Numerous human medical problems or diseases have been aided by the devel-
opment of effective treatments such as drugs and medical devices. Clinical trials
are an integral part of the development process, determining the safety and effi-
cacy of the new proposed treatment, as required by the Food and Drug Admin-
istration of the United States. A reliable, efficient and cost-effective way of con-
ducting the clinical trials is important for advancing useful treatments/devices to
market and screening out the useless ones, thus benefiting public health in a timely
manner. I developed several statistical methods and applications toward this pur-
pose, ranging from early, small scale Phase I studies to late, large scale Phase III
studies in clinical trials.
In Phase I studies, I establish a general framework for a multi-stage adaptive
design where I jointly model a continuous efficacy outcome and continuous toxi-
city endpoints from multiple treatment cycles, unlike the traditional method that
only considers a binary toxicity endpoint (joint work with Mayo Clinic). Extensive
simulations confirmed that the design had a high probability of making the correct
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dose selection and good overdose control. To our best knowledge, this proposed
Phase I dual-endpoint dose-finding design is the first to incorporate multiple cy-
cles of toxicities and a continuous efficacy outcome.
I also propose and evaluate a two-stage, adaptive clinical trial design for Phase
II studies. Its goal is to determine whether future phase 3 (confirmatory) trials
should be conducted, and if so, which population should be enrolled. I compute
an approximate Bayes optimal design considering a combination of future health
benefits and costs.
Turning to Phase III studies, I analyze the performance of adaptive enrichment
designs with delayed outcome, leveraging information in baseline variables and
short-term outcomes to improve precision by using semiparametric, locally effi-
cient estimators at each interim analysis. I also propose a prediction method for
analyzing heterogeneity in treatment response, as a secondary analysis, through
the identification of treatment covariate interactions honoring different hierarchi-
cal conditions.
Advisors: Michael Rosenblum, Ravi Varadhan, Vadim Zipunnikov
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Before introducing a new experimental drug / treatment / device into the
market, clinical trials are required by the regulatory agencies, like the Food and
Drug Administration of the United States, the European Medicines Agency, etc.,
to demonstrate the efficacy and the safety of the product on the patients. Clini-
cal trials typically consist of four phases, from Phase I studies to Phase IV studies,
with each phase being a separate trial. At the completion of a phase, a decision
will be made by the regulatory agency regarding whether or not to allow the prod-
uct to advance to the next phase. Phase I studies usually recruit small number
of patients (20 - 100), which mainly focus on the assessment of the safety of the
product. Phase II studies involve a larger number of patients, up to hundreds,
and start exploring the efficacy of the product. Phase III studies give a thorough
testing of the product efficacy in up to thousands of patients, strictly controlling
1
CHAPTER 1. INTRODUCTION
the rate of false positive findings. Most of the Phase II and III studies are blinded,
randomized trials, where patients are assigned randomly to the experimental arm
and to the placebo/control arm, and neither patients nor researchers know about
these assignments. Once the product passes Phase III trials and is approved by the
regulatory agency, it can make a debut in the market for consumer use. Phase IV
studies are Post Marketing Surveillance Trials, where the real-world effectiveness
and/or the safety of the drug is evaluated.
Novel statistical methods do play an imperative role in the designs and analyt-
ics of clinical trials, making trials more efficient and cost-effective. For example,
leveraging the baseline information into the estimation of treatment effect can lead
to desirable gain in precision, thus substantial reduction in sample size of patients
required to complete a trial, a huge saving. Also, individuals may vary in their
responses to treatment, and the treatment may only benefit a subset of the overall
study population. Therefore, statistical methods are needed to take into account
the patient heterogeneity and to facilitate personalized medicine. Ignoring patient
heterogeneity easily causes dilution of the treatment effect, and creates unethical
situations where patients who do not benefit from the treatment are treated. Ad-
ditionally, the interpretation of overall effect for treatment may not be meaningful,
and in fact can be misleading. In this dissertation, I dedicate Chapters 2 to 5 to
the study of the statistical methods and applications developed for Phase I to III
studies, which are key to determining whether a product can be marketed or not.
2
CHAPTER 1. INTRODUCTION
Phase I designs traditionally use the dose-limiting toxicity (DLT), a binary end-
point from the first treatment cycle, to identify the maximum-tolerated dose (MTD)
assuming a monotonically increasing relationship between dose and efficacy. In
Chapter 2, I establish a general framework for a multi-stage adaptive design where
I jointly model a continuous efficacy outcome and continuous/quasi-continuous
toxicity endpoints from multiple treatment cycles. The normalized Total Toxicity
Profile (nTTP) is used as an illustration for quasi-continuous toxicity endpoints,
and I replace DLT with nTTP to take into account multiple grades and types of
toxicities. In addition, the proposed design accommodates non-monotone dose-
efficacy relationships, and longitudinal toxicity data in effort to capture the ad-
verse events from multiple cycles. Extensive simulations showed that the design
had a high probability of making the correct dose selection and good overdose
control across various dose-efficacy and dose-toxicity scenarios. Furthermore, the
proposed design allows for early termination when all doses are too toxic. To our
best knowledge, the proposed Phase I dual-endpoint dose-finding design is the
first such study to incorporate multiple cycles of toxicities and a continuous effi-
cacy outcome.
In adaptive enrichment designs based on accrued data, early stopping of a sub-
population with sufficient evidence of treatment efficacy, futility, utility or harm
is allowed according to preplanned rules for modifying enrollment criteria, while
the remaining subpopulations continue to be enrolled. In Chapter 3, I propose and
3
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evaluate a two-stage, Phase II adaptive enrichment clinical trial design. Its goal is
to determine whether future phase III (confirmatory) trials should be conducted,
and if so, which population should be enrolled. The population selected for phase
III enrollment is defined in terms of a disease severity score measured at baseline.
I optimize the phase II trial design and analysis in a decision theory framework.
The resulting design is compared to simpler designs in simulation studies. I also
apply the designs to resampled data from a completed, phase II trial evaluating a
new surgical intervention for stroke.
Most existing methods for constructing trial designs are limited to situations
where patient outcomes are observed soon after enrollment. This is a major barrier
to the use of such designs in practice, since for many diseases the outcome of most
clinical importance does not occur shortly after enrollment. In Chapter 4 for Phase
III studies, I provide a general framework for the adaptive enrichment designs
with delayed outcome, where I use semiparametric, locally efficient estimators at
each interim analysis to leverage information in baseline variables and short-term
outcomes to improve precision. I then evaluate power, expected sample size, bias,
variance, and mean squared error for our design and compare with a non-adaptive
design and unadjusted estimator. I demonstrate the advantage of our proposed
methods, through simulations of a real trial. I strongly control the familywise Type
I error rate, asymptotically.
Chapter 5 presents a useful and general method for exploring treatment effect
4
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heterogeneity in Phase III studies, through identification of treatment-covariate
interactions honoring different hierarchy conditions. I construct a single-step l
1
norm penalty procedure that maintains the hierarchical structure of interactions
in a sense that the treatment-covariate interaction term is included in the model
only when either the covariate or the covariate and the treatment both have non-
zero main effects. I explore several parameterization schemes with different con-
straints added to Lasso that enforce the hierarchical interaction restriction. I solve
the resulting constrained optimization problem using a spectral projected gradi-
ent method. I compare our methods to the unstructured Lasso using simulation
studies covering a variety of scenarios for treatment-covariate interactions. The
simulations show that our methods yield more parsimonious models and outper-
form unstructured Lasso in terms of prediction performance, and in terms of the
ability to correctly identify non-zero treatment covariate interactions. The superior
performance of our methods are also corroborated by an application to a large ran-
domized clinical trial data investigating a drug for treating congestive heart failure
(N=2,569). Our methods can be applied to continuous, binary and time to event
outcome, providing a well-suited approach with sufficient flexibility in terms of
parameterization for doing secondary analysis in Phase III trials to analyze hetero-
geneity in treatment effect.
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tic Baseline Variables and Short Term Outcomes in Adaptive Enrichment Trial Designs
with Delayed Outcomes.” Chapter 5 is adapted from the working paper “Yu Du,




Phase I Studies: An Adaptive,
Multi-Stage Dose-finding Design
SUMMARY.1 Phase I designs traditionally use the dose-limiting toxicity (DLT), a
binary endpoint from the first treatment cycle, to identify the maximum-tolerated
dose (MTD) assuming a monotonically increasing relationship between dose and
efficacy. In this chapter, we establish a general framework for a multi-stage adap-
tive design where we jointly model a continuous efficacy outcome and continuous
/ quasi-continuous toxicity endpoints from multiple treatment cycles. The nor-
malized Total Toxicity Profile (nTTP) is used as an illustration for quasi-continuous
toxicity endpoints, and we replace DLT with nTTP to take into account multiple
grades and types of toxicities. In addition, the proposed design accommodates
1This Chapter 2 is adapted from the working paper “Yu Du, Jun Yin, Daniel J. Sargent, Sumithra
J. Mandrekar. An Adaptive Multi-Stage Phase I Dose-finding Design Incorporating Continuous Efficacy
and Toxicity Data from Multiple Treatment Cycles.”
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non-monotone dose-efficacy relationships, and longitudinal toxicity data in effort
to capture the adverse events from multiple cycles. Stage 1 of our design uses tox-
icity data to perform dose-escalation and identify a set of initially allowable (safe)
doses; stage 2 of our design incorporates an efficacy outcome to update the set of
allowable doses for each new cohort and randomizes the new cohort of patients
to the allowable doses with emphasis towards those with higher predicted effi-
cacy. Stage 3 uses all data from all treated patients at the end of the trial to make
final recommendations. Simulations showed that the design had a high probabil-
ity of making the correct dose selection and good overdose control across various
dose-efficacy and dose-toxicity scenarios. In addition, the proposed design allows
for early termination when all doses are too toxic. To our best knowledge, the
proposed dual-endpoint dose-finding design is the first such study to incorporate
multiple cycles of toxicities and a continuous efficacy outcome.
2.1 Background
Phase I clinical trials are designed to identify the recommended Phase II dose
(RP2D) for future trials. For cytotoxic agents, the recommended dose is gener-
ally the maximum-tolerated dose (MTD). Traditionally, grade 3 or 4 toxicity events
in the first treatment cycle are defined as dose-limiting toxicity (DLT) events and
used to determine MTD. Late cycle toxicity events are recorded but not used in the
8
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dose assessment. The current development of molecularly targeted agents (MTAs)
poses new challenges for the study design of phase I cancer clinical trials. Unlike
the cytotoxic agents that are often administrated for a limited number of treatment
cycles, MTAs are administered until disease progression and often have a very dif-
ferent toxicity profile, characterized by chronic, prolonged events or cumulative
toxicity as opposed to the early onset of severe adverse events. Therefore, it be-
comes important to consider toxicity events after the first treatment cycle, as well
as repeated and chronic occurrence of lower grade events besides just grade 3 and
4 events. The idea of using longitudinal toxicity information have been explored
by Legedza and Ibrahim (2000), Braun et al. (2007) and Yin et al. (2017).
MTAs also have different toxicity-efficacy relationships compared to cytotoxic
agents. Numerous studies have identified that lower doses of MTAs may offer
similar efficacy as higher doses. As a result, searching for the MTD may not be
the optimal treatment strategy for MTAs. Incorporation of early efficacy signals
if available has become important for these novel agents. Only limited methods
exist for dose-finding designs that account for toxicities and continuous efficacy
as dual-endpoints in the selection of recommended Phase II dose. Thall and Cook
(2004) used a set of efficacy-toxicity trade-off contours to accommodate either tri-
nary or bivariate binary outcomes that include efficacy. Bekele and Shen (2005)
incorporated the correlation between the binary toxicity and continuous activity
outcome via a latent Gaussian variable. Houede et al. (2010) used a generalization
9
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of the Aranda-Ordaz model and a Gaussian copula to model the marginal outcome
and joint distribution of dual toxicity and efficacy endpoints. A common feature
of these designs is that they only considered binary toxicity endpoints in Phase
I dose-finding designs, ignoring the fact that toxicity data are high dimensional
in nature, with various types, grades, attribution over multiple treatment cycles.
Bekele and Thall (2004) proposed the total toxicity burden (TTB) as the arithmetic
sum of different grades and types of toxicities, weighted by the severity weights
elicited from clinicians. Lee et al. (2012) proposed the toxicity burden score (TBS)
to summarize toxicity using a weighted sum, where the severity weights were
estimated via regression using historical data. Ezzalfani et al. (2013) proposed an-
other flexible toxicity endpoint, called the total toxicity profile (TTP), upon which
our proposed method is based as an illustration. However, the proposed design
can easily be generalized to any continuous/quasi-continuous toxicity endpoints,
including TTB, TBS, and etc.
The total toxicity profile (TTP) was developed to overcome the oversimplifica-
tion of toxicity data in phase I trials (Ezzalfani et al., 2013). The TTP score captures
multiple types and grades of toxicities occurring during the first treatment cycle.
Following the notation in Ezzalfani et al. (2013), let wlh denote the elicited weight
of toxicity type l (l 2 {1, . . . , L}) occurring at grade h (h 2 {0, . . . , 4}). Hence,
the weight vector for toxicity l is wl = (wl0, . . . , wl4)0 and the weight matrix is de-
noted as W = (w1, . . . ,wL)0. For patient i, denote the maximum observed grade
10
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w2lh1(Gil = h), (2.1)
where 1(Gil = h) is an indicator function which takes value 1 if the maximum
observed grade is h for toxicity type l, and 0 otherwise. The TTP is further normal-
ized to nTTP, in order to constrain the continuous toxicity endpoint to be within
0 and 1, nTTPi = TTPiv , where v is a normalization constant (for details, please
refer to Ezzalfani et al. (2013)). This is an improvement from using the traditional
DLT based endpoint in that it takes into account clinical multidimensionality of
multiple types/grades of toxicities for a given toxicity profile, as well as the mod-
erate toxicity events commonly ignored by using DLT endpoint. However, patients
participating in Phase I clinical trials usually receive more than one cycle of exper-
imental regimen in the absence of DLT or disease progression. To account for this
limitation, an extension to this design to incorporate nTTP scores from multiple
treatment cycles was proposed by Yin et al. (2017).
We propose a three-stage dose-finding design based on both longitudinal toxi-
city data of nTTP scores and an efficacy outcome. This is an extension of our pre-
vious work (Yin et al., 2017), which only uses nTTP scores from multiple treatment
cycles. Furthermore, the proposed design is easily extended to other continuous
/ quasi-continuous toxicity endpoints than nTTP. To our best knowledge, it is the
11
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first design to simultaneously account for both the multiple types/grades toxicity
events over multiple treatment cycles and a continuous efficacy outcome. In Sec-
tion 2.2, a joint model is introduced that takes into account the correlation between
the toxicity data over multiple treatment cycles and a continuous efficacy outcome.
Section 2.3 describes a three-stage dose-finding algorithm where stage 1 of the de-
sign uses toxicity data to perform dose-escalation and to identify a set of initially
allowable (safe) doses; stage 2 of the design incorporates an efficacy outcome to
update the set of allowable doses and randomizes the new cohort of patients to
the allowable doses with emphasis towards those with higher predicted efficacy;
stage 3 uses all data from all treated patients at the end of the trial to make final
recommendations. The recommended Phase II dose is, as we suggest, the lowest
allowable dose with acceptable efficacy, although the final decision of dose selec-
tion is left to the discretion of the physicians upon completion of the trial, based on
the estimated profile of efficacy and toxicities the method outputs. In Section 2.4,
extensive simulations are conducted to evaluate the operating characteristics of the
proposed design under various clinical relevant scenarios. Section 2.5 concludes
the chapter with a discussion of the proposed design, as well as some insights into
future work.
12
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2.2 Joint Model
We jointly model the toxicity profile, nTTP scores across multiple cycles, and
a continuous efficacy outcome for each patient. The joint model, introduced by
Wang et al. (2000), is comprised of two submodels: for longitudinal nTTP scores, a
linear mixed effect model; while for continuous efficacy outcome, a linear model.
Here, we transform any continuous efficacy outcome so that it ranges from 0 to 1
by using empirical distribution function. Suppose we have cumulative data for n
patients. Let Yij be the nTTP score for patient i (i = 1, 2, . . . , n) at cycle j, where
tij = tj = j represents the jth (j = 1, 2, . . . , J) cycle of treatment, the same across
all patients. We use x (x = 1, 2, . . . , K) to denote the dose of the agent and xi is the
dose allocated to patient i. We assume that the same dose is given to a patient in
each cycle of the treatment. Let Ei be the continuous efficacy outcome for the ith
patient.
The linear mixed effect submodel with a random intercept for the longitudinal
nTTP scores is such that
Yij =  0 +  1xi +  2tj + ui + ✏ij, (2.2)
where
✏ij ⇠ N(0,  2✏ ),
13
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ui ⇠ N(0,  2u),
and the linear submodel for the efficacy outcome is given below:
Ei = ↵0 + ↵1xi + ↵2x
2
i +  ui + ✏ei , (2.3)
where
✏ei ⇠ N(0,  2e).




, . . . , un, ✏11, ✏12, . . . , ✏nJ , ✏e1 , ✏e2 , . . . , ✏en are independent
where ui is the random intercept for the ith patient, shared with the two submodels,
✏ij is the measurement error for patient i nTTP score at cycle j and ✏ei is the mea-
surement error for efficacy outcome for patient i. Let ✓ represent the parameters to












,  ,  ✏,  u,  e)
0.
Let us use ⇡Y (x, ✓, tj) to denote the mean of nTTP score for a randomly selected
patient who undergoes the jth treatment cycle with allocated dose level x given
the parameters ✓, so that ⇡Y (x, ✓, tj) =  0 +  1x +  2tj . Therefore,  0,  1,  2 relate
to the mean structure of toxicity profile. In order to reflect the fact that the toxic-





> 0. Also, let ⇡E(x, ✓) represent the mean of efficacy
outcome for the patient to whom dose level x is allocated given the parameters
✓, so that ⇡E(x, ✓) = ↵0 + ↵1x + ↵2x2. Hence, ↵0,↵1,↵2 maneuver a quadratic
14
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mean structure of efficacy outcome. This quadratic mean structure, ⇡E(x, ✓), is
capable of describing most common patterns between efficacy and dose, includ-
ing a flat (the efficacy does not change with dose), increasing/decreasing (the ef-
ficacy increases/decreases as dose level goes up), plateau (the efficacy increases
and reaches a plateau as dose level increases) and a parabolic (the efficacy first
increases and then decreases as dose level varies from low to high) relationship.
We will explore these scenarios in Section 2.4.  ✏,  e are standard deviations of the
measurement errors for nTTP score and efficacy outcome, respectively while  u is
the standard deviation of random intercepts. Random intercepts ui serve as the
linkage between two submodels, and   indicates the strength of the association
such that the covariance between the nTTP score and efficacy outcome for a pa-
tient, given the treatment cycle, the parameters ✓ and the allocated dose level, is
  2u.
A patient will discontinue the treatment anytime they experience a DLT. Hence,
patients can have difference number of treatment cycles. However, efficacy out-
come is assumed to be always measured at a fixed time point during the treatment
(e.g., at the end of cycle 3), patients who drop out due to DLT before that time point
will have missing efficacy data.
In the early stages of our design, we do not have patients’ toxicity/efficacy
information for all J cycles of treatment. We, therefore, introduce a simplified
15
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version of submodel (2.2), as below:
Yij =  0 +  1xi +  2t
0
j + ui + ✏ij, (2.4)











0 if j = 1
1 if j = 2, . . . , J,
where all other components are the same. This, in addition, emphasizes our con-
cern about the toxicity at the first cycle of treatment and the toxicities for the other
cycles beyond as an aggregate measure.
2.2.1 Estimation
For parameter estimation of the joint model, we implement Bayesian methods,
Markov Chain Monte Carlo (MCMC) to estimate the posterior distribution of the
parameters, using JAGS (Plummer, 2003). Non-informative prior distributions are
specified since elicitation in this context is difficult, therefore, the estimation of











specify independent normal priors with mean 0 and precision 0.001 (the inverse
of the variance). For all other parameters,  ✏,  u,  e, we use uniform priors from 0
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to 1000. We discard the first 5, 000 samples as burn-in and sample the subsequent
5, 000 iterations. The posterior mean of ⇡Y (x, ✓, tj) and ⇡E(x, ✓) are used to guide
the dose-escalation/de-escalation which will be specified in Section 2.3.
2.3 Dose-finding Algorithm
A three-stage Phase I dose-finding algorithm, whose goal is to find efficacious
doses that are also safe, is proposed. Suppose N is the maximum sample size.
Stage 1 only utilizes longitudinal data of nTTP scores to navigate the dose-escalation
for each subsequent patient cohort of size m as well as identifies initially allowable
(safe) doses in terms of toxicity when cumulative sample size reaches N
2
. Stage
2 involves efficacy outcome, and by jointly modeling the toxicity and efficacy as
specified in Section 2.2, it keeps updating the set of allowable doses and random-
izes patients to the allowable doses with emphasis towards those with higher pre-
dicted efficacy for each new cohort. Stage 3 concludes the algorithm when all the
data from all treated patients becomes available (i.e., at the end of the trial), where
we fit the joint model to the full data and find the efficacious doses that are also
allowable (safe). Early termination of the trial is allowed, when there are no al-
lowable (safe) doses in terms of toxicity but skipping of dose levels not previously
tried is not allowed at any time. Below we specify how each stage works in more
details.
17
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2.3.1 Stage 1
Stage 1 aims to perform the dose-escalation and define initially allowable (safe)
doses in terms of toxicity, based on longitudinal data of nTTP scores only until the
sample size of patients enrolled reaches N
2
. We enroll patients by cohorts of size m.
Dose 1 is assumed to be the starting dose and from the first cohort of patients,
we use the 3+3 design for dose escalation until we escalate to dose 2. Once dose 2
is allocated to a new cohort and when its first cycle nTTP scores become available,
we switch to the linear mixed effect submodel (2.4) in Section 2.2, fitting the cumu-
lative longitudinal toxicity data for dose escalation. We employ the submodel (2.4)
when we have toxicity data for more then one dose level, in order to give more
accurate estimates than applying the model with only one dose level.
Suppose O denotes the current cumulative data and based on O, the dose-
escalation is guided by Bayesian risk evaluation. We define a loss function L for
dose level x and cycle 1 of the treatment such that












is the target toxicity in nTTP score in the first cycle of treatment, and
⇡Y (x, ✓, t
0
1
) is the mean nTTP score given parameter ✓, at cycle 1 of the treatment
for dose level x. This loss function L was used by Yin et al. (2017). The dose




) |O], namely minimizing the
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Bayesian risk, will be allocated to the next cohort of patients. Once the first cycle
toxicity data becomes available for the third enrolled cohort of patients, the dose
x will be declared an allowable (safe) dose based on safety if the following two
conditions are met:












are the upper bounds of the mean nTTP score for the first and sub-




are the corresponding probability cutoffs
respectively. These parameters need to be pre-defined, and should be chosen based
on both physicians’ discretion and design’s operating characteristics, which will
be discussed in Section 2.5. Condition (2.5) concerns the toxicity at the first cy-
cle of treatment, while condition (2.6) regards the toxicities for the other cycles,
with ⇡Y (x, ✓, t0j = 1) serving as an aggregate mean nTTP score for treatment cy-
cles beyond cycle 1 at dose level x, given the parameter ✓. These two probability
conditions (2.5) and (2.6) act here as a stopping rule such that the trial shall be
terminated early if there is no allowable (safe) dose. Otherwise, stage 1 continues
until the cumulative sample size of patients enrolled reaches N
2
and at the end of
stage 1, we identify a set of initially allowable doses, A, ready to enter stage 2.
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2.3.2 Stage 2
Once the efficacy data becomes available on patients from stage 1, we fit the
joint model (2.3) and (2.4), and update the set of allowable (safe) doses, A, using
the two probability conditions (2.5), (2.6). The next cohort of patients are random-
ized to the allowable doses with emphasis towards those dose levels with higher
predicted efficacy. The probability that dose level a 2 A is assigned is as follows:
exp {E [⇡E(a, ✓)|O]}
P
x2A exp{E [⇡E(x, ✓)|O]}
,
where E [⇡E(a, ✓)|O] is the posterior mean of efficacy outcome, the predicted effi-
cacy, for dose level a 2 A. Thus, the higher the predicted efficacy of a dose, the
more likely it will be assigned to the next cohort of patients. We continue this up-
date for the set of allowable doses, A, and efficacy-based randomization for each
new cohort until the maximum sample size N is reached. Again, early termination
is allowed if there is no allowable (safe) dose at any time in this stage, i.e., A = ;.
2.3.3 Stage 3
The purpose of Stage 3 is to define the efficacious doses that are also safe at the
end of the trial and make a final recommendation of the dose level for future, Phase
II trial. When all data from all treated patients become available, we implement
the joint modeling (2.2) and (2.3) as described in Section 2.2, a fully parameterized
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version.Again, we update the set of allowable doses A using the two probability
conditions (2.5) and (2.6), with t0j replaced by tj , and for the second condition (2.6)
regarding later cycles of treatment beyond cycle 1, we use instead
P{⇡Y (x, ✓, tj > 1) < c2|O} > p2, (2.7)
where ⇡Y (x, ✓, tj > 1) = 1J 1
P
j=2,...,J ⇡Y (x, ✓, tj = j). We aggregate the toxic-
ity information for cycles 2 through J by taking the average. Subsequently, for
each allowable dose a 2 A, we compute the posterior mean of efficacy response,
E [⇡E(a, ✓)|O]. Let l 2 A be the allowable dose that gives the largest posterior
mean of efficacy, such that l = argmaxa2A E [⇡E(a, ✓)|O]. We define a proximity
threshold   such that any dose a 2 A that satisfies the condition |E [⇡E(a, ✓)|O]  
E [⇡E(l, ✓)|O] |    will be declared an efficacious dose since it is in the efficacy
proximity of the dose l, that gives the largest posterior mean of efficacy. We thus
define the set of efficacious doses that are also safe, H, such that H = {h 2 A :
|E [⇡E(h, ✓)|O]  E [⇡E(l, ✓)|O] |   }.
We report the set H at the end of the trial along with the toxicity profile from dif-
ferent cycles of the treatment, E [⇡Y (h, ✓, tj)|O], and efficacy profile, E [⇡E(h, ✓)|O],
for any h 2 H. Any dose h 2 H can be picked based on physician’s judgment and
preference but in our work, we suggest the lowest (safest) dose in set H as the final
recommendation for future, Phase II trial. We explore several scenarios with differ-
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ent toxicity and efficacy structures, and conduct simulation studies in Section 2.4
to evaluate the performance of operating characteristics for the design.
2.4 Simulation Studies
2.4.1 Generation of the Toxicity Data
Let us assume that there are three independent types of toxicities related to
the treatment: renal, neurological and hematological toxicities. The clinical weight
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DLT, in this setting, is defined as the occurrence of a grade 3 or 4 renal / neuro-
logical toxicity or a grade 4 hematological toxicity. Based on this weight matrix, we
compute the TTP score for patients. The maximum TTP score that can be acquired
from the matrix is 2.34, corresponding to the scenario where a patient experiences
grade 4 toxicities for all three types. We thus normalize TTP by dividing the value
by a normalization constant, 2.5, to obtain nTTP for each patient. The target toxic-
ity nTTP elicited from the physician is set at 0.28. For details on the normalization
constant and the target nTTP at cycle 1 of the treatment, please refer to Ezzalfani
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et al. (2013). In the simulation, however, we need to simulate the toxicity profile
for each patient in order to compute an nTTP score. Please see Appendix for more
details on how toxicity data is generated non-parametrically.
2.4.2 Generation of the Efficacy Outcome
The efficacy outcome, in our setting, is assumed to be a continuous variable
from 0 to 1. We explore 5 common dose-efficacy patterns in the simulation study,
as described in Section 2.2. We generate efficacy outcome for each patient from
the beta distribution. Figure 2.1 displays the dose-efficacy patterns and the distri-
bution of efficacy outcome for each dose in each pattern. It is clearly seen from
dose-efficacy pattern 1 to 5 that efficacy data distributions have large variation
and/or skewness. For more details, please refer to Appendix.
2.4.3 Simulation Settings
We consider 14 scenarios in total, that takes into account 6 toxicity structures
and 5 dose-efficacy patterns. For each scenario, we simulated 1,000 trials that ex-
plore 6 dose levels with maximum 6 treatment cycles, where dose level 1 is the
starting dose. We enroll patients by cohorts of 3 and the maximum sample size for
each trial is set at 36. We assume that efficacy outcome is measured at the end of
cycle 3 of the treatment so if the patient drops out of the trial before cycle 3, his/her
23
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(a) Dose-efficacy Patterns (b) Dose-efficacy Pattern 1
(c) Dose-efficacy Pattern 2 (d) Dose-efficacy Pattern 3
(e) Dose-efficacy Pattern 4 (f) Dose-efficacy Pattern 5
Figure 2.1: Dose-efficacy patterns and the distribution of efficacy outcome for each
dose in each pattern.
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efficacy data will be missing. Missing information is also present for toxicity data












, the upper bounds of toxicity for cycle 1 and the subsequent







= 0.2, the two probability cutoffs for conditions (2.5) and (2.6)
are set at 0.2.
–   = 0.1, so that all the safe doses whose posterior means of efficacy
are within 0.1 away from the largest one among the safe doses will be
declared efficacious.
• Performance metrics
– Precom, the percentage of dose recommendation, where we recommend
the lowest dose that is efficacious.
– Palloc, the percentage of dose allocation, computed by dividing the num-
ber of patients allocated to the dose by the total number of patients en-
rolled.
– Peffy, the percentage of dose being efficacious and safe.
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Note that Peffy is often different from Precom since Peffy indicates the probability
that any particular dose is selected as an efficacious dose that is also safe while
Precom encodes the probability that a dose is recommended as the lowest dose that
is also efficacious. There may be multiple safe and efficacious doses for each trial,
among which we suggest the lowest dose in the study, though in practice, the final
recommendation is at physician’s discretion. The simulation study is performed
using R (R Core Team, 2016).
2.4.4 Results
The simulation results for scenario 1 to 5 are summarized in Table 2.1. Scenario
1 to 5 correspond to the dose-efficacy pattern 1 to 5 in Figure 2.1, i.e., the increasing,
flat, plateau, decreasing and parabolic relationship for efficacy with dose, respec-
tively. In addition, they have a toxicity structure where the target toxicity dose
(MTD) at cycle 1 of the treatment is dose 5 and the cycle effect is flat, namely, the
mean nTTP (mnTTP) for each dose level is the same across cycles.
In scenario 1, the most efficacious dose among the safe doses is dose 5 whose
mean of efficacy is 0.7. seventy-seven percent of the trials declare this dose as an
efficacious dose and 72% of the recommendations correspond to this dose. Dose
4 is the second best choice in this scenario if physician prefers a lower toxicity,
which shares 11.1% chance of the recommendations. In total, 83.1% of the recom-
mendations go to these top 2 choices. Scenario 2 has a flat relationship in terms
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Table 2.1: Simulation results for scenario 1 to 5: Palloc, the percentage of dose allo-
cation, Precom, the percentage of dose recommendation, where we recommend the
lowest (safest) dose that is also efficacious, and Peffy, the percentage of dose being
efficacious and safe. mnTTP represents the mean nTTP score while pDLT refers to
the probability of DLT event. The target toxicity dose at cycle 1 of the treatment is
dose 5, with flat cycle effect.
Dose Levels
1 2 3 4 5 6 None
mnTTP(cycle 1) 0.046 0.054 0.108 0.183 0.280 0.359
mnTTP(cycle 2 through 6) 0.046 0.054 0.108 0.183 0.280 0.359
pDLT 0.008 0.011 0.064 0.195 0.330 0.446
Scenario 1
Mean Efficacy 0.1 0.2 0.3 0.4 0.7 0.9
Palloc 16.4 17.3 18.2 21.1 20.9 6.2
Precom 1.3 0.1 1.8 11.1 72.0 13.7 0.0
Peffy 1.3 0.2 2.1 13.7 77.7 15.5 0.0
Scenario 2
Mean Efficacy 0.5 0.5 0.5 0.5 0.5 0.5
Palloc 18.2 18.3 19.0 20.7 18.2 5.5
Precom 68.5 17.8 6.2 2.1 3.3 2.1 0.0
Peffy 68.5 71.1 69.8 69.6 62.4 11.3 0.0
Scenario 3
Mean Efficacy 0.2 0.5 0.8 0.8 0.8 0.8
Palloc 15.0 17.6 20.0 22.9 19.2 5.4
Precom 0.0 0.2 41.1 53.6 4.5 0.6 0.0
Peffy 0.0 0.2 41.3 94.5 79.5 8.3 0.0
Scenario 4
Mean Efficacy 0.8 0.6 0.4 0.3 0.2 0.1
Palloc 21.7 19.7 18.0 19.0 16.7 4.9
Precom 99.7 0.2 0.0 0.0 0.0 0.1 0.0
Peffy 99.7 12.7 2.8 0.1 0.0 0.4 0.0
Scenario 5
Mean Efficacy 0.3 0.6 0.8 0.6 0.3 0.1
Palloc 16.5 19.6 21.0 21.7 16.7 4.7
Precom 3.2 40.8 55.9 0.0 0.0 0.0 0.1
Peffy 3.2 43.9 99.7 58.5 0.8 0.0 0.1
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of dose-efficacy pattern since all doses have a mean of efficacy equal to 0.5. About
69% of the recommendations correspond to the lowest dose, dose 1, which is the
optimal one. Around 18% of simulated trials recommend dose 2, which is equally
desirable as dose 1 since they have very close toxicity across all cycles, 0.046 (dose
1) vs 0.054 (dose 2). Nearly 87% of the trials, in total, make a recommendation for
dose 1 or dose 2. Scenario 3 demonstrates a plateau relationship between efficacy
and dose, where the efficacious doses, by its definition, are dose 3 to 5. When doses
have comparable efficacy, the lower doses will be preferred since they give lower
toxicities. Almost 95% of the recommendations correspond to dose 3 or dose 4,
which are lower doses than dose 5 yet have the same efficacy. Almost 100% of the
trials recommend dose 1, the most efficacious dose, in scenario 4, where the mean
of efficacy decreases as dose level varies from low to high. Scenario 5 shows a
parabolic relationship for dose-efficacy pattern and 99.7% of the trials declare that
dose 3, whose mean of efficacy is at the peak, is an efficacious dose. Nearly 97% of
the recommendations come to the top 2 choices, dose 3 and dose 2.
Table 2.2 displays the simulation results for scenario 6 to 10, where the only
change from scenario 1 to 5 is that target toxicity dose is dose 3 instead of dose
5, so that dose 4 to 6 are not considered safe doses. In scenario 6, dose 2 and 3,
by definition, are efficacious doses since their mean of efficacy are within   = 0.1
distance. Around 70% of the recommendations correspond to the efficacious doses.
Again, in a flat relationship between efficacy and dose, in scenario 7, 95.4% of the
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trials recommend top 2 choices, dose 1 or dose 2, which are lower doses than dose
3. Scenario 8 behaves similarly as scenario 10, since when we focus on the safe
doses, dose 1 to 3, they have a similar increasing dose-efficacy pattern in both of
these two scenarios. Around 96% of the recommendations go for the two best
doses, dose 3 or dose 2 in both scenario 8 and 10. Scenario 9 resembles scenario
4, where 99.2% of the trials recommend the best dose, dose 1, that has the highest
mean of efficacy.
In terms of the metric Palloc, all scenarios 1 to 10 allocate less than 6.2% of the
patients to the doses more toxic than the target toxicity dose, which demonstrates
good overdose control of our design.
The simulation results for the last four scenarios, scenario 11 to 14, are demon-
strated in Table 2.3, where we fix a dose-efficacy pattern, the parabolic relationship.
Scenario 11 demonstrates a case where all doses are toxic with mnTTP larger than
the target toxicity, 0.28. None of the doses are recommended in this scenario, with
88% of the patients being allocated to the starting dose, dose 1. Since our design
allows early termination if all doses are too toxic, the average number of patients
enrolled is 10. Therefore, in scenario 11, most of the trials terminate early after
enrolling 3 cohorts of patients. Scenario 12 corresponds to the case where only
dose 1 is safe and our design recommends dose 1 for 94.6% of the simulated trials.
Scenario 13 and 14 show the increasing cycle effect and the decreasing cycle effect
respectively, where the mnTTP for each dose increases/decreases as patients go
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Table 2.2: Simulation results for scenario 6 to 10: Palloc, the percentage of dose
allocation, Precom, the percentage of dose recommendation, where we recommend
the lowest (safest) dose that is also efficacious, and Peffy, the percentage of dose
being efficacious and safe. mnTTP represents the mean nTTP score while pDLT
refers to the probability of DLT event. The target toxicity dose at cycle 1 of the
treatment is dose 3, with flat cycle effect.
Dose Levels
1 2 3 4 5 6 None
mnTTP(cycle 1) 0.108 0.183 0.280 0.359 0.409 0.433
mnTTP(cycle 2 through 6) 0.108 0.183 0.280 0.359 0.409 0.433
pDLT 0.064 0.195 0.330 0.446 0.513 0.558
Scenario 6
Mean Efficacy 0.1 0.2 0.3 0.4 0.7 0.9
Palloc 28.4 40.5 26.6 4.3 0.2 0.0
Precom 27.9 40.7 28.9 2.3 0.0 0.1 0.1
Peffy 27.9 63.9 59.6 3.2 0.0 0.1 0.1
Scenario 7
Mean Efficacy 0.5 0.5 0.5 0.5 0.5 0.5
Palloc 30.3 40.6 25.1 3.8 0.2 0.0
Precom 75.1 19.3 3.9 1.3 0.1 0.3 0.0
Peffy 75.1 75.2 43.0 2.3 0.2 0.3 0.0
Scenario 8
Mean Efficacy 0.2 0.5 0.8 0.8 0.8 0.8
Palloc 25.9 41.6 28.1 4.2 0.2 0.0
Precom 2.4 36.8 59.5 1.1 0.1 0.0 0.1
Peffy 2.4 38.6 62.0 1.8 0.1 0.0 0.1
Scenario 9
Mean Efficacy 0.8 0.6 0.4 0.3 0.2 0.1
Palloc 33.3 40.0 23.0 3.5 0.2 0.0
Precom 99.2 0.7 0.0 0.0 0.0 0.0 0.1
Peffy 99.2 15.6 0.8 0.3 0.0 0.0 0.1
Scenario 10
Mean Efficacy 0.3 0.6 0.8 0.6 0.3 0.1
Palloc 25.8 43.1 26.7 4.0 0.3 0.1
Precom 2.6 49.4 46.7 0.9 0.3 0.0 0.1
Peffy 2.6 51.3 63.0 2.9 0.3 0.0 0.1
30
CHAPTER 2. PHASE I DOSE-FINDING DESIGN
through later cycles. Both of these scenarios have similar results under parabolic
dose-efficacy relationship: around 97% of the recommendations go for the best two
doses, dose 3 or dose 2, while more than 99% of the trials declare that dose 3, at the
efficacy peak, is an efficacious dose.
2.5 Remarks
Conventional dose-finding designs for Phase I clinical trials do not utilize effi-
cacy data and toxicity data from late treatment cycles in the dose-finding decision.
The rapid development of cancer immunotherapy and MTAs require the consid-
eration of both efficacy and toxicity data that are often ignored in traditional dose-
finding studies. As a result, new strategies must be developed for these Phase I
dose-finding studies.
This chapter presents a novel Phase I design that combines an early-stage ef-
ficacy endpoint and toxicity profiles from multiple treatment cycles during the
dose-finding process. It is an extension of our previous work (Yin et al., 2017) that
only uses toxicity data from multiple treatment cycles. The proposed design uses
a novel three-stage procedure in dose-finding. The advantage of the three-stage
procedure is: (1). use the first stage to ensure the patient safety while exploring
doses in the dose-finding procedure using continuous toxicity profiles (e.g., nTTP)
from multiple toxicity types and multiple treatment cycles; (2). recruit additional
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Table 2.3: Simulation results for scenario 11 to 14: Palloc, the percentage of dose allo-
cation, Precom, the percentage of dose recommendation, where we recommend the
lowest (safest) dose that is also efficacious, and Peffy, the percentage of dose being
efficacious and safe. mnTTP represents the mean nTTP score while pDLT refers to
the probability of DLT event. In Scenario 11, all doses are too toxic, with flat cycle
effect; In Scenario 12, only dose 1 is non-toxic, with flat cycle effect; Scenario 13/14
has an increasing/decreasing cycle effect, whose target toxicity dose at cycle 1 of
the treatment is dose 5. Scenario 11-14 share a parabolic efficacy structure.
Dose Levels
1 2 3 4 5 6 None
Efficacy Structures
Mean Efficacy 0.3 0.6 0.8 0.6 0.3 0.1
Scenario 11
mnTTP(cycle 1 through 6) 0.359 0.409 0.433 0.439 0.452 0.465
pDLT 0.446 0.513 0.558 0.559 0.588 0.613
Palloc 88.0 12.0 0.0 0.0 0.0 0.0
Precom 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Peffy 0.0 0.0 0.0 0.0 0.0 0.0 100.0
Scenario 12
mnTTP(cycle 1 through 6) 0.183 0.409 0.433 0.439 0.452 0.465
pDLT 0.195 0.513 0.558 0.559 0.588 0.613
Palloc 79.4 20.6 0.0 0.0 0.0 0.0
Precom 94.6 0.1 0.0 0.0 0.0 0.0 5.3
Peffy 94.6 0.1 0.0 0.0 0.0 0.0 5.3
Scenario 13
mnTTP(cycle 1) 0.046 0.054 0.108 0.183 0.280 0.359
mnTTP(cycle 2) 0.054 0.063 0.124 0.206 0.303 0.381
mnTTP(cycle 3) 0.063 0.073 0.142 0.230 0.326 0.404
mnTTP(cycle 4) 0.073 0.085 0.161 0.255 0.349 0.426
mnTTP(cycle 5) 0.085 0.097 0.181 0.280 0.373 0.448
mnTTP(cycle 6) 0.097 0.110 0.203 0.307 0.396 0.469
Palloc 17.0 20.4 22.7 22.3 13.8 3.8
Precom 1.6 39.7 58.5 0.1 0.0 0.0 0.1
Peffy 1.6 41.3 99.6 57.6 0.0 0.0 0.1
Scenario 14
mnTTP(cycle 1) 0.046 0.054 0.108 0.183 0.280 0.359
mnTTP(cycle 2) 0.039 0.046 0.093 0.162 0.257 0.336
mnTTP(cycle 3) 0.032 0.039 0.080 0.141 0.234 0.314
mnTTP(cycle 4) 0.027 0.033 0.068 0.123 0.213 0.291
mnTTP(cycle 5) 0.022 0.027 0.057 0.106 0.192 0.269
mnTTP(cycle 6) 0.018 0.023 0.047 0.090 0.171 0.247
Palloc 16.1 19.0 20.9 21.3 17.1 5.6
Precom 2.8 39.8 57.1 0.1 0.1 0.0 0.1
Peffy 2.8 42.5 99.4 62.3 0.8 0.0 0.1
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patients in the second stage to explore the early-stage efficacy endpoint among safe
doses; and (3). combine all data from all treated patients at the end of the study to
find the lowest possible (safest) dose that is also efficacious. The proposed design
can easily be generalized to any continuous / quasi-continuous toxicity endpoints,
including TTB, TBS, and etc. To our best knowledge, this is the first design to
combine an early-stage efficacy outcome and longitudinal toxicity endpoints over
multiple treatment cycles in the dose-finding studies.
Simulation studies have been conducted to demonstrate that the proposed de-
sign consistently finds the safe doses with desired efficacy profiles in a wide range
of scenarios. A Bayesian framework with MCMC is adopted because it naturally
fits with the adaptive nature of Phase I dose-finding trials.
The design also allows for patient dropouts due to DLT, Therefore, missing data
is present in both the longitudinal toxicities and the efficacy outcome. Around
20%   40% of efficacy data is missing in our simulation studies depending on
the scenarios. One exception is scenario 11 where all doses are too toxic and al-
most all efficacy data are missing since very few patients continue to cycle 3 of
the treatment. In addition, our efficacy data generating distribution has quite a
large amount of skewness / variation. Under these conditions, our joint modeling
performs quite well, as shown by simulation results in Section 2.4.4.




are picked based on the trial: if more toxicity is accept-
able, then a higher upper bound of toxicity than the target toxicity can be chosen,
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were set at 0.8.
The maximally tolerated toxicity, therefore, was 0.36. The simulation result for sce-
nario 1 showed a higher percentage of recommendations, 42%, for dose 6, whose
mnTTP is 0.36 and thus an allowable (safe) dose in this setting. It has the largest
mean efficacy of 0.9, among all doses. Another 52% of the recommendations cor-
respond to the second best dose, dose 5, with a mean efficacy of 0.7. Around 94%
of the trials, in total for scenario 1, recommend these two best doses. Across all
scenarios, the design is more likely to define the target toxicity dose, with mnTPP
0.28, as the allowable (safe) dose, thus recommending this dose more frequently
if it is the only efficacious dose. The selection of different weight matrices of the
nTTP-based toxicity profiles and the selection of an appropriate efficacy endpoint
can also have an impact on the dose-finding. Close collaborations with physicians
and medical researchers are therefore required for this design, as with any other
trials. Our method assumes that the same dose is given to a patient in each cycle of
the treatment, thus it is an area of future research to allow dose modification across
treatment cycles.
In summary, this chapter presents a new dose-finding method that accommo-
dates an early efficacy endpoint and multiple toxicity types/grades over mul-
tiple treatment cycles in the dose-finding and dose recommendation for future
studies. The simulations demonstrate that the proposed design performs well
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in terms of identifying the optimal doses in various scenarios. An R package
(phase1RMD) has been developed on CRAN to facilitate the use of the design
(https://cran.r-project.org/web/packages/phase1RMD/index.html).
2.6 Appendix
2.6.1 Generation of Toxicity Data
In order to generate toxicity data, nTTP, for each patient, we need to define a
matrix of probabilities, for each type of toxicity and each cycle of the treatment, of
observing grades 0 to 4 toxicity, for K dose levels. For example, a possible such






















0.823 0.152 0.022 0.002 0.001
0.791 0.172 0.032 0.004 0.001
0.758 0.180 0.043 0.010 0.009
0.685 0.190 0.068 0.044 0.013
0.662 0.200 0.078 0.046 0.014






















where grades from 0 to 4 define the columns of the matrix while the dose levels
from 1 to 6 define the rows. Such matrices for all three types of toxicities and all
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treatment cycles define a toxicity structure, where the mnTTP (mean nTTP) for
each dose level and cycle can be derived. When all such matrices are known, we
can compute, for each dose level and cycle, the probabilities (weights) of each of
the 53 combinations of the TPs (toxicity profile). For each combination, we can
also compute its nTTP score from the clinical weight matrix. The weighted sum
of nTTP for all combinations is thus the mnTTP associated with the dose level and
the cycle. The pDLT (probability of DLT) can be computed similarly.
These probability matrices are used to generate nTTP for each patient, given
the dose allocated and the cycle of the treatment. For example, suppose a pa-
tient is assigned dose 1 at cycle 1 of the treatment. For the renal toxicity, we
look at the first row of matrix Prenal, (0.823, 0.152, 0.022, 0.002, 0.001), which cor-
responds to the probabilities of observing renal toxicity grades 0 to 4 respectively
at dose 1. We thus sample a renal toxicity grade for this patient, according to
this probability distribution. We repeat this sampling for the other two types of
toxicities and in the end, we have a combination of the TP for the patient, for
example, grade 1 renal associated with grade 1 neurological and grade 3 hemato-
logical toxicities. The nTTP is thus given by the clinical weight matrix, such that
nTTP =
p
0.52 + 0.52 + 0.52/2.5 = 0.35. We also assess if the patient experiences
a DLT by its definition, and if a patient has a DLT, he/she will drop out for the
subsequent cycles, if any.
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2.6.2 Generation of Efficacy Outcome
Figure 2.1b to 2.1f show the distribution of efficacy outcome for dose-efficacy
pattern 1 to 5 across each dose level. Pattern 1 (Figure 2.1b) corresponds to an
increasing relationship between efficacy and dose, as reflected by the red solid
line in Figure 2.1a, “Dose-Efficacy Patterns”, where the mean of efficacy outcome
increases as dose level goes up. Pattern 4 (Figure 2.1e), the blue dashed line in
Figure 2.1a, represents a decreasing relationship, opposite to the pattern 1. Pattern
2 (Figure 2.1c) , a flat line, indicates a flat relationship where the mean of efficacy
outcome does not change with dose. Pattern 3 (Figure 2.1d) demonstrates a situ-
ation where the mean of efficacy outcome increases and then reaches a plateau as
dose level increases, corresponding to the green dashed line in Figure 2.1a and let
us call this plateau relationship. The last pattern, pattern 5 (Figure 2.1f), shows a
parabolic relationship, as seen from the purple dotted line in Figure 2.1a that the
mean of efficacy outcome first increases and then decreases as dose level varies
from low to high.
It is clearly seen from dose-efficacy pattern 1 to 5 that efficacy data distributions
have large variation and/or skewness.
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Phase II Studies: An Adaptive
Enrichment Design to Determine the
Population to Enroll in Phase III
Trials
SUMMARY.1
We propose and evaluate a two-stage, Phase II, adaptive clinical trial design. Its
goal is to determine whether future Phase III (confirmatory) trials should be con-
ducted, and if so, which population should be enrolled. The population selected
1This Chapter 3 is adapted from the working paper “Yu Du, Gary L. Rosner, Michael Rosen-
blum. Phase II Adaptive Enrichment Design to Determine the Population to Enroll in Phase III Trials, by
Selecting Thresholds for Baseline Disease Severity.”
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for Phase III enrollment is defined in terms of a disease severity score measured at
baseline. We optimize the Phase II trial design and analysis in a decision theory
framework. Our utility function represents a combination of the cost of conducting
future Phase III trials and, if the Phase III trials are successful, the improved health
of the future population minus the cost of treatment. Given such a utility function
and a discrete prior distribution on the conditional treatment effect, we compute
an approximate Bayes optimal adaptive design. The resulting design is compared
to simpler designs in simulation studies. We also apply the designs to resampled
data from a completed, Phase II trial evaluating a new surgical intervention for
stroke.
3.1 Background
A new treatment may be effective only for a subset of the overall study popu-
lation. This poses important challenges for designing a randomized clinical trial
to evaluate such a treatment. On the one hand, ignoring participant heterogeneity
and enrolling the overall population can lead to a dilution of the treatment effect,
and may create an unethical situation where participants who do not benefit from
the treatment are treated. On the other hand, enrolling only a narrow proportion
of the overall population would not answer the question of whether the treatment
benefits the larger population; furthermore, such restrictive enrollment could lead
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to slower recruitment and longer trial duration.
Our work is motivated by a multicenter, randomized trial where the new sur-
gical intervention called Minimally-Invasive Surgery Plus rt-PA for Intracerebral
Hemorrhage Evacuation (MISTIE) was compared to standard medical care (Han-
ley et al., 2016). An important baseline (i.e., pre-randomization) characteristic is
intracerebral hemorrhage (ICH) volume, which is one measure of disease sever-
ity. Based on their understanding of brain hemorrhage, the clinical investigators
conjectured that the new treatment may have different effects depending on a par-
ticipant’s pre-randomization ICH volume. We compare different types of Phase II,
randomized trial designs whose goal is to inform a future recommendation about
which (if any) range of ICH volume should be used as the enrollment criterion
in future Phase III, confirmatory trials. For computational reasons, we discretize
ICH volume by partitioning the range of its possible values; in general, if one has
a continuous-valued baseline score, our approach can be applied to a discrete ver-
sion of it.
We consider two-stage, adaptive enrichment designs for the Phase II random-
ized trial. Adaptive enrichment designs involve preplanned rules for modifying
enrollment criteria based on data accrued in an ongoing trial (Wang et al., 2009).
We hypothesized that adaptive enrichment in the Phase II trial might be useful
for making an optimal recommendation for the population (if any) to enroll in fu-
ture Phase III confirmatory trials. In such a Phase II design, information from the
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first stage of the Phase II trial can be used to target whom to enroll in the second
stage of the Phase II trial. For example, if early Phase II data indicated a treatment
benefit only for those with high baseline scores, participants near the boundary
of such scores could be oversampled in the second stage of the Phase II trial; this
may lead to improved information for recommending which population to enroll
in Phase III. We investigate whether such an adaptive feature adds value (in terms
of expected utility, defined below) or not, compared to a non-adaptive Phase II
design.
Related work aimed at determining the population who benefits from a treat-
ment includes, e.g., Jiang et al. (2007), Zhou et al. (2008), Barker et al. (2009), Frei-
dlin et al. (2010), Lee et al. (2010), Kim et al. (2011), Cai et al. (2011), Lai et al. (2014),
Xu et al. (2014), Ohwada and Morita (2016), Spencer et al. (2016). Our approach
differs from these in that we explicitly define the performance goal of our Phase
II design (the objective function) in a decision theory framework and compute an
approximate Bayes optimal adaptive enrichment design over a class of designs
defined in Section 3.2.
We next discuss related work that uses a decision theory approach for opti-
mizing trial designs. Colton (1963, 1965) aim to select the best of two treatments;
Banerjee and Tsiatis (2006) aim to minimize expected sample size; Cheng and Berry
(2007) aim to maximize the expected number of effectively treated participants in
the trial; Hampson and Jennison (2015) aim to optimize power to detect the best
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of multiple treatments. Each of the aforementioned references involves a single
population. In contrast, we consider multiple populations defined by a baseline
score, and aim to determine which population (if any) to recommend for a pair
of future Phase III trials. Our designs also differ from the above related work in
terms of the types of designs we consider, i.e., Phase II designs that can adapt the
population enrolled (called adaptive enrichment). The work of Graf et al. (2015),
Krisam and Kieser (2015), Götte et al. (2015), and Rosenblum et al. (2016) involves
adaptive enrichment using a binary biomarker that divides participants into two
subpopulations. In contrast, by allowing the population selected for Phase III to
be an interval of the baseline score, we allow a larger number of possible subpop-
ulations.
In Section 3.2, we define the class of trial designs that we optimize over. The
trial design optimization problem and our approach to solving it are given in Sec-
tion 3.3. In Section 3.4, we use simulations to compare the performance of an opti-
mized, two-stage, adaptive design versus an optimized (non-adaptive) one-stage
design. The main result is that the two-stage, adaptive design did not improve
expected utility, where the utility function measures the quality of the recommen-
dation for whom to enroll in future Phase III trials; however, as shown in Sec-
tion 3.4.4, the two-stage, adaptive design leads to fewer participants assigned to
a non-efficacious or harmful treatment during Phase II. We apply the designs to
resampled data from a completed, Phase II trial (MISTIE II) evaluating a new sur-
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gical intervention for stroke, in Section 3.5. In Section 3.6, we present areas for
future research.
3.2 Data Generating Process and Phase II Trial
Designs
3.2.1 Overview of Fixed and Adaptive Designs
We focus on Phase II randomized trials comparing a new treatment to standard
of care (control) with a 1:1 randomization ratio. We compare two-stage, adaptive
enrichment designs to one-stage, fixed designs. Both designs have the same total
sample size (denoted as 2n), and both have the goal of making an optimal recom-
mendation for the population (if any) to enroll in two, future Phase III trials. Two,
future Phase III trials are considered since this is what the U.S. Food and Drug Ad-
ministration typically requires for approval of a new drug; the Phase III trials are
assumed to be fixed (non-adaptive) and have predefined sample size N .
Figure 3.1 illustrates two types of Phase II designs: the one-stage, fixed design
and the two-stage, adaptive enrichment design, referred to as the fixed design and
adaptive design, respectively. In the fixed design, shown in Figure 3.1a, 2n par-
ticipants are enrolled from the overall population. A preplanned rule at the end
of the trial determines the population to enroll in two future Phase III trials. The
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population is defined by a range of the baseline score.
(a) Fixed Design, 2n participants are enrolled in Phase II from
the overall population. At the end, a recommendation of the
population (if any) to enroll in two, future Phase III trials is
made.
(b) Adaptive Design, n participants are enrolled in each of
Stages A and B in Phase II with the Stage B enrollment crite-
rion depending on the results of Stage A. After Stage B, a rec-
ommendation of the population (if any) to enroll in two, future
Phase III trials is made.
Figure 3.1: Phase II fixed design (top-left) and Phase II adaptive design (bottom-
left), each of which may be followed by two Phase III trials.
The adaptive design, shown in Figure 3.1b, has two stages. In Stage A, n par-
ticipants are recruited from the overall population. At the end of Stage A, a deci-
sion is made as to which population to enroll in Stage B, in terms of the baseline
score. This allows an enrollment modification for Stage B (which always has n
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participants), with the goal of providing more targeted information to help in the
population selection at the end of Stage B for the future Phase III trials.
For both the fixed and adaptive Phase II designs, the data from the 2n par-
ticipants are ultimately used to select a range of the baseline score to set as the
enrollment criterion for 2 future Phase III trials. If the range selected is the empty
set, this corresponds to not conducting any Phase III trials; this option is important
since one of the main goals of Phase II is to weed out useless treatments.
For the Phase II adaptive design, the only feature that is adapted is the Stage B
enrollment criterion. The decisions involved in the Phase II adaptive designs:
(i) After collecting the Stage A data, what will be the enrollment criterion will
be for Stage B?
(ii) After Stage B data has been collected, what will be the enrollment criterion
for the future Phase III trials?
3.2.2 Data Collected on Each Participant
Let R denote the continuous-valued baseline score, e.g., ICH volume in the
MISTIE trial example. We assume the population distribution of R is uniform on
the interval (0, 1), which can be achieved by a quantile transformation of any con-
tinuous variable. In order to make our computations feasible, we discretize R by
partitioning (0, 1) into M consecutive, equal length intervals. Let ˜R = dR ⇥ Me
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denote the corresponding interval number, which has values in {1, . . . ,M}. We
refer to ˜R as the discrete score.
Let T denote the treatment arm indicator, where T = 1 means assignment to
treatment and T = 0 means assignment to control. Let Y 2 R denote the primary
outcome, which we assume to be measured on each participant relatively soon
after her/his enrollment. Let   : (0, 1) ! R denote the conditional treatment effect
function  (r) = E(Y |T = 1, R = r)   E(Y |T = 0, R = r) given the continuous-
valued baseline score r 2 (0, 1). Define the discrete analog of  , which represents
the average treatment effect for stratum ˜R = r̃, as:
˜




for any r̃ 2 {1, . . . ,M}.
Conditional on the discrete baseline score and treatment indicator, the primary
outcome Y is assumed to be a random, independent draw from a normal distribu-
tion with common variance  2. That is, we assume the conditional distribution of





(r̃) = ˜ (r̃) and common, conditional variance  2. For simplicity,
we assume µ
1
(r̃) = ˜ (r̃)/2 and µ
0
(r̃) =   ˜ (r̃)/2.
The data vector contributed by each participant i, used as input to the decision
rules in the trial design, is denoted Vi = ( ˜Ri, Ti, Yi). Let X(A) and X(B) denote
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the sets of data vectors Vi collected during Stage A and Stage B, respectively. Let
X = (X(A), X(B)) denote the entire data set at the end of Stage B.
3.2.3 Definition of Phase II Adaptive Designs
Let E (A) and E (B) denote the allowed enrollment choices at the end of Stage A
and Stage B, respectively. The action sets E (A), E (B) each consist of a prespecified,
finite set of intervals (rl, ru) with endpoints rl, ru 2 {0, 1/M, 2/M, . . . , 1} and rl 
ru; each interval represents a range of the baseline score. If the interval (rl, ru) 2
E (A) is selected at the end of Stage A, it means that n participants will be enrolled
during Stage B using inclusion criterion R 2 (rl, ru). If the interval (rl, ru) 2 E (B)
is selected at the end of Stage B, it means that the two, Phase III trials will enroll
N participants using inclusion criterion R 2 (rl, ru). We assume that E (A) contains
the full interval (0, 1) and that E (B) = E (A) [ {;}, where the empty set ; represents
not conducting any Phase III trials. By convention, we represent the empty set by
an interval (rl, ru) with rl = ru.
An adaptive design is defined as a pair of decision rules (d(A), d(B)), where d(A)
is a map from the Stage A data X(A) to the set of enrollment choices E (A), and
d(B) is a map from the cumulative data X to E (B). We assume these maps are
measurable, which is generally required for adaptive designs (Liu et al., 2002).
Whenever maxima are taken over pairs of decision rules (d(A), d(B)), we assume
that this is over all possible pairs of such measurable maps.
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After collecting the Stage A data X(A), the prespecified decision rule d(A) is
applied to select the action from E (A); this determines the population to be enrolled
during Stage B. At the end of Stage B, the cumulative data X = (X(A), X(B)) has
been collected, and the prespecified decision rule d(B) is applied to determine the
action in E (B); this action represents the enrollment criterion for the two, future
Phase III confirmatory trials. The fixed design is a special case of the adaptive
design with d(A) always mapping to the action (0, 1).
3.2.4 Data Generating Process for Adaptive Phase II
Design
The data generating process for a trial conducted using an adaptive design
(d(A), d(B)) is summarized in Figure 3.2. First, the treatment effect function   is





as defined in Section 3.2.2. Next, Stage A data from n participants are
generated, where each participant has baseline score R drawn from the uniform
distribution over (0, 1) corresponding to the full range of the severity score; this
determines her/his discrete baseline score ˜R. Treatment indicator T is assigned
independent of the baseline score with probability 1/2 of being 0 or 1. Next, the
outcome is drawn according to the conditional distribution Y |T = t, ˜R = r̃, which
was assumed to be Normal(µt(r̃),  2).
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Figure 3.2: Data generating process for Phase II adaptive design using decision
rule (d(A), d(B)).
In the third step, the decision function d(A) 2 D(A) maps the Stage A data X(A)
to an action in E (A). This action represents the population enrolled during Stage
B. Each Stage B participant has baseline score R drawn uniformly from the in-
terval d(A)(X(A)). The treatment assignments and outcomes given ˜R are drawn
analogously as in Stage A. At the end of Stage B, given the cumulative data X , the
decision function d(B) determines the population to enroll in the Phase III trials,
including the option to conduct no future trials.
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3.2.5 Prior Distribution on Conditional Treatment Ef-
fect Function
We assume a prior ⇡ on the conditional treatment effect function  . In our
simulations, ⇡ is set to be a finite set of point masses on the functions   =  
1
, . . . ,  
6
,
shown in Figure 3.3. We refer to each  k as a possible state of nature.
In Figure 3.3, the function  
1
represents the conditional treatment effect being 1
for all values of the baseline score R in (0, 1). The function  
2
represents the treat-
ment only benefiting the population with baseline scores greater than 1/2, while
the function  
4
represents the treatment benefiting the population whose baseline
scores are between 1/4 and 3/4. Under the conditional treatment effect function  
5
,
the treatment benefit is  1, i.e., the treatment is harmful, for all values of the base-
line score. Under  
6
, there is zero treatment benefit for every baseline score value;
this represents the global null hypothesis of no treatment effect for any stratum of
the baseline score. The discrete versions of  
1
, . . . ,  
6
, based on applying (3.1) to
each, are given in Table 3.5 of the Appendix.
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Figure 3.3: Six states of nature  
1
, . . . ,  K . The solid line represents the treatment
effect function  k, while the dashed line is a horizontal zero line as a reference.
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3.3 Optimization Problem and Algorithm to
Solve It
3.3.1 Utility Function
Our utility function focuses on what happens as a consequence of the Phase II
trial. It represents a combination of the cost of conducting future Phase III trials
(if they are recommended after Phase II) and the improved health of the future
population minus the treatment’s cost (if the Phase III trials succeed). The utility
function U(rl, ru; ) takes the function   and an action (rl, ru) 2 E (B) (which repre-
sents the interval recommended for Phase III enrollment) as inputs, and is defined
as follows: if no Phase III trials are recommended (which occurs when rl = ru)
then U(rl, ru; ) = 0, and otherwise U(rl, ru; ) equals




























where P (2 Phase III Trials Succeed| , rl, ru) is the conditional probability, defined
below, that both Phase III trials enrolling those with baseline scores in (rl, ru) suc-
ceed given  .
The components in curly braces in (3.2) represent the population health and
52
CHAPTER 3. PHASE II ADAPTIVE DESIGN
treatment cost due to the treatment being approved (after 2 successful Phase III
trials) for use in the population with baseline scores in the range (rl, ru). The term
R ru
rl
 (r)dr represents the health benefit that would result from the population with
baseline score in the interval (rl, ru) using the treatment instead of the control. This
term is maximized if the interval (rl, ru) contains precisely those who benefit from
treatment (and possibly also those who have no effect from treatment).
The second term in curly braces c(ru   rl) represents health system costs to the
future population if both Phase III trials succeed leading to the drug being ap-
proved and used by the recommended population (rl, ru). Here, c is a constant,
and we assume that the health system cost is proportional to the size of the pop-
ulation with baseline score in (rl, ru). We use the term “cost” in the general sense
that captures negative impacts of administering the treatment to a future popula-
tion. For example, cost may reflect monetary cost and negative impacts in terms of
frequency and severity of side effects caused by treatment. If the cost c > 0, then
there is a penalty for approving the treatment for any stratum r 2 (0, 1), especially
for those whose treatment effect  (r) is less than c; in particular, it penalizes for
approving the treatment for strata that have zero treatment effect (unlike the first
term in curly braces).
The component P (2 Phase III Trials Succeed| , rl, ru) is the probability of suc-
cess of two, future Phase III trials enrolling from the population with baseline score
in the interval (rl, ru). Assuming that the two Phase III trials are independent given
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(rl, ru), this probability is the squared power of a fixed (non-adaptive) design for




the average height of the treatment effect curve   over the interval (rl, ru). The
prespecified sample size N for each Phase III trial is determined by the minimum,
clinically meaningful benefit  min, type I error, type II error, and outcome variance
 2.
The last term of the utility function,  /(ru   rl), is proportional to the duration
of each Phase III trial enrolling participants with baseline scores in (rl, ru), where
we made the approximation that the enrollment rate is proportional to the size of
the recommended population to be enrolled. This could apply, for example, to
the MISTIE trial where ICH volume is only determined after recruitment based on
neuroimaging, and so excluding more participants would require longer recruit-
ment to reach the total sample size N .
Though Type I error control in the Phase II trial is not our focus, we do evalu-
ate design performance when there is no treatment effect to determine how often
future Phase III trials are (erroneously) recommended.
3.3.2 Optimization Problem
The goal is to compute the pair of optimal decision rules at the end of Stage A
and at the end of Stage B in Phase II, denoted by d(A)opt and d
(B)
opt , respectively. These
are the rules that maximize expected utility, where the expectation is with respect
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where the maximum is taken over all pairs (d(A), d(B)) of decision rules as defined
in Section 3.2.3. Throughout, expectation E and probability P are with respect to
the prior ⇡ and a generic Phase II adaptive design (d(A), d(B)) unless indicated oth-
erwise. As described in Section 3.3.1, the utility U depends on the action d(B)(X)
taken at the end of Stage B (i.e., who to enroll in the future Phase III trials) and
the conditional treatment effect function  . The action taken at the end of Stage
B depends on the data from Stages A and B, i.e., X = (X(A), X(B)). We write
X(B) = X(B)[d(A){X(A)}] in the display above to make explicit that the Stage B data
generating distribution depends on the decision d(A){X(A)} at the end of Stage A
regarding the population to be enrolled during Stage B. This highlights the sequen-
tial nature of the decision problem.
3.3.3 Algorithm to Solve the Optimization Problem
Banerjee and Tsiatis (2006), Cheng and Berry (2007) and Hampson and Jennison
(2015) used backward induction to provide closed form solutions to their optimal
adaptive designs under a decision-theoretic framework. Since this is not possible
in our problem, we instead use backward induction with Monte-Carlo forward
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simulation. Such backward induction has been implemented to solve problems in
different contexts by, e.g., Carlin et al. (1998), Brockwell and Kadane (2003), Rossell
et al. (2006), Ding et al. (2008).
Let n(j)(r̃) denote the cumulative sample size per arm for participants with
baseline score ˜R = r̃ enrolled during or before Stage j 2 {A,B} of the Phase II
trial, for each r̃ 2 {1, . . . ,M}. We assume that in Stage A, n/M are enrolled from
each baseline stratum r̃ 2 {1, . . . ,M}. For Stage B of the adaptive design, we as-
sume an equal number are enrolled from each stratum r̃ contained in the selected
population d(A)(X(A)), such that a total of n are enrolled in that stage. We assume
that within each stage and enrolled stratum of the baseline score, an equal number
are assigned to treatment and control; this can be accomplished (approximately)
by stratified block randomization.
Define the sample mean difference between arms of the primary outcome using










1(Ti = 1, ˜Ri = r̃)Yi  
X
i
1(Ti = 0, ˜Ri = r̃)Yi
)
,
where the summations are over the participants i with outcomes observed at or
before the end of Stage j, and 1(S) is the indicator variable taking value 1 if S
is true and 0 otherwise. The statistic b (j)(r̃) is an estimator of  (r̃), the average
treatment effect in stratum r̃. Let b (j) denote the vector of cumulative sample
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mean differences for each category of baseline score r̃ 2 {1, . . . ,M} using all data
up through the end of Stage j 2 {A,B}.
We next define minimal sufficient statistics ˜S(A), ˜S(B) for   based on the data
X(A) available at the end of Stage A and the data X available at the end of Stage
B, respectively. Stage A is equivalent to a fixed design, and we define ˜S(A) = b (A),
i.e., the sample mean differences within each stratum r̃ 2 {1, . . . ,M}. Since Stage
B involves a potential enrollment modification that is determined by the decision
d(A)(X(A)), we define ˜S(B) = (d(A)(X(A)), b (B)).
Backward induction starts from the end of Stage B, where we have collected
the overall data X = (X(A), X(B)). The first step is to maximize the conditional




opt (X) = argmax
d(B)
E[U{d(B)(X); }|X], (3.4)
where the expectation is with respect to the distribution of   given X .
We assume the prior distribution ⇡ on   consists of K point masses  
1
, . . . ,  k,
each representing a conditional treatment effect function. For any candidate action
(rl, ru) 2 E (B), Monte Carlo simulation is used where we draw posterior samples
of   given the data X in order to approximate the conditional expected utility if
this action is followed. i.e., E[U(rl, ru; )|X]. The posterior distribution P (  | X)
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depends on the data X only through the sufficient statistics ˜S(B). Given the data
X , we compute the corresponding sufficient statistics ˜S(B) and then draw posterior
samples of   from P (  | ˜S(B)) as described below.
Consider any Stage A decision rule d(A) and data vector X = (X(A), X(B)) that
can be generated under the Phase II adaptive design using Stage A decision rule
d(A). Let E = d(A)(X(A)) denote the decision at the end of Stage A; without loss
of generality, we assume d(A) depends on the data X(A) only through the suffi-
cient statistic ˆ (A). We prove the following in the Appendix, where / represents
proportionality with respect to functions of the data X :
P (  =  k | X) / PE(b (B) = b (B)(X) |   =  k)P (  =  k), (3.5)
where PE denotes the probability density function of X under the deterministic
(non-adaptive) Stage A decision rule that always enrolls population E 2 E (A) dur-
ing Stage B regardless of the Stage A data. The above display reduces (up to a
proportionality constant) the problem of computing P (  =  k | X) to the fol-
lowing simpler problem: computing the conditional probability density that the
cumulative sample mean differences (at the end of Stage B) equal b (B)(X) given
  under the non-adaptive Stage A decision rule that always enrolls population
E = d(A)(X(A)) during Stage B.
We describe how to compute d(B)opt (X) given X . Under the probability density
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PE , the statistic b (B) conditional on   =  k has a multivariate normal distri-
bution with mean vector determined by integrating  k over each interval ((m  
1)/M,m/M) : m = 1, . . . ,M using the formula on the right side of (3.1) and
covariance matrix ⌃ the diagonal matrix with zeros off the main diagonal and
⌃mm = 2 2/n(B)(m) for each m = 1, 2, . . . ,M . Given the observed b (B), for each
k = 1, . . . , K we compute the density PE(b (B) = b (B)(X) |   =  k) from this
multivariate normal distribution and multiply by the prior P (  =  k) to obtain
the right side of (3.5), which was shown above to be proportional to the posterior
probability P (  =  k | X). For each interval (rl, ru) in the action space E (B), we
repeatedly draw from this posterior distribution to approximate the posterior ex-
pected utility
P
kK U(rl, ru;  k)P (  =  k | X), which is E[U{d(B)(X); }|X] under
the decision d(B)(X) = (rl, ru). We set d
(B)
opt (X) to be the interval (rl, ru) in E (B) that
gives the maximum posterior expected utility.
The derivation of d(A)opt is analogous to that of d
(B)
opt , and is described in the Ap-
pendix. All of the above computations were implemented in R (R Core Team,
2015).
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3.4 Simulation Study with Six Possible Treat-
ment Effect Curves
3.4.1 Simulation Setup
We implement the optimization algorithm from the previous section in a sim-
ulation study comparing the performance of the fixed versus adaptive Phase II
design. The prior ⇡ on   is a discrete distribution on the conditional treatment
effect curves { k}6k=1 in Figure 3.3 that places 50% weight on  6 (the global null hy-
pothesis) and equal weights on  
1
, . . . ,  
5
. We allocate greater weight to  
6
in order
to reflect the realistic possibility that an experimental treatment has no effect at
all. Intuitively, the impact of having greater weight on  
6
is that the corresponding
optimal design will be more conservative in initiating Phase III follow-up trials,
thereby saving resources at the cost of lowering the chance of successful Phase III
trials.
The prior ⇡ is one possible choice; our general approach can be applied to an
arbitrary set of weights and any finite set of conditional treatment effect functions,
i.e., applied to any prior consisting of a finite set of point masses. The choice of
prior would ideally be chosen based on prior scientific knowledge and data from
earlier studies. Here we demonstrate a relatively simple case as a proof of concept.
For a given state of nature  , the population that benefits from treatment is defined
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as {r 2 (0, 1) :  (r) > 0}. For example, under   =  
2
, the treatment benefits
precisely those with r 2 (0.5, 1). Depending on which of  k, k = 1, . . . , 6, is the
true state of nature, the population who benefit from treatment is an interval of the
baseline score r in the set
E (B) = {(0, 1), (0.5, 1), (0, 0.5), (0.25, 0.75), ;}. (3.6)
Let
E (A) = {(0, 1), (0.5, 1), (0, 0.5), (0.25, 0.75)}.
We use the above sets E (A), E (B) as the action sets for our decision problem, repre-
senting the possible choices for whom to enroll next based on the data at the end
of Stages A and B, respectively.
We define ˜R to have M = 4 levels corresponding to the baseline score being
in the intervals (0, 0.25), (0.25, 0.5), (0.5, 0.75), (0.75, 1), respectively. We chose this
discretization since any non-empty interval in E (A) or E (B) can be represented as a
union of these intervals (ignoring the interval endpoints).
We selected the Phase II total sample size, denoted 2n, to be 528. This was,
roughly, based on the sample size required for the fixed design (Figure 3.1a) to
have type I error ↵ and power 1    , in the simple case of a constant conditional
treatment effect   = ⌧ > 0 and conditional variance  2. This sample size is
4{  1(1   ↵) +   1(1    )}2( 2/⌧ 2); to maintain a realistic signal to noise ratio
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in the Phase II trial, we set ↵ = 0.1,   = 0.2,  2 = 9 and ⌧ = 0.554 in this formula
(and rounded down), which implies the total Phase II sample size is 2n = 528.
Our choices of ↵,   are typical for Phase II trials as described by Rubinstein et al.
(2005). However, our choices of ⌧ and   were somewhat arbitrary; the value of ⌧
was taken to be between the average treatment effect of 1 (under   =  
1
) and 0.25
(under each   =  k, k = 2, 3, 4). We set the prespecified sample size N = 2473 for
each Phase III trial based on the above formula with parameters ⌧ = 0.3 (repre-
senting the minimum, clinically meaningful benefit), type I error ↵ = 0.05, type II
error   = 0.2, and outcome   = 3.
Our optimization problem is invariant to rescaling in that the optimal decision
rules (as functions of the sufficient statistics ˜S(A), ˜S(B)) are unchanged if we multi-
ply all of n,  2, N by the same positive constant. For example, the optimal decision
rules would be the same if we multiply these parameters by 1/4, i.e., setting the
Phase II total sample size 2n = 132, outcome conditional variance  2 = 9/4, and
Phase III sample size N = 618.
3.4.2 Optimal Adaptive Phase II Designs in Simula-
tion Study
The optimal decision rules d(A)opt and d
(B)
opt are defined by (3.3), which depends on
the prior ⇡ and the utility function U defined above. These rules are optimal for
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a pair (⇡, U) in terms of the Bayes criterion (3.3). These rules may be suboptimal
for any single state of nature  j , since the rules find the best tradeoff in expected
utility U across these different states of nature, where the relative importance of
each state of nature depends on ⇡. The approximate optimal decision rules were
computed using the backward induction method in Section 3.3.3.
We explored the performance of the optimal decision rules (d(A)opt , d
(B)
opt ) by con-
ducting simulated trials with data generated from one treatment effect function  k
at a time. For each  k, we simulated 200 trials under   =  k using the precom-
puted decision rules (d(A)opt , d
(B)
opt ). The frequency of each population in E (A) getting
selected for Stage B enrollment was recorded; also recorded was the frequency of
each population in E (B) getting selected for the future Phase III trials. The optimal
rules d(A)opt and d
(B)
opt depend on the prespecified ⇡ and U , and are determined prior
to the start of the study, regardless of our setting   to be different curves  
1
, . . . ,  k,
indicating the decisions to make according to the observed data during the course
of the simulation study.
Table 3.1 shows the operating characteristics of the optimal, adaptive Phase II
design (d(A)opt , d
(B)
opt ) using the utility function (3.2) with   = 0.01, c = 0.32. The top
half of Table 3.1 shows the frequency of different choices for Stage B enrollment
corresponding to d(A)opt . For example, 34% of the simulated trials recommend to
enroll participants from the overall population in Stage B of the Phase II adaptive
design when   =  
1
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half of the overall population benefits from the treatment, there is a 67% chance of
enrolling at least the population who benefit from treatment in Stage B.
Table 3.1: Operating Characteristics of d(A)opt (top) and d
(B)
opt (bottom) for   = 0.01, c =
0.32.
Distribution of Population Recommended for Stage B Enrollment by d(A)opt
d
(A)
opt = (0, 1) d
(A)
opt = (0.5, 1) d
(A)
opt = (0, 0.5) d
(A)
opt = (0.25, 0.75)
  =  
1
0.34 0.27 0.24 0.15
  =  
2
0.30 0.37 0.21 0.12
  =  
3
0.34 0.22 0.33 0.11
  =  
4
0.27 0.26 0.26 0.21
  =  
5
0.67 0.14 0.13 0.06
  =  
6
0.30 0.34 0.27 0.09
Distribution of Population Recommended for Phase III trials by d(B)opt
d
(B)
opt = (0, 1) d
(B)
opt = (0.5, 1) d
(B)
opt = (0, 0.5) d
(B)





0.96 0.01 0.01 0.02 0.00
  =  
2
0.07 0.53 0.04 0.09 0.27
  =  
3
0.11 0.02 0.56 0.09 0.22
  =  
4
0.12 0.04 0.09 0.40 0.35
  =  
5
0.00 0.00 0.00 0.00 1.00
  =  
6
0.01 0.09 0.06 0.12 0.72
The bottom half of Table 3.1 shows the frequency of different choices for the
population to enroll in the two, Phase III trials under the decision rule d(B)opt . We un-
derline the number corresponding to the population who benefit from treatment
(defined in Section 3.4.1) under the corresponding treatment effect function  k. We
mark in bold the largest proportion in each row, which represents the population
that is recommended most frequently for the future Phase III trials. For example,
when data are generated under treatment effect function  
2
(row 2), the proportion
0.53 is both underlined and in bold, which means that the corresponding popula-
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tion (0.5, 1) is the population who benefits and is the population most frequently
recommended for Phase III trials. In every row in Table 3.1, the bold number coin-
cides with the underlined number, which shows that in the plurality of simulated
trials the optimal design chooses the population who benefits.
The results in Table 3.1 are for a particular choice of utility function parameters
  and c, which encode the relative importance of the cost of conducting Phase III
trials and the treatment cost if the treatment is approved (including both financial
costs and health costs such as side effects), respectively. We next show the impact
of increasing c from 0.32 to 0.34, while holding all other parameters constant. Using
Table 3.2: Operating Characteristics of d(B)opt for   = 0.01, c = 0.34.
Distribution of Population Recommended for Phase III trials by d(B)opt
d
(B)
opt = (0, 1) d
(B)
opt = (0.5, 1) d
(B)
opt = (0, 0.5) d
(B)





0.95 0.01 0.02 0.02 0.00
  =  
2
0.07 0.48 0.04 0.08 0.33
  =  
3
0.09 0.03 0.55 0.08 0.25
  =  
4
0.11 0.05 0.07 0.39 0.38
  =  
5
0.00 0.00 0.00 0.00 1.00
  =  
6
0.01 0.07 0.05 0.08 0.79
the utility function (3.2) with   = 0.01, c = 0.34, we computed the operating char-
acteristics of the component d(B)opt of the optimal design, summarized in Table 3.2.
There is a higher chance of making the decision not to conduct any Phase III tri-
als (rightmost column), compared to Table 3.1, under each  k (except  5 where no
Phase III trials are conducted with probability 1 in both tables). Under the global
null hypothesis   =  
6
, the probability of conducting Phase III trials (which would
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be a waste of resources) drops from 28% to 21% comparing c = 0.32 to c = 0.34.
The tradeoff is that the optimal decision rule for c = 0.34 (Table 3.2) has lower
probabilities of selecting the optimal population for enrollment in Phase III when









3.4.3 Optimal Adaptive versus Fixed Phase II Trial De-
sign
We solved the same optimization problem as in Section 3.4.2 using   = 0.01, c =
0.32, except restricting to a fixed design, i.e., setting d(A) to be the constant function
that always selects the full population (0, 1) to enroll in Stage B of Phase II; only
the function d(B) is optimized. The resulting design is referred to as the optimal
fixed design. We compare its performance to that of the optimal adaptive Phase
II design in order to determine the value added by adaptive enrichment, i.e., the
value added by allowing enrollment to be restricted to a subset of the population
in Stage B of Phase II.
The recommendation frequencies for Phase III trials for the optimal fixed de-
sign are very similar to those for the optimal adaptive design in Table 3.1, with
the maximum difference between any 2 corresponding entries being 3%. Also, we
computed the expected utility for the optimal adaptive design versus the fixed de-
sign, based on 15,000 simulated trials. The expected utility is 0.07 for both designs.
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We also compared the contribution from each component of the utility function for
these two designs, summarized in Table 3.3.
Table 3.3: Expected utility and expected value of its 4 components under the opti-
mal fixed design and adaptive designs, respectively, based on the simulation setup
in Section 3.4.1 using   = 0.01, c = 0.32. Expectation is with respect to the prior
⇡. The interval (rl, ru) in the formulas below represents the Phase III enrollment
decision d(B)opt (X).
Fixed Design Adaptive Design
Expected Utility E[U ] 0.07 0.07
Components of Expected Utility:




Expected Treatment Cost E[c(ru   rl)] 0.10 0.10
P (2 Phase III Trials Conducted and Both Succeed) 0.27 0.27
Expected Phase III Cost E[ 1(rl 6= ru)/(ru   rl)] 0.82 0.80
The probability of having 2 successful Phase III trials is 0.27, averaged over the
prior ⇡. This is the probability of successfully demonstrating treatment efficacy
when considering the combined Phase II/III trial sequence. This may seem like a
low probability of the trial sequence succeeding. However, we next show that our
choice of prior ⇡ implies that regardless of what is done during phases 2 and 3 (e.g.,
even if both sample sizes were arbitrarily increased), there is no way to achieve a
probability greater than 41% of having a successful trial sequence. Intuitively, this
is because the prior selects   =  
5
or   =  
6
with probability 0.6, and in such cases
the treatment is not beneficial for any stratum of the baseline score.
We provide an upper bound for the probability of two successful Phase III trials
under the prior ⇡ and an arbitrary rule for deciding which population to enroll in
Phase III. Under ⇡, for the event maxr2(0,1)  (r)  0, there is at most 0.05 probabil-
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ity of each Phase III trial succeeding. Therefore, the probability of two successful
Phase III trials (regardless of both the decision rule for Phase III enrollment and
the Phase III sample size) is at most 1   0.6(1   0.052) = 0.4015. By compari-
son, the corresponding 0.27 probability for the utility-maximizing designs above
(where the objective function involves terms other than just power in Phase III) is
not insubstantial.
3.4.4 Impact of Adaptive Design on Number Assigned
to Superior Treatment During Phase II
In this section, we shift our focus to what happens to participants during Phase
II, rather than after Phase II. Specifically, we measure the impact of being enrolled
in the Phase II trial compared to not being enrolled; we assume not being enrolled
in the trial means that a patient would have received the standard of care, i.e., the
control. We focus only on Stage B participants in the Phase II trial since our goal
is to contrast the fixed versus adaptive designs, and these designs have identical
patient outcome distributions during Stage A.
We say that Stage B participant i with baseline score Ri in study arm Ti is as-
signed to a superior treatment (compared to control) if  (Ri) > 0 and Ti = 1, that
is, if the conditional treatment effect is positive in that participant’s baseline stra-
tum and she/he is assigned to the treatment arm Ti = 1. For example, if   =  2,
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each participant i with baseline score Ri > 0.5 in arm Ti = 1 is assigned to a supe-
rior treatment. We denote the proportion of Stage B participants who are assigned
to a superior treatment as fprop = 1n
P
i 1{Ti = 1, (Ri) > 0}, where the sum
is over the n Stage B participants. Similarly, define the average benefit to Stage





i 1(Ti = 1) (
˜Ri), where the sum is over the n Stage B participants.
Table 3.4 presents the expected proportion E(fprop| ) of Stage B participants
who are assigned to a superior treatment and the expected average benefit E(fben| ),
respectively, conditional on the treatment effect function  . These expectations
depend on the decision rule d(A). We evaluated the optimal rule d(A) = d(A)opt from
Section 3.4.3, which was optimized for the utility function U in (3.2) using   =
0.01, c = 0.32. We also evaluate the fixed (non-adaptive) decision rule d(A) ⌘ (0, 1).
The evaluation of these decision rules was based on the same set of simulations
from Section 3.4.3.
For every treatment effect function  k where some but not all strata of r ben-
efit from the treatment (i.e., for  k : k 2 {2, 3, 4}), the difference between the ex-
pected proportion assigned to a superior treatment E(fprop|  =  2) for d(A)opt ver-
sus the fixed design is 3-5%, as shown in Table 3.4. For the expected benefit fben,
the relative improvement comparing adaptive versus fixed designs ranges from
(0.132  0.125)/0.125 ⇡ 5% to (0.151  0.125)/0.125 ⇡ 20%, as we consider different
 k.
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Table 3.4: Expected value of fprop and fben, comparing fixed design versus adap-
tive design. Top half shows E(fprop|  =  k) and bottom half shows E(fben|  =
 k).
(a) E(fprop|  =  k) :






















(b) E(fben|  =  k) :






















Despite not providing a higher expected utility than the optimal fixed design
(as shown in Section 3.4.3), the adaptive design turned out to have advantages over
the fixed design in the number of participants assigned to a superior treatment in
the Phase II trial (which is not reflected in the utility function from Section 3.3.1).
That is, although the original aim of the Phase II adaptive design was to provide
more targeted information to assist in the decision at the end of Phase II, a by-
product is that the optimal adaptive design can lead to more participants assigned
to a superior treatment in Phase II. From this perspective, such adaptive designs
may be more ethical to conduct (under the assumptions built into our simulation
study).
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3.5 Simulation Study Mimicking Features from
the MISTIE II Trial
We applied our optimized Phase II designs in simulation studies where the
data generating distribution mimics features from the completed MISTIE II trial.
The baseline score R is the quantile of intracerebral hemorrhage (ICH) volume.
We define M = 4 baseline score categories demarcated by the 25%, 50% and 75%
percentiles of ICH volume, which correspond to 33ml, 43ml, 57ml, respectively.
The discrete baseline scores ˜R = 1, 2, 3, 4 correspond to the ranges of ICH volume
(in ml) [17, 33), [33, 43), [43, 57), [57, 120], respectively. The data set consists of 90
participants with complete observations ( ˜Ri, Ti, Yi) : i = 1, . . . , 90 in the MISTIE
trial. The primary outcome is the indicator of whether the participant’s functional
disability score, as measured by the modified Rankin Scale, is 3 or less.
We consider adaptive Phase II trial designs that are optimized for the problem
setup in Section 3.4.1 using sample size n = 64 per stage, and utility function
parameters c = 0.1 and each of   2 {0.004, 0.01}; the resulting optimal designs
are denoted d(A)opt , d
(B)
opt (which differ for the two different values of   used). These
optimization problems did not incorporate any features of the MISTIE data except
that the baseline score is discretized into 4 categories.
We investigated the performance of the above, optimized designs in simulated
Phase II trials where the distribution of the outcome Y given study arm T and
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baseline score ˜R is the empirical distribution in the MISTIE trial. The estimated
treatment effects ˜ (r̃) from this distribution are -0.07 for r̃ = (0, 0.25), 0.22 for
r̃ = (0.25, 0.5), 0.12 for r̃ = (0.5, 0.75) and 0.19 for r̃ = (0.75, 1).
Data in Stage A of each simulated Phase II trial were generated as follows:
equal numbers from each baseline category were enrolled and assigned to each
arm; for each participant i, a random outcome Y was drawn from the MISTIE data
set empirical distribution conditioned on that participant’s study arm and baseline
score (Ti, ˜Ri). Stage B data were generated analogously, except enrollment was
only from the selected population.
The above data generating distribution violates our assumption that the out-
come is normally distributed conditional on the study arm and baseline score.
Also, the induced treatment effect function is not in the support of the prior ⇡.
This provided an opportunity to evaluate the performance of our optimized Phase
II designs in a scenario that differs from those it was optimized for.
Using the above data generating distribution, we simulated 200 Phase II tri-
als and computed the proportion of trials with each population recommendation
for Phase III. The results are summarized in Figures 3.4 and 3.5. In each figure,
each rectangle’s base represents the interval corresponding to a population recom-
mendation in E (B) for Phase III enrollment, and its height represents the observed
proportion of that recommendation under the optimal design d(B)opt . In Figure 3.4,
for example, the population ˜R 2 (0.5, 1) (base) is recommended for Phase III en-
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rollment in 30% (height) of simulated trials.
Figures 3.4 and 3.5, which differ only in the Phase III duration cost   = 0.004
vs.   = 0.01, show the impact of increasing this cost. This increase in   incen-
tivizes recommending a broader population for Phase III enrollment (to increase
the enrollment rate) or recommending no Phase III trials. Comparing Figures 3.4
and 3.5, the overall population is recommended with frequencies 4.5% vs. 8%, and
no Phase III trials are recommended with frequencies 17.5% and 32.5%, respec-
tively.
Since we sampled data from the empirical distribution of the MISTIE II trial as
described above, the true state of nature ˜ (r̃) is ( 0.07, 0.22, 0.12, 0.19) for baseline
ICH quartiles r̃ = 1, 2, 3, 4, respectively. The population who benefit from treat-
ment, in terms of baseline ICH quartiles ˜R, consists of the last 3 categories, which
represent ICH volume quantiles (0.25, 1]. Our Phase II designs only allowed rec-
ommending a population to enroll in Phase III from the action set E (B) defined
in (3.6). This precluded enrolling the true population who benefit from treatment
(0.25, 1]. The allowed enrollment choices were the following: (0, 1), which has the
disadvantage of including the first quartile who are slightly harmed by treatment;
(0.5, 1) or (0.25, 0.75), each of which has the disadvantage of excluding a quartile
who benefit; (0, 0.5), which has both types of disadvantages; and the empty set.
Each optimized decision rule d(B)opt in Figures 3.4 and 3.5 selects one of the most de-
sirable options, i.e., one of (0.25, 0.75),(0.5, 1),(0, 1), with total probability ranging
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Figure 3.4: The plot shows the proportion of simulated trials in which the opti-
mized adaptive Phase II design makes each recommendation in E (B) for Phase III
trial enrollment, at   = 0.004.
from 60-68.5%.
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Figure 3.5: The plot shows the proportion of simulated trials in which the opti-
mized adaptive Phase II design makes each recommendation in E (B) for Phase III
trial enrollment, at   = 0.01.
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3.6 Remarks
We optimized a Phase II adaptive enrichment design where the utility function
U represents a combination of the cost of conducting Phase III trials (if they are rec-
ommended after Phase II) and the improved health of the future population due
to treatment minus the treatment’s cost (if the Phase III trials succeed). Despite
not providing a higher expected utility than the optimal fixed design, the adap-
tive design turned out to have advantages over the fixed design in the number of
participants assigned to a superior treatment in the Phase II trial. A limitation of
our designs is that we require the primary outcome to be measured on each par-
ticipant relatively soon after her/his enrollment, in order to avoid a long pause
in enrollment between Stages A and B; this limitation is shared by many adaptive
enrichment designs.
In Section 3.4.1, we discretized the continuous-valued baseline score R into the
4 level categorical variable ˜R by partitioning the support (0, 1) of R into 4 equal
length intervals. It may be possible to increase the expected utility of the optimal
decision functions if we modify the problem by using a finer discretization of (0, 1).
Using a finer discretization, e.g., consecutive intervals of width 1/8, could increase
the information available about the unknown value of  ; this could be used to
improve decisions and increase expected utility. A tradeoff is that increasing the
fineness of the discretization leads to increased variation and computational com-
plexity. It is an area for future investigation to determine how much added value
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a finer discretization provides, and at what computational cost.
The prior ⇡ used in the simulation studies is one possible choice; our general
approach can be applied to an arbitrary set of weights and any finite set of con-
ditional treatment effect functions, i.e., applied to any prior consisting of a finite
set of point masses. The choice of prior would ideally be chosen based on prior
scientific knowledge and data from earlier studies, aiming to provide an exhaus-
tive list of possibilities. A possible future extension is to consider a mixture of such
conditional treatment effect functions. The value of the parameters c and   in the
utility function (3.2) can be picked by considering the operating characteristics of
the simulations conducted prior to the study as well as the subject expertise.
Another area for future research is to incorporate the possibility of early stop-
ping for futility at the end of Stage A of Phase II, which could potentially save
resources. We also could consider sample sizes in Stage B of Phase II that differ
from the sample size in Stage A, or that are adaptively selected based on Stage A
data. Similarly, we could consider setting the sample size for the Phase III trials
based on the data from Phase II. Another area for future research is to consider a
variety of different utility functions, e.g., incorporating the trial design cost func-
tion from Emerson et al. (2011).
The R code for our computations in Section 3.4 and 3.5 is available at https:
//github.com/duyu8411/Phase2AdaptDesign.
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3.7 Appendix
3.7.1 Discretized versions of  
1
, . . . ,  
6
Table 3.5 gives the discretized versions of  
1
, . . . ,  
6
, based on applying (3.1) to
each.
Table 3.5: Average treatment effect ˜ (r̃) in each stratum r̃ 2 {1, 2, 3, 4}, under




, . . . ,  
6
, as derived from Figure 3.3. In the row above the
horizontal line, each stratum r̃ is followed by the interval of the baseline score that
it represents.
Average Treatment Effect ˜ (r̃) in Each Statum r̃ and Overall (E[ ˜ ( ˜R)])
r̃ = 1; (0, 0.25) r̃ = 2; (0.25, 0.5) r̃ = 3; (0.5, 0.75) r̃ = 4; (0.75, 1) Overall
  =  
1
1 1 1 1 1
  =  
2
0 0 0.25 0.75 0.25
  =  
3
0.75 0.25 0 0 0.25
  =  
4
0 0.5 0.5 0 0.25
  =  
5
-1 -1 -1 -1 -1
  =  
6
0 0 0 0 0
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3.7.2 Proof of (3.5)
We prove (3.5) from Section 3.3.3.
P (  =  k | X) / P (X |   =  k)P (  =  k) (3.7)
/ P (b (B), d(A)(X(A)), b (A) |   =  k)P (  =  k) (3.8)
= PE(b (B), b (A) |   =  k)P (  =  k) (3.9)
= PE(b (B) |   =  k)PE(b (A) | b (B),  =  k)P (  =  k) (3.10)
= PE(b (B) |   =  k)PE(b (A) | b (B))P (  =  k) (3.11)
/ PE(b (B) |   =  k)P (  =  k), (3.12)
where (3.7) follows from Bayes’ rule; (3.8) holds since ˜S(B) is a sufficient statistic for
 ; (3.9) follows from the sequential structure of the data generating process; (3.10)
follows from the definition of conditional probability; (3.11) follows since b (B) is a
sufficient statistic for   in the design that always enrolls population E in Stage B;
(3.12) holds because PE(b (A) | b (B)) does not depend on  , and thus is absorbed
into the proportionality constant that depends only on X .
3.7.3 Computation of d(A)opt
At the end of Stage A, we have collected Stage A data X(A). The goal at this
point in the backward inductive computation is to maximize the expected utility
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conditioned on X(A) over all possible enrollment choices at the end of Stage A,
E (A), assuming that d(B)opt will subsequently be used after Stage B; the maximizer is








































where the expectation is with respect to the conditional distribution of ( , X(B))
given the Stage A data X(A) (which is induced by the prior ⇡). Analogous to the
computation of d(B)opt , we use Monte-Carlo simulation to approximate the poste-
rior conditional expectation in (3.13) via the posterior distribution of ( , X(B))




via (3.12), and generate the Stage B data, X(B), given   and an enrollment choice
d(A)(X(A)) 2 E (A), according to the data generating distribution specified in Sec-
tion 3.2.2. We thus obtain the full data, X = (X(A), X(B)), and a value for the utility
function. The average values of the utility function from multiple such draws of
data approximates the posterior conditional expectation for this particular enroll-
ment choice. We consider each possible enrollment choice in E (A), and set the opti-




Phase III Studies: Bias, Variance, and
Sample Size Reductions due to
Adjustment in Adaptive Enrichment
Designs
SUMMARY.1
In adaptive enrichment designs, early stopping of a subpopulation with suffi-
cient evidence of treatment efficacy, futility or harm is allowed according to pre-
planned rules for modifying enrollment criteria, while the remaining subpopula-
1This Chapter 4 is adapted from the working paper “Yu Du, Tianchen Qian, Huitong Qiu,
Michael Rosenblum. Bias, Variance, and Sample Size Reductions due to Adjustment for Prognostic Base-
line Variables and Short Term Outcomes in Adaptive Enrichment Trial Designs with Delayed Outcomes.”
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tions continue to be enrolled. Most existing methods for constructing adaptive
enrichment designs are limited to situations where patient outcomes are observed
soon after enrollment. This is a major barrier to the use of such designs in practice,
since for many diseases the outcome of most clinical importance does not occur
shortly after enrollment. For the Phase III studies, we propose to use semipara-
metric, locally efficient estimators, at each analysis of adaptive enrichment designs
for delayed outcome, leveraging information in baseline variables and short-term
outcomes to improve precision. We evaluate power, expected sample size, bias,
variance, and mean squared error for our design and compare with a non-adaptive
design and unadjusted estimator, through simulations of a trial for a new surgi-
cal intervention for stroke. We strongly control the familywise Type I error rate,
asymptotically.
4.1 Background
We address the problem of designing a confirmatory randomized trial of an ex-
perimental treatment versus control when the primary outcome is measured with
delay and there are multiple subpopulations of interest. Our methods were devel-
oped to solve a problem in designing a trial for a new surgical treatment for stroke,
where there are two subpopulations of interest and outcomes are measured a fixed
time (180 days) from enrollment. However, our general method applies to larger
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numbers of subpopulations and to time-to-event outcomes.
We propose to use semiparametric, locally efficient estimators, at each analysis
of adaptive enrichment designs for delayed outcome, leveraging information in
baseline variables and short-term outcomes to improve precision. To illustrate our
approach, consider an interim analysis that occurs just after 50% of a trial’s total en-
rollment. Due to delayed outcomes, less than 50% of final (i.e., primary) outcomes
will be observed. However, all enrolled participants will have baseline variables
observed, some will have short-term outcomes observed, and a further subset will
have the final outcome observed. If the short-term outcomes and baseline variables
are correlated with the final outcome, they can provide valuable information that
we harness through the estimators described below. For example, in the stroke
trial that motivated this work (described in Section 4.2), baseline stroke severity
and 30-day disability score are strongly correlated with the primary outcome of
disability score at 180 days.
In our context of a randomized trial, these semiparametric, locally efficient esti-
mators converge to the true average treatment effect, without having to make any
parametric model assumptions. As stated in the Patient-Centered Outcomes Re-
search Institute Methodology Report (PCORI, 2013, Section 9), the chief statistical
concerns for adaptive designs include “type I error, power, and sample size dis-
tributions, as well as the precision and bias in the estimation of treatment effects".
Similar concerns are emphasized in the FDA draft guidance on adaptive designs
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for drugs and biologics (FDA, 2010) and for medical devices (FDA, 2015). We there-
fore evaluate power, expected sample size, maximum sample size, bias, variance
and mean squared error for the proposed estimator and adaptive enrichment de-
sign, comparing to standard, unadjusted estimator and non-adaptive design in
simulations designed to mimic key features of a completed stroke trial. The un-
adjusted estimator ignores short-term outcomes and baseline variables. The sim-
ulation witnesses tangible improvements in precision, a 19-20% reduction in both
expected sample size and maximum sample size, and comparable power, bias,
variance and mean squared error, over unadjusted estimator.
Our designs strongly control the familywise Type I error rate as required, e.g.,
by the U.S. Food and Drug Administration in their draft guidance on adaptive
designs for drugs and biologics (FDA, 2010). This means that the probability of
rejecting one or more true null hypotheses is at most the desired level, under any
data generating distribution.
A general method for ensuring strong control of the familywise Type I error
rate is the p-value combination approach of Bauer (1989), Bauer and Köhne (1994),
Lehmacher and Wassmer (1999), which has been applied to adaptive enrichment
designs by, e.g., Bretz et al. (2006); Schmidli et al. (2006); Jennison and Turnbull
(2007); Brannath et al. (2009). Another general method for achieving this goal is
the conditional error function approach of Müller and Schäfer (2001), which has
been applied to adaptive enrichment designs by Friede et al. (2012). Both of the
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above methods require assumptions that do not generally hold when using semi-
parametric, locally efficient estimators in our context, as described in Section 4.4.
To take advantage of precision gains that these estimators make possible, we use
a multiple testing procedure proposed by Rosenblum et al. (2016) for adaptive en-
richment designs that takes full advantage of correlations among related statistics,
including statistics for the same population at different times, and statistics for
different but overlapping populations.
If information for the subpopulations of interest is low throughout the trial
(e.g., if accrual is slower than projected), the trial reverts to a standard, group se-
quential trial for the overall population. This feature protects against the realistic
possibility of insufficient information at interim analyses to make an informed de-
cision regarding changing enrollment criteria.
We describe our motivating application in Section 4.2. The general problem is
defined in Section 4.3. In Section 4.4, we present semiparametric, locally efficient
estimators that are used in our designs. The general framework of adaptive en-
richment designs for delayed outcomes is introduced in Section 4.5. We apply our
designs to the stroke trial application in Section 4.6. An evaluation of bias, vari-
ance and mean squared error for the proposed estimator and adaptive enrichment
design is given in Section 4.7. Section 4.8 gives limitations of our approach and
areas for future research.
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4.2 Motivating Application: MISTIE stroke
trial
As introduced in Chapter 3, Minimally-Invasive Surgery Plus rt-PA for Intrac-
erebral Hemorrhage Evacuation, abbreviated as MISTIE (Morgan et al., 2008), is
a new surgical treatment for intracerebral hemorrhage (ICH). Unlike the Phase II
studies in 3, we consider the problem of planning a Phase III trial to compare the
MISTIE surgical treatment to the standard of care, assessing if it provides more
treatment benefit. A binary disability score, as measured by the modified Rankin
Scale (mRS) at 180 days from enrollment, serves as the primary outcome where a
mRS score of 3 or less is considered a success. The difference between the probabil-
ity of success comparing MISTIE treatment to standard of care (control) is therefore
defined to be the average treatment effect.
Prior data indicated greater uncertainty of the treatment effect for the subpopu-
lation of participants with large (at least 10ml) intraventricular hemorrhage (IVH)
at baseline, called large IVH participants. All others are called small IVH partici-
pants. The clinical investigators conjectured that two scenarios were most likely to
occur if the treatment is beneficial:
1. Treatment benefits both subpopulations.
2. Treatment benefits only subpopulation with small IVH.
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We consider the adaptive enrichment designs for testing the corresponding two
null hypotheses: the MISTIE treatment provides no benefit for the overall popula-
tion as well as for the small IVH subpopulation.
4.3 General Problem Definition
4.3.1 Subpopulations and Data Structure for Each Par-
ticipant
We assume the overall population is partitioned into m disjoint subpopula-
tions, which are functions of variables measured before randomization. For each
s 2 {1, . . . ,m}, let ps denote the proportion of the overall population in subpopu-
lation s, which we assume is known. In all our designs, subpopulation definitions
must be specified before the trial starts. We do not consider the more challenging
problem of selecting from a set of candidate biomarkers to define subpopulations
of interest using data accrued in an ongoing trial as in, e.g., (Freidlin and Simon,
2005).
Each participant i, when followed up completely, has full data vector
Di = (Si,Wi, Ai, L
(1)
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where Si denotes subpopulation, Wi is a vector of baseline (pre-randomization)
variables, Ai is the treatment indicator (Ai = 1 indicates treatment and Ai = 0
indicates control), L(1)i , . . . , L
(T )
i are variables observed after randomization, and Yi
is the final (i.e., primary) outcome. We assume that L(1)i , . . . , L
(T )
i , Yi are observed
at preplanned durations d
1
, . . . , dT , dY , respectively, from the time of enrollment,
such that 0 < d
1
< · · · < dT < dY . The subscript i is omitted when referring to a
generic participant.
A special case of interest is where L(1), . . . , L(T ) represent the the same quan-
tity as in the primary outcome, but measured at the earlier times d
1
, . . . , dT ; we
refer to L(1), . . . , L(T ) as short-term outcomes, though in general they can be any
variables measured after randomization. For example, in the MISTIE trial we have
T = 1 and the following data are measured for each participant: subpopulation
S 2 {1, 2} (small IVH and large IVH participants, respectively); baseline variables
W = (NIH Stroke Scale, clot volume, and Glasgow Coma Scale); treatment indi-
cator A; indicator L(1) of functional disability score (mRS)  3 at 30 days from
enrollment; the primary outcome Y , which is the indicator of mRS  3 at 180 days
from enrollment.
4.3.2 Interim Analyses
The timing of interim analyses can be any preplanned function of calendar time
and/or information accrued. Also preplanned are the maximum number of stages
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K and the maximum, cumulative sample size Ns,max for each subpopulation s. At
the start of the trial, all subpopulations are continuously enrolled. Enrollment of
subpopulation s continues until either Ns,max have been enrolled or the preplanned
rule for enrollment restriction causes enrollment to cease. The latter case is called
an early stop for subpopulation s (as opposed to stopping enrollment once the
maximum sample size Ns,max is reached). Enrollment from a subpopulation cannot
be restarted if it has stopped. We assume the first interim analysis time is set so that
at least n
min
participants from each subpopulation have final outcomes observed.
We assume subpopulation enrollment rates are proportional to subpopulation
sizes, i.e., if enrollment has not stopped for subpopulations s and s0, the ratio of
the cumulative number enrolled from subpopulation s and s0 is ps/ps0 .
4.3.3 Assumptions on Data Generating Distribution
The subpopulations enrolled in each stage depend on data from previous stages
and the decision rule for modifying enrollment criteria. For each participant i from
subpopulation s, we assume his/her baseline data Wi is a random draw from an
unknown distribution Q(W )s , independent of the data from all previously enrolled
participants. We assume each participant is randomized with probability 1/2 to
each study arm, independent of subpopulation S and baseline variables W , i.e.,
P (A = 1|S,W ) = 1/2; we call this the randomization assumption. We assume that
for each participant i enrolled during stage k, conditioned on his/her subpopula-
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tion Si and treatment assignment Ai, we have (Wi, L
(1)
i , . . . , L
(T )
i , Yi) is a random
draw from an unknown distribution QSiAi that is independent of the data from all
other participants enrolled at or before stage k.
The sets of unknown distributions are denoted by Q = {Qsa : s = 1, . . . ,m; a =
0, 1} and Q(W ) = {Q(W )s : s = 1, . . . ,m}. We make no parametric model assump-
tions about these distributions. Nor do we assume that L(1), . . . , L(T ) are surrogates
for the primary outcome Y . We assume a nonparametric model where the only as-
sumptions are that P (A = 1|S,W ) = 1/2 by randomization, and that Q and Q(W )
satisfy regularity conditions such as being dominated by  -finite measures ⌫ and
⌫(W ), respectively, as described in Section 4.9.1 of the Appendix.
4.3.4 Definitions of Treatment Effects and Hypotheses
For each s 2 {1, . . . ,m}, define the average treatment effect for subpopulation
s as
 s = E(Y |A = 1, S = s)  E(Y |A = 0, S = s).
For each j 2 {0, . . . , J}, define ˜Sj ✓ {1, . . . ,m} to represent the jth composite pop-
ulation of interest, consisting of the union of subpopulations in ˜Sj . The overall
population, which includes all subpopulations, will generally be a composite pop-
ulation of interest, and we denote it by ˜S
0
= {1, . . . ,m}. The average treatment
90
CHAPTER 4. PHASE III ADAPTIVE DESIGN
effect in composite population ˜Sj is defined as








Throughout,   represents the treatment effect in a subpopulation, and   represents
the treatment effect in a composite population. For each j 2 {0, . . . , J}, let H
0j
denote the null hypothesis of no average benefit of treatment compared to control
for composite population ˜Sj , that is H0j :  j  0; the corresponding alternative
hypothesis is  j > 0. We are interested in testing the set of null hypotheses {H0j :
j = 0, . . . , J}.
4.3.5 Censoring
For each participant i and stage k, we define censoring variables that indicate
which subset of the full data (Si,Wi, Ai, L
(1)
i , . . . , L
(T )
i , Yi) is observed by the end of
stage k. Let C(0)i,k denote the indicator of being enrolled during or prior to stage
k; if C(0)i,k = 1, then at least (Si,Wi, Ai), which are recorded when participant i is
enrolled, are observed by the end of stage k. Let C(t)i,k be the indicator that L
(t)
i is
observed by the end of stage k, and let C(T+1)i,k be the indicator of observing Yi by
the end of stage k. In the special case of the MISTIE trial, for any participant i and




i,k ) has one of the following forms:
• (0, 0, 0): no data observed, i.e., not yet enrolled by end of stage k;
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• (1, 0, 0): subpopulation S, baseline variables W and treatment indicator A
observed;
• (1, 1, 0): S, W , A, and short-term outcome L(1) observed;
• (1, 1, 1): complete data vector (S,W,A, L(1), Y ) observed.
In general, we assume a monotone missingness structure, i.e., that C(t)i,k   C
(t+1)
i,k for
each t 2 {0, . . . , T}, k  K, i  n, and that C(t)i,k  C
(t)
i,k+1 for each t 2 {0, . . . , T +
1}, k  K   1, i  n.
For clarity of presentation, throughout we assume the only cause of missing
data is administrative censoring due to some participants not yet having experi-
enced short-term and/or final outcomes at an interim analysis. In Section 4.8 we
describe how to incorporate additional right censoring due to loss to follow-up,
under the assumptions of censoring at random and that the censoring distribution
can be correctly modeled.
4.3.6 Unadjusted Estimator
For a given population, the unadjusted estimator of the average treatment ef-
fect is defined to be the difference between sample means of the final outcome Y
comparing those assigned to A = 1 versus A = 0. The unadjusted estimator at the
end of stage k uses only data from participants who have Y observed at or before
that time. For each subpopulation s 2 {1, . . . ,m}, the unadjusted estimator of  s at
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i,k 1 [Ai = 0, Si = s]
,
where 1[X] is the indicator variable taking value 1 if X is true and 0 otherwise. The








4.4 Semiparametric, Locally Efficient Estima-
tors that Adjust for Baseline Variables and
Short-term Outcomes
To take advantage of prognostic information in baseline variables and short-
term outcomes, we use estimators that build on the general theory of semipara-
metric, local efficiency of Robins and Rotnitzky (1992). The main advantage of
these estimators versus the unadjusted estimator is that when baseline variables
and short-term outcomes are strongly correlated with the final outcome, as in the
MISTIE trial example, these estimators can have greater precision than standard
estimators. This allows for more informed decisions at interim analyses, improved
power, or reduced expected sample size, with comparable bias, variance and mean
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squared error. We use a targeted maximum likelihood estimator (TMLE) for lon-
gitudinal data developed by van der Laan and Gruber (2012) and implemented in
the R package ltmle (Schwab et al., 2014); this estimator combines features of the
general targeted maximum likelihood template of van der Laan and Rubin (2006)
with the sequential regression approach of (Robins, 2000; Bang and Robins, 2005).
We call this the adjusted estimator. Let ˆ j,k,adj denote the adjusted estimator of  j
based on all data from participants in population ˜Sj collected up to and including
stage k. The precise definition of this estimator is given in Section 4.9.2 of the Ap-
pendix. It is also possible to use the semiparametric, locally efficient estimators of,
e.g., Lu and Tsiatis (2011); Rotnitzky et al. (2012); Gruber and van der Laan (2012);
Parast et al. (2014); Zhang (2015), as we discuss in Section 4.8.
To provide intuition for the adjusted estimator, consider the case of T = 1,
so that each participant’s data is a vector (S,W,A, L(1), Y ). The adjusted estimator
accounts for chance imbalances in short-term outcomes between the following two
groups: those with observed final outcomes, and the larger group of those with
at least short-term outcomes measured; for example, if the short-term outcomes
in this larger group predict worse final outcomes are coming in the pipeline, the
estimator will adjust to reflect this. This adjustment is based on the working model
fits that use data on participants with both short-term and long-term outcomes
to estimate how predictive the former is for the latter. A similar adjustment is
done for chance imbalances in baseline variables between those with at least short-
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term outcomes measured and those with only baseline variables and study arm
assignment measured. The above idea and estimator we use are not new (though
the software implementing this TMLE estimator only recently became available).
What is new is our proposing for a general framework to apply this in adaptive
enrichment designs, and we show this leads to tangible improvements in precision
through simulations in Section 4.6. We also show the impact of such estimators
on power, expected sample size, maximum sample size, bias, variance and mean
squared error.
The adjusted estimator involves working models, e.g., models for the mean of
Y given (L(1), A,W, S 2 ˜Sj) for each j  J , which are fit using data accrued at a
given interim analysis. These are called working models since we do not assume
the true, unknown data generating distribution Q satisfies any of the assumptions
of these models. For example, we use logistic regression models as working mod-
els, but do not assume the conditional distribution of Y given (L(1), A,W, S) has the
functional form of a logistic regression model. Under regularity conditions given
in Section 4.9.1 of the Appendix, the adjusted estimator is consistent; this holds
regardless of whether the working models are correctly specified. If the working
models are correctly specified, then the adjusted estimator achieves the semipa-
rameteric efficiency bound; this is the local efficiency property of the estimator.
When our discussion applies to a generic estimator, we suppress adj and unadj
in the subscript. For a given estimator ˆ j,k of  j , define the corresponding Wald
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statistic Zj,k = ˆ j,k/Var( ˆ j,k)1/2, where Var( ˆ j,k) is the variance of ˆ j,k. For a given
population ˜Sj , the statistics Zj,1, . . . , Zj,K for the adjusted estimator do not gener-
ally have the canonical covariance matrix that arises when estimators (rescaled
by the corresponding information) have the independent increments property de-
scribed in (Scharfstein et al., 1997; Jennison and Turnbull, 1999). This means that
the combination test approach and conditional error function approach (see refer-
ences in Section 4.1) cannot be directly applied, since they assume this property
or more generally the so-called p-clud property, neither of which holds for the ad-
justed estimator. This is shown in Section 4.9.1 of the Appendix.
4.5 Adaptive Enrichment Designs
We use the general framework proposed by Rosenblum et al. (2016) to define
a new adaptive enrichment design, where we employ the error spending function
approach to construct a set of group sequential boundaries for testing the corre-
sponding null hypothesis (Rosenblum et al., 2016, Section 3.2), extending the ap-
proach of Slud and Wei (1982); Lan and DeMets (1983) to multiple populations.
Consider an estimator ˆ j,k and its corresponding Wald statistic Zj,k. We as-
sume Z = {Zj,k}jJ,kK is a multivariate normal family with covariance matrix
⌃, satisfying for all k, EZj,k  0 whenever H0j is true. This assumption holds
asymptotically if { ˆ j,k}jJ,kK are consistent, asymptotically normal estimators,
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such as the unadjusted and adjusted estimators described in Section 4.4. Define
Z0 = {Z 0j,k}jJ,kK to be a multivariate normal family of random variables with
covariance ⌃ and all components having zero mean. Then {Zj,k   EZj,k}jJ,kK
has the same joint distribution as Z0. For clarity, in this subsection we assume ⌃ is
known.
Let ↵⇤ denote the desired upper bound on the familywise Type I error rate, e.g.,
↵⇤ = 0.025 (since we use one-sided tests). Define error spending functions ↵j(t) for
each j 2 {0, . . . , J} that are nondecreasing functions from the nonnegative reals
to [0,↵⇤] that take the value 0 at t = 0 and satisfy
PJ
j=0 ↵j(t)  ↵⇤ for all t > 0.
For each null hypothesis H
0j , at each interim analysis k, let Ij,k = 1/Var( ˆ j,k)
denote the information corresponding to the estimator ˆ j,k. Define the increment
↵j,k = ↵j(Ij,k/Ij,max)   ↵j(Ij,k 1/Ij,max), where Ij,max is a predefined maximum
information level for population ˜Sj , and Ij,0 = 0 for all j. We define information
Ij,k with respect to a particular estimator since this is the relevant quantity for
decisions about interim monitoring when using such an estimator.
Let Rk denote the set of null hypotheses that have been rejected by the end of
interim analysis k, and let R
0




✓ · · · ✓ RK .
The set RK represents all null hypotheses that are rejected by the end of the trial.
We let the rule rk be any prespecified, measurable function from the data ac-
crued up to and including stage k, to the set of subpopulations to enroll during
stage k + 1. An example is given in Section 4.6.3. We assume that once enrollment
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for a population has been stopped, it cannot be restarted. Let Ek denote the sub-
set of null hypotheses H
01
, . . . , H
0J for which all component subpopulations were
enrolled through the end of stage k, i.e.,
Ek = {H0j : for each s 2 ˜Sj, subpopulation s is enrolled through the end of stage k}.
Multiple Testing Procedure M , as stated in Rosenblum et al. (2016):
At each interim analysis k  K, for each j in 0, . . . , J in turn:










0j if H0j /2 Rk 1, j 2 Ek, and Zj,k > uj,k.
The left side of (4.1) can be computed using the multivariate normal distribu-
tion function, e.g., implemented in the mvtnorm R package of Genz et al. (2014),
which takes as input ⌃. Given the previously computed values {uj0,k0}k0k,j0<j , the
solution uj,k to (4.1) can be computed to high precision by the bisection (binary
search) method. Rosenblum et al. (2016) has proved that for any early stopping
rule (adaptive enrichment rule) rk (even modified for any reason during an on-
going trial), multiple testing procedure M strongly controls the familywise Type I
error rate at level ↵⇤.
Above we considered the case where ⌃, is known. In practice, ⌃ will be esti-
mated as the trial progresses, just as in the error spending approach for a single
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null hypothesis in a standard, group sequential design. The covariance matrix ⌃
can be consistently estimated with the nonparametric bootstrap. We describe a
procedure for this in Section 4.9.3 of the Appendix.
4.6 Simulations
4.6.1 Overview
Consider the problem of planning the Phase III MISTIE trial, as introduced in
Section 4.2. The variables (S,W,A, L(1), Y ) defined in the third paragraph of Sec-
tion 4.3 are measured for each participant. We refer to those with small IVH as
subpopulation 1, and those with large IVH as subpopulation 2. The composite
populations of interest are the combined population, denoted by ˜S
0
= {1, 2}, and
subpopulation 1, denoted by ˜S
1





. In the adaptive enrichment design literature, it is not uncommon to
focus on the null hypotheses for a single subpopulation and the combined popu-
lation, e.g., Wang et al. (2007); Brannath et al. (2009); Jenkins et al. (2011); Boessen
et al. (2013), Stallard et al. (2014, Section 5). We assume p
1
= 1/3 based on prior
studies (Hanley, 2012). We assume the enrollment rate to be 50 patients per year
for subpop 1, and 100 for subpop 2, based on projected enrollment rates for the
MISTIE Phase III trial.
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The clinical investigators in the MISTIE trial were interested in the following

















in scenario (a) are based on the point estimate of the average
treatment effect from the MISTIE II trial. We had the following goals: (i) 80%
power to reject H
00
in scenario (a); (ii) 80% power to reject H
01
in scenario (b); (iii)
strong control of familywise Type I error rate at level ↵⇤ = 0.025. These goals were
also considered by Rosenblum et al. (2016) in the context of immediately observed
outcomes and not considering baseline variables. This allows us to compare the
impact of delayed outcomes and adjusted estimators versus the simpler case of
immediately observed outcomes considered there.
4.6.2 Data Generating Distributions used in Simula-
tion Study
To make our simulations realistic, we mimic features in the data from the com-
pleted MISTIE II trial introduced in Section 4.2. A simple approach would be to
construct simulated trials by resampling with replacement from the MISTIE II data,
so that the data generating distribution is the empirical distribution of the MISTIE
II data. Unfortunately, the resampling distribution does not satisfy the key fea-
ture of a randomized trial that is set by design, i.e., that treatment A is assigned
independently of baseline variables. This assumption is violated in the empirical
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distribution of the MISTIE II data since there are slight correlations between base-
line variables and treatment assignment in the actual MISTIE II data set (as would
generally be expected in any given dataset). Furthermore, since no two partici-
pants in this data have identical values of the baseline variables W , the treatment
A is a deterministic function of W .
We construct data generating distributions that mimic key features of the MISTIE
II data, while satisfying the randomization assumption. Specifically, we construct
distributions that have similar correlations among W,L(1), Y as the Phase II trial
data. This is achieved by augmenting the original data set by adding, for each par-
ticipant, a “twin" participant with identical baseline variables but opposite treat-
ment assignment, whose L and Y values are generated using regression models
fit to the original data, with perturbations to the outcomes Y depending on the
desired treatment effect in each subpopulation. Each scenario has a different data
generating distribution, based on resampling with replacement from a suitably
augmented data set, as described in Section 4.9.4 of the Appendix. We assume the
enrollment rate is constant over time.
4.6.3 Specific Adaptive Enrichment Design Used
We define our adaptive enrichment design by first giving the multiple test-
ing procedure and enrollment modification rule, and then presenting the interim
analysis timing and error spending functions. We use multiple testing procedure
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M , described in Section 4.5. The enrollment modification rule rk involves futility
boundaries lj,k defined below. The following encodes our enrollment modification
rule (and indicates when null hypotheses are rejected, based on multiple testing
procedure M ) at the interim analysis just after completion of stage k  K:
1. if Z
0,k > u0,k or Z1,k > u1,k reject the corresponding null hypotheses and stop
the trial;
2. else, if Z
1,k  l1,k or k = K stop all enrollment;
3. else, if both subpopulations were enrolled during stage k and Z
2,k  l2,k,
stop subpopulation 2 enrollment but continue subpopulation 1 enrollment
in stage k + 1;
4. else, if k < K enroll the same subpopulations in stage k + 1 as in stage k.
This design strongly controls the familywise Type I error rate at level ↵⇤. Step 2 is
motivated by the clinical investigator’s judgment that if the treatment benefits any
subpopulation, it will very likely benefit subpopulation 1, so we should stop the
entire trial for futility if Z
1,k is below its futility boundary l1,k. The above design
(steps 1-4) is just one possible choice; our general method can be applied for any
enrollment rule rk if multiple testing procedure M is used.
It remains to define the timing of interim analyses and the error spending func-
tions. We set the maximum number of stages K = 5. Alpha spending functions
are from the ⇢-family of Jennison and Turnbull (1999, Section 7.3) at ⇢ = 2, i.e.,
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0,max, I1,max, and each lj,k were
chosen by searching over a set of candidate values to find those that minimize the
average of the expected sample size over scenarios (a)-(c), under the constraint that
goals (i)-(iii) are satisfied. We followed the optimization procedure from Rosen-






0,max = 1115, I1,max = 795 and the lj,k values given in Table 4.1. The futility bound-
aries lj,k equal 0 in most cases, with the notable exception l2,3 = 1; this causes
enrollment of subpopulation to stop at or before interim analysis 3; intuitively, this
is because at interim analysis 3, sufficient information has accrued to achieve goal
(i), so that further enrollment of subpopulation 2 would be counterproductive.
We use information-based monitoring times, i.e., we set the timing of interim
analyses to occur when the accrued information reaches certain preset fractions
of the maximum information values Ij,max, j = 0, 1 (which were preset as above
based on desired values of power and Type I error under scenarios (a)-(c), and do
not differ by the estimator used). The impact is that interim analyses will occur
earlier in terms of calendar time (and number of participants enrolled) when us-
ing the adjusted estimator rather than the unadjusted estimator, since information
accrues more quickly for the former. Each of the first three interim analyses occurs
when the information accrued for the combined population reaches the equally
spaced increments 1/3, 2/3, 1 times I
0,max, i.e., each interim analysis k 2 {1, 2, 3} is
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triggered when the accrued information for the combined population reaches the
threshold I
0,k = t0,kI0,max = (k/3)I0,max. If subpopulation 2 is stopped before the
end of stage 3, then future interim analysis timing is based on accrued information
for subpopulation 1, which has equal increments for the first three stages. Since
our rule rk always stops subpopulation 2 at or before interim analysis 3, we set the
4th and 5th interim analysis times based on the information for subpopulation 1;
specifically, interim analysis 4 occurs when the accrued information for subpopu-
lation 1 reaches the midpoint between the information that accrued by the end of
stage 3 (I
1,3) and the maximum I1,max.
In addition to comparing the unadjusted and adjusted estimators, we consider
a modified data generating distribution where the baseline variables W and the
short-term outcome L(1) are exogenous, i.e., independent of the treatment and out-
come. This is to assess whether the adjusted estimator performs worse than the
unadjusted estimator when the adjustment variables are pure noise. We denote
the TMLE under this type of data generating distribution by TMLE prog;, and de-
note the TMLE using the data generating distributions in Section 4.6.2 (where W
and L(1) are prognostic) by TMLE progW,L.
For each stage and each estimator, Table 4.1 shows the cumulative sample sizes
corresponding to the above information levels. Because information accrues more
quickly when using the adjusted estimator TMLE progW,L, its corresponding sam-
ple sizes are smaller than those for the unadjusted estimator and for TMLE prog;.
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Table 4.2 shows the per-stage information levels Ij,k for each estimator. There are
small differences between the corresponding values for each estimator due to our
interim analysis times being selected from a discrete set of calendar times (that
were closest to achieving the information thresholds above).
Table 4.3 gives the increments ↵j,k for the unadjusted estimator, which are com-
puted at the end of each stage k from the error spending function ↵j(t) = cj min{t2, 1}
evaluated at t = tj,k = Ij,k/Ij,max. These values differ very slightly by scenario and
by estimator due to slight differences in the covariance matrix ⌃ and the informa-
tion levels at which analyses are conducted.
Table 4.1: Adaptive enrichment design per-stage sample sizes for scenarios (a) -
(c). The cumulative sample size (Cum.S.S.) at each interim analysis has the for-
mat: number of participants with Y observed (+ number enrolled with Y not yet
observed).
Interim Analysis (k) 1 2 3 4 5
Unadjusted estimator
Cum.S.S. Subpop. 1 104 (+24) 208 (+24) 312 (+24) 480 (+24) 648 (+0)
Cum.S.S. Subpop. 2 208 (+49) 416 (+49) 624 (+0) 624 (+0) 624 (+0)
Cum.S.S. Comb. Pop. 312 (+73) 624 (+73) 936 (+24) 1104 (+24) 1272 (+0)
Adjusted estimator (TMLE progW,L)
Cum.S.S. Subpop. 1 84 (+24) 168 (+24) 252 (+24) 382 (+24) 512 (+0)
Cum.S.S. Subpop. 2 168 (+49) 336 (+49) 504 (+0) 504 (+0) 504 (+0)
Cum.S.S. Comb. Pop. 252 (+73) 504 (+73) 756 (+24) 886 (+24) 1016 (+0)
Futility Boundary (l
1,k) 0 0 0 0 -
Futility Boundary (l
2,k) 0 0 1 - -
The efficacy boundaries uj,k, which are determined by (4.1), depend on the co-
variance matrix ⌃ of the statistics under consideration. To ease the computational
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Table 4.2: When using the adjusted or unadjusted estimator, information accrued
at each stage for subpopulation 1, subpopulation 2, and the combined population.
adjusted estimator unadjusted estimator
stg 1 stg 2 stg 3 stg 4 stg 5 stg 1 stg 2 stg 3 stg 4 stg 5
Subpop. 1 124 250 370 558 749 126 251 376 590 795
Subpop. 2 256 524 763 249 487 739
Comb. Pop. 389 785 1140 372 740 1115
Table 4.3: Type I error (↵) spent at each stage, for the unadjusted estimator in
scenario (a). Results are very similar for the other scenarios and the adjusted esti-
mator.
Interim Analysis (k) 1 2 3 4 5
↵
0,k (for Comb. Pop.) 0.0004 0.0011 0.0016
↵
1,k (for Subpop. 1) 0.0006 0.0019 0.0029 0.0068 0.0098
Table 4.4: Efficacy boundaries for scenario (a) and unadjusted estimator. Efficacy
boundaries under other scenarios and for the adjusted estimator are very similar,
with all absolute differences within 0.01 of those below.








1,k) 3.27 2.89 2.66 2.33 2.14
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burden in our simulations, we precomputed an approximation to ⌃ using Monte
Carlo simulation, and treated ⌃ as known, as described in Section 4.9.3 of the Ap-
pendix. The resulting boundaries uj,k for scenario (a) and the unadjusted estimator
are given in Table 4.4. These boundaries were quite similar for both estimators and
each scenario (a)-(c) (maximum absolute difference within 0.05).
4.6.4 Results: Power, Expected Sample Size, and Max-
imum Sample Size
Based on 50,000 simulated trials for each estimator and each scenario (a)-(c),
we computed the empirical Type I error, power, and expected sample size (ESS,
defined as the expected number enrolled, which includes those in the pipeline). In
computing Type I error, we assume there is no early futility stopping, in order to
ensure the familywise Type I error rate is at most 0.025 even when futility bound-
aries are ignored. In all other computations, we assume the futility boundaries are
adhered to.
Figure 4.1 shows the probability of rejecting at least H
00
and at least H
01
at
each interim analysis. Plots 4.1a and 4.1d display power to reject at least H
00
un-
der scenario (a), and power to reject at least H
01
under scenario (b), respectively.
These plots demonstrate that goals (i) and (ii) from Section 4.6.1 are approximately
achieved by all estimators. Plots 4.1b and 4.1c show low power for all estimators
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to reject at least H
00
when only subpopulation 1 benefits, and to reject at least H
01
when both subpopulations benefit. This behavior may be regarded as advanta-
geous since it is ideal to reject only H
00
in scenario (a) and only H
01
in scenario
(b), these corresponding precisely to the populations who benefit in each scenario,
respectively.
The top half of Table 4.5 corresponds to the adaptive design from Section 4.6.3,
and shows the value added from using the adjusted estimator when baseline vari-
ables and short-term outcomes are prognostic. We compare the unadjusted esti-
mator, the adjusted estimator (denoted TMLE progW,L), and the adjusted estima-
tor where W and L are set to be exogenous (denoted prog;). Using the adjusted
estimator (TMLE progW,L) instead of the unadjusted estimator (unadj) leads to a
reduction in expected sample size of 20% under scenario (a), 19% under scenario
(b), and 19% under scenario (c). Also, the maximum sample size for the design us-
ing the adjusted estimator (TMLE progW,L) is 20% less than that for the unadjusted
estimator. In each of scenarios (a) and (b), the power of each estimator is very sim-
ilar due to the information-based design using the same I
max
for each estimator.
All the gains from adjusting for prognostic W and L are channeled to reducing the
expected sample size. In scenario (c), the familywise Type I error rate (assuming no
early stopping) is 0.025 for each estimator, as desired; early futility stopping would
only decrease the Type I error. Comparing the unadjusted estimator versus TMLE
prog; shows that when W and L provide no prognostic information, the adjusted
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estimator is almost identical to the unadjusted estimator in power and expected
sample size.
The design from Section 4.6.3 involves a rule for early stopping of subpopula-
tion 2 for futility while subpopulation 1 is continued if Z
2,k  l2,k at interim analy-
sis k = 1 or k = 2; we call this the adaptive enrichment feature. To show the value
added by this feature, consider the same design except setting l
2,1 = l2,2 =  1,
which disables the ability to stop only subpopulation 2 for futility based on Z
2,k be-
fore stage 3. We call this the non-adaptive design, and its performance in scenarios
(a)-(c) is shown in the bottom half of Table 4.5. The main difference between this
design and the adaptive design from Section 4.6.3 is that the former has substan-
tially larger expected sample size in scenarios (b) and (c). This is not surprising,
since it is in these scenarios when futility stopping of subpopulation 2 is espe-
cially useful. The two designs have similar power and Type I error rate in all three
scenarios, and similar expected sample sizes in scenario (a). In the non-adaptive
design, the adjusted estimator (TMLE progW,L) substantially reduces the expected
sample size compared to the unadjusted estimator, just as for the adaptive design.
Though it is possible to further modify the non-adaptive design to remove the rule
that subpopulation 2 enrollment is always stopped at or before the end of stage 3,
this would only result in increased expected sample sizes in scenarios (b) and (c),
and would not help attain the goals from Section 4.6.1 since these are already met
by the non-adaptive design.
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Figure 4.1: Stage-wise and overall power bars comparing TMLE and unadjusted
estimator. Top row corresponds to scenario (a); bottom row corresponds to sce-
nario (b). Left column represents power to reject at least H
00
; right column repre-
sents power to reject at least H
01
. Black bar corresponds to adjusted estimator that
leverages prognostic W and L; yellow bar corresponds to adjusted estimator with
non-prognostic W and L; white bar corresponds to the unadjusted estimator.
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Table 4.5: Power and expected sample size (ESS) for adaptive and non-adaptive
designs. Power under scenario (a) is the probability of rejecting at least H
00
; power









ESS Type I error ESS
Estimator:
unadjusted 0.79 712 0.82 795 0.025 640
TMLE progW,L 0.81 568 0.82 643 0.025 521
TMLE prog; 0.79 711 0.82 794 0.025 638
Non-Adaptive Design





ESS Type I error ESS
Estimator:
unadjusted 0.80 718 0.82 958 0.025 729
TMLE progW,L 0.82 575 0.82 771 0.025 591
TMLE prog; 0.80 718 0.81 959 0.025 727
4.7 Bias, Variance, and Mean Squared Error
of Estimators
We now change focus from hypothesis testing to estimation of the average treat-
ment effect for each subpopulation and the combined population when using the
adaptive design in Section 4.6. For a given subpopulation s, consider the unad-
justed and adjusted estimators evaluated at the end of the last stage in which sub-
population s gets enrolled. These estimators generally suffer from selection bias
induced by early stopping rules. Our goal is to investigate whether such bias is
better or worse when using the adjusted/unadjusted estimator, and when using
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the adaptive design from Section 4.6.3 versus the corresponding non-adaptive de-
sign defined in 4.6.4. We consider not only the bias, but also the standard error and
mean squared error of the unadjusted and adjusted estimators in scenarios (a)-(c).
We first summarize our findings. The bias, standard error, and mean squared
error are very similar for the unadjusted and adjusted estimators in all cases. Also,
these quantities are very similar comparing the adaptive design from Section 4.6.3
to the corresponding non-adaptive design defined in 4.6.4. This is reassuring, in
that these quantities are not worse when using the adaptive design and/or the
adjusted estimator (each of which provides benefits in terms of sample size reduc-
tion).
We consider the design from Section 4.6.3. Let   denote the covariance matrix
of the estimators {ˆ 
1,k, ˆ 2,k, ˆ 0,k : k = 1, 2, 3, 4, 5}, which is related to the covariance
⌃ of the corresponding Wald statistics by ⌃ij =  ij( ii jj) 1/2 for each i, j. Let
ˆk(s) denote the last stage in which subpopulation s is enrolled. This is a random
quantity, since early stopping of a subpopulation depends on accrued data. For a
given stagewise estimator ˆ s,k of  s, define  ?s = ˆ s,ˆk(s), i.e., the estimator evaluated
at the last stage subpopulation s is enrolled. Similarly, for any composite popu-
lation ˜Sj and estimator ˆ j,k, define the final estimator as the following weighted
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We focus on estimators of the average treatment effect for each subpopulation
and for the combined population. For a given estimator (adjusted or unadjusted),
design, and data generating distribution, the bias in estimating the subpopulation
s average treatment effect  s is E [ ?s ]    s, the standard error is {E[ ?s   E[ ?s ]]2}1/2
while the mean squared error is E[ ?s    s]2.
Computation is based on Monte-Carlo simulation. To make the computation
feasible, instead of generating a data vector for each trial participant, we use the
asymptotic approximation of the estimators {ˆ 
1,k, ˆ 2,k, ˆ 0,k : k = 1, 2, 3, 4, 5} and
corresponding Wald statistics {Z
1,k, Z2,k, Z0,k}, k = 1, . . . , 5 as having a multivariate
normal distributions with covariance matrices   and ⌃ computed by the method
in the last paragraph of Section 4.6.3. The standard error ses,k of the estimator ˆ s,k
is the square root of the corresponding element on the main diagonal of  .




, we generated 50,000 independent ran-
dom vectors of the Wald statistics {Z
1,k, Z2,k, Z0,k}, k = 1, . . . , 5 from the corre-
sponding multivariate normal distribution using the rmvnorm function from the
mvtnorm R package (Genz et al., 2014). For each vector, the stopping time ˆk(s)
is then determined for each subpopulation s based on the stopping rule in Sec-
tion 4.6.3. Next, we set  ?s = ˆ s,ˆk(s) = Zs,ˆk(s)ses,ˆk(s) using the precomputed standard
errors ses,k. The estimator  ?
0
is set using equation (4.2). The above procedure






), from which the empirical bias,
standard error and mean squared error can be computed. For example, the average
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Table 4.6 shows that the bias, standard error and mean squared error are very
similar for the adaptive design and standard design(where we will always enroll
subpopulation 2 until stage 3 if no early termination of the whole trial), and for the
unadjusted and adjusted estimators in scenarios (a)-(c).
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4.8 Remarks
Alternative methods exist for covariate adjustment in our longitudinal setting,
e.g., the estimators of Lu and Tsiatis (2011); Rotnitzky et al. (2012); Gruber and
van der Laan (2012). These estimators have enhanced efficiency properties, but to
the best of our knowledge there is not currently an R package implementing any of
these methods that incorporates both baseline variables and short-term outcomes.
It is an area of future work to apply these advanced methods in the context of
adaptive enrichment designs.
We assumed that the only cause of missing data was administrative censoring
due to some participants not yet having their final outcomes observed. In Sec-
tion 4.9.2 of the Appendix, we describe how to incorporate additional right cen-
soring due to loss to follow-up, under the assumption of censoring at random, i.e.,
the sequential randomization assumption in (van der Laan and Gruber, 2012) stat-
ing that censoring is conditionally independent of the potential outcomes given
the past observed data.
We focused on outcomes measured a fixed duration from enrollment. Our
adaptive design framework in Section 4.5 can also be applied for survival times,
e.g., by using a modified TMLE or the estimators of Lu and Tsiatis (2011); Parast
et al. (2014); Zhang (2015).
When a decision is made to stop a subpopulation or the entire trial early for ef-
ficacy, the corresponding null hypothesis is immediately rejected without waiting
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for pipeline patients to complete the trial. It is possible to improve efficiency by
waiting until pipeline patients complete the trial, and using a modified test that
takes their outcomes into account, e.g., by extending the approach of Hampson
and Jennison (2013) that was developed for standard, group sequential designs
and a single population. It is an open problem to extend this method to our setting
where we desire strong control of the familywise Type I error rate, since this is not
guaranteed if we directly apply their method in our context (which their method
was not designed for).
We stated in Section 4.4 that the covariance matrix ⌃ does not generally have
the canonical structure from (Scharfstein et al., 1997; Jennison and Turnbull, 1999)
in the case where ˆ j,k is the adjusted estimator. This does not contradict the main
result of Scharfstein et al. (1997), since the adjusted estimator is generally not glob-
ally, semiparametric efficient (only locally efficient); in general, no globally, semi-
parametric efficient estimator exists for our problem, unless one makes model as-
sumptions on the outcome distributions (which we avoid since these cause biased
and difficult to interpret estimates when the model assumptions fail to hold). The
above issue does not pose any problem for our framework in Section 4.5, since the
error spending function approach can be applied without requiring the canonical
structure of Scharfstein et al. (1997); Jennison and Turnbull (1999).
We focused on the case of two subpopulations of interest. The general frame-
work in Section 4.5 can be applied to any number of subpopulations and composite
117
CHAPTER 4. PHASE III ADAPTIVE DESIGN
populations. However, as the number of such populations increases, the required
sample size to achieve high power for each population (while maintaining strong
control of the familywise Type I error rate) will also increase. It is an open prob-
lem to determine how many populations can be accommodated before sample size
becomes prohibitively large.
4.9 Appendix
4.9.1 Regularity Conditions for Q and Q(W ) and Asymp-
totic Results
We define our asymptotic framework, and then show that the unadjusted and
adjusted estimators are consistent and asymptotically normal. Consider any dis-
tributions Q and Q(W ) that satisfy the regularity conditions in Theorem A5 in Ap-
pendix A18 of van der Laan and Rose (2011). These conditions imply the TMLE
that we used, described in Section 4.9.2 of the Appendix below, is consistent and
asymptotically normal, under independent, identically distributed sampling of
participants. The sampling in our designs is slightly different, but the same re-
sults hold in our setting, as described below.
We use the notation L(T+1) to represent the final outcome Y . Let N (t)s,k denote the
cumulative number of participants enrolled from subpopulation s by the end of
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i,k1[Si = s]. Similarly, let ˜N
(t)
j,k denote the cumulative number of participants
enrolled from composite population ˜Sj by the end of stage k who have (at least)




i,k1[Si 2 ˜Sj]. Define
Ns,k = N
(0)
s,k , i.e., the cumulative number enrolled from subpopulation s by the
end of stage k, assuming no early stopping. Similarly, let ˜Nj,k = ˜N
(0)
j,k , i.e., the the
cumulative number enrolled from composite population ˜Sj by the end of stage k,
assuming no early stopping. Let Ci,k = {C(t)i,k}
T+1
t=0 .
Let e denote the combined population enrollment rate in number of partici-
pants per day, which we assume to be constant over time. By the assumption from
Section 4.3 of sampling proportional to subpopulation size, the enrollment rate for
subpopulation s is eps. The maximum trial duration is the time from the start of
enrollment to the time the last participant has his/her final outcome Y observed if
there is no early stopping, which equals
D = max
s2{1,...,m}
Ns,max/(eps) + dY . (4.3)
(Recall dY is the delay time from enrollment to observation of Y .) The maximum
total sample size is denoted by N =
P
s2{1,...,m} Ns,max.
In our asymptotic framework, we fix the maximum trial duration, the delay
times d
1
, . . . , dT , dY , and the interim analysis times. These are in terms of calendar
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time, but can equivalently be expressed in terms of information time. We let the
maximum total sample size N go to infinity such that the cumulative sample size
proportions {Ns,k/N}sm,kK converge to a fixed set of nonnegative proportional-
ity constants {qs,k}sm,kK that satisfy qs,k  qs,k+1 for each k < K and
P
s qs,K = 1.
Let q̃j,k =
P
s2 ˜Sj qs,k. Since we fix the maximum trial duration D and delay times
d
1
, . . . , dT , dY , this implies by (4.3) that the combined population enrollment rate e











Ns,max/{ps(D dY )} = max
s2{1,...,m}
qs,K/{ps(D dY )}, (4.4)
where the rightmost term is a nonnegative constant.
The number of pipeline participants in subpopulation s at interim analysis k <
K, assuming enrollment has not stopped for subpopulation s, is epsdY ; therefore,
by (4.4), the proportion of enrolled participants from subpopulation s that are in















This shows that the proportion of enrolled participants from subpopulation s that
are in the pipeline at interim analysis k converges to a nonnegative constant (that
depends on s and k). This is a desirable feature of our asymptotic framework,
since it allows us to consider the impact, in the limit, of a constant fraction of par-
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ticipants in the pipeline at each interim analysis. In contrast, if this proportion had
converged to zero then the asymptotic framework would not reflect the impact of
pipeline participants (since their impact would disappear asymptotically). We will
see that the pipeline participants can improve precision of the adjusted estimator,
if baseline variables or short-term outcomes are prognostic of the final outcome.
Our asymptotic framework has the following similarities with that of Scharf-
stein et al. (1997, Section 2): data are collected over a fixed time interval (that does
not change with sample size); each participant’s data is a longitudinal process;
sample size goes to infinity, which implies the average number enrolled per unit of
time goes to infinity and that the expected proportion enrolled at each interim anal-
ysis k converges to a constant (that depends on k); in the special case of fixed delay
times, the expected proportion in the pipeline at interim analysis k converges to a
constant (that depends on k). The main differences between these frameworks are
the following: we assume a constant enrollment rate and fixed delay times while
they consider a random enrollment process and participant data can be measured
at variable times (or in continuous time); they assume the existence of a globally,
semiparametric efficient estimator, while we do not. The main reason we focus on
a constant enrollment rate is that it makes computations faster in our simulations,
since for any Q,Q(W ) and any information-based monitoring times, the stage-wise
cumulative sample sizes N (t)s,k are then fixed. It is an area of future work to let these
sample sizes be variable (depending on randomness in the enrollment procedure),
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and to do all analyses conditional on the observed enrollment times. The frame-
work of Scharfstein et al. (1997, Section 2) also has the important advantage that it
allows for changes to the population distribution over time; however, it requires
existence of a globally semiparametric efficient estimator, which is generally not
available for our problem setting without making parametric model assumptions
or smoothness assumptions on the model for Q,Q(W ), which we do not do.
In order to illustrate the main idea behind our results, we first consider the
special case where the following hold: there is no early stopping, i.e., each sub-
population s is enrolled until Ns,max is reached; T = 0 (no short-term outcome);
and the only cause of missing data is administrative censoring (as defined in Sec-
tion 4.3.5). Even in this special case, Wald statistics based on the adjusted estimator
(TMLE) do not generally have the canonical covariance matrix of Scharfstein et al.
(1997); Jennison and Turnbull (1999). In this special case, the censoring times Ci,k
are fixed (non-random) and independent of the participant data {Di}Ni=1. It also
follows by the assumptions in Section 4.3.3 that the data {Di}Ni=1 are independent,
identically distributed vectors Di = (Si,Wi, Ai, Yi) drawn from the data generat-
ing distribution ˜Q = (Q,Q(W )) (and P (A = 1|W,S) = 1/2 by the randomization
assumption). We let D denote a generic vector with components (S,W,A, Y ) hav-
ing this distribution. We use the TMLE ˆ s,k defined in Section 4.9.2 that uses the
known quantities P (A|W,S) = 1/2 and the known fractions of total participants
i 2 {1, . . . , N} who have C(t)i,k = 1, i.e., the fraction N
(t)
s,k/N . Let P ⇤(Y = 1|A,W, S)
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denote the limit in probability of the working logistic regression model for the
corresponding probability; this model will generally be misspecified, and P ⇤ de-
notes its limit which may differ from the true conditional probability. Under the
aforementioned regularity conditions, ˆ s,k is consistent for the average treatment
effect  s and is asymptotically normal, i.e., (where op(1) represents a quantity that
converges to 0 in probability as N goes to infinity)
p






IFs,k(Di) + op(1), (4.5)


















{P ⇤(Y = 1|A = 1,Wi, Si)  P ⇤(Y = 1|A = 0,Wi, Si)   s} .
(4.7)
The influence function IFs,k(Di) depends on ˜Q and the fixed (non-random) set of
censoring times Ck = {Ci,k}Ni=1, but we suppress this in our notation for concise-
ness. The above asymptotic distribution follows from Theorem A5 in Appendix
A18 of van der Laan and Rose (2011), except using the empirical process result
for non-identically distributed (but independent) random variables of Alexander
(1984) that handles a fixed sequence of censoring times rather than random, in-
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dependent, identically distributed censoring times; the results are analogous by
the assumption above that the censoring is due only to administrative censoring
that is independent of the participant data Di. The form of the influence function
IFs,k(Di) is similar to the form in van der Laan and Gruber (2012) except that we
use the known value 1/2 in place of P (A = Ai|Wi, Si) and the known censoring
frequency N (t)s,k/N in place of P (C
(t)
i,k = 1) for each t 2 {0, 1}.




{Y   P ⇤(Y = 1|A,W, S)} ;
H(0)s (D) = [P
⇤
(Y = 1|A = 1,W, S)  P ⇤(Y = 1|A = 0,W, S)   s] .
Let Vars and Covs denote variance conditional on S = s and covariance condi-
tional on S = s, respectively.
It follows from (4.5) that for any stages k  k0  K the asymptotic covariance
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An important feature of (4.8) is that the covariance term does not generally equal 0
if the limit distribution P ⇤(Y = 1|A,W, S) of the logistic regression working model
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does not equal the true distribution P (Y = 1|A,W, S), which we expect will gener-
ally occur in practice due to misspecification of the outcome regression model. As
we discuss below, this is the reason that the Wald statistics derived from the TMLE
estimator do not have the canonical covariance structure of Scharfstein et al. (1997);
Jennison and Turnbull (1999).
We now give analogous results as above, but for estimators of  j rather than of
 s.
p






IF j,k(Di) + op(1), (4.9)


















{P ⇤(Y = 1|A = 1,Wi, Si)  P ⇤(Y = 1|A = 0,Wi, Si)   s} .
(4.11)






{Y   P ⇤(Y = 1|A,W, S)} ;
˜H
(0)
j (D) = [P
⇤
(Y = 1|A = 1,W, S)  P ⇤(Y = 1|A = 0,W, S)  j] .
Let Varj and Covj denote variance conditional on S 2 ˜Sj and covariance condi-
tional on S 2 ˜Sj , respectively. By a similar derivation as above, for any stages
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I⇤j,1( ˆ j,1   j), . . . , I⇤j,K( ˆ j,K   j)
⌘
converges to a multivariate normal distribution with zero mean vector and covari-






which does not generally equal I⇤j,k due to the covariance term in (4.12) which
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depends on k as well as k0. In contrast, if that covariance term were equal to 0,
then we would have acov( ˆ j,k, ˆ j,k0) = avar( ˆ j,k0) which implies (4.13) equals
I⇤j,k; this means that the asymptotic covariance matrix of the (scaled) Wald statis-
tics would have an independent increments structure as in Scharfstein et al. (1997,
Theorem 1) and Jennison and Turnbull (1999, Chapter 3). The impact is that mul-
tiple testing procedures based on the p-value combination approach may not be
applicable, since they require independent increments or the more general p-clud
property (that under the null hypothesis, the conditional distribution of each stage
k p-value given all prior stage data stochastically dominates the uniform distribu-
tion on [0, 1]), neither of which are guaranteed to hold in our setting when using
the adjusted estimator.
The covariance term in (4.12) does not generally equal 0 in our setting if the
logistic regression model used in the TMLE for P (Y = 1|A,W, S = s) (called the
outcome regression model) is misspecified. This is because the limit distribution
P ⇤(Y = 1|A,W, S) of such a misspecified model will not equal the true distribution
P (Y = 1|A,W, S), and so Y   P ⇤(Y = 1|A,W, S) will generally not be orthogonal
to all functions of A,W, S. We expect the outcome regression model to be at least
somewhat misspecified in practice for W continuous valued with a few or more
components.
In contrast, if the outcome regression model were correctly specified, then P ⇤(Y =
1|A,W, S) = P (Y = 1|A,W, S) and so Y   P ⇤(Y = 1|A,W, S) would be orthogo-
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nal to all functions of A,W, S; then the covariance term in (4.8) would equal 0.
The TMLE is semiparametric efficient at a given distribution ˜Q if and only if the
limit P ⇤ of the outcome regression model equals the true distribution of Y given
A,W, S; that is why the corresponding covariance term disappears in the setting
of Scharfstein et al. (1997) (where a semiparametric efficient estimator is assumed)
resulting in the canonical distribution in their Theorem 1. We also note that in
the special case where the outcome regression working model is a linear model,
then the covariance term equals 0; however, for other working models (including
logistic regression) the covariance term will not disappear.
Above we considered a special case where T = 0, there is no early stopping,
and the only cause of missing data is administrative censoring. We now relax these
constraints one by one. Consider the case of arbitrary T > 0. The results above are
similar, except that the influence function for ˆ s,k has additional components, as






































{P ⇤(Y = 1|A = 1,Wi, Si)  P ⇤(Y = 1|A = 0,Wi, Si)   s} . (4.14)
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The above holds since in the case only administrative censoring and no early stop-
ping, the censoring times C(t)i,k are fixed (non-random) and Di are independent,
identically distributed, by the assumptions above. An analogous generalization of
the influence function for  j,k holds. The covariance formulas (4.8) and (4.12) have
additional components corresponding to the additional terms in (4.14).
Consider the case where there is early stopping according to a prespecified rule
rk. Then the above asymptotic linearity result (4.5) holds only up through stages in
which subpopulation s is enrolled. Similarly, the above asymptotic linearity results
(4.9) and (4.13) hold only up through stages in which every subpopulation s 2 ˜Sj is
enrolled. If enrollment is stopped early for any subpopulation, the corresponding
estimators and Wald statistics involving that subpoplation are no longer used in
the multiple testing procedures in Section 4.5, by construction. Therefore, asymp-
totically, the multiple testing procedure has familywise Type I error rate equal to
that computed by assuming the statistics Zj,k have the asymptotic, multivariate
normal distribution with zero mean vector and covariance matrix (4.13).
The form of the influence functions given above assumed that we use the TMLE
ˆ s,k defined in Section 4.9.2 that uses the known quantities P (A|W,S) = 1/2 and
the known fractions of total participants i 2 {1, . . . , N} who have C(t)i,k = 1, i.e., the
fraction N (t)s,k/N . If P (A|W,S) and P (C
(t)
i,k = 1|¯L(t 1), C
(t)
i,k = 1, A,W, S) are instead
estimated using logistic regression models (which is what we used for the TMLE
in our simulations), then each influence function is as above except one subtracts
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its projection on the space of nuisance scores corresponding to these models, as de-
scribed in (van der Laan and Gruber, 2012, Section 4). This leads to unchanged or
reduced asymptotic variance, and may also affect the asymptotic covariance. The
nonparametric bootstrap can still be used as a consistent estimator of the covari-
ance matrix of the adjusted estimator ˆ j,k (and of the corresponding Wald statis-
tics).
Last, we consider the case where data are missing not only due to administra-
tive censoring but also due to drop-out. Under the assumption that drop-out is a
random, right-censoring process satisfying the censoring at random assumption,
i.e., the sequential randomization assumption in (van der Laan and Gruber, 2012),
the above results can be generalized. Additional missing outcomes due to drop-
out will generally reduce the information available at each interim analysis. Also,
unless outcomes are assumed to be missing completely at random (i.e., indepen-
dent of D), consistency of the adjusted and unadjusted estimators will generally
require additional assumptions such as that the outcome regression model or cen-
soring model is correctly specified. This reflects the double robustness property of
the TMLE, which is described in (van der Laan and Gruber, 2012).
4.9.2 TMLE Estimator
We give an overview of the targeted maximum likelihood estimator of van der
Laan and Gruber (2012) that is implemented in the R package ltmle (Schwab et al.,
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2014), and describe the details of our implementation of this estimator (called
the adjusted estimator in the main paper); this estimator combines features of
the general targeted maximum likelihood template of van der Laan and Rubin
(2006) with the sequential regression approach of (Robins, 2000; Bang and Robins,
2005). We focus on the setting with a single short-term outcome, i.e., T = 1,
which was used in our simulation studies; the more general case of T > 1 is de-
scribed by van der Laan and Gruber (2012). Assume the longitudinal data struc-
ture D = (S,W,A, L, Y ), where S is the subpopulation, W is the vector of baseline
variables, A is the treatment assignment, L = L(1) is the short-term outcome, and
Y is the final outcome. At each interim analysis k < K, only a subset of those en-
rolled have the short-term outcome observed, and a further subset have the final
outcome observed.
Consider any interim analysis k  K. Let CL denote the indicator that L is
observed and let CY denote the indicator that Y is observed. (Formally, for each
participant i, we define CL,i = C
(1)
i,k and CY,i = C
(2)
i,k .) We first give the initial work-
ing models used in the algorithm for computing TMLE, and then give the general
TMLE algorithm.
We describe the TMLE estimator of E(Y |A = a, S = s) for each a 2 {0, 1}, s 2
{1, 2} using the method of van der Laan and Gruber (2012). We consider two base-




). For each study arm a 2 {0, 1} and subpopulation
s 2 {1, . . . ,m}, define the following logistic regression working models (where
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logit(x) = log{x/(1  x)}):
















































The following is the TMLE algorithm from van der Laan and Gruber (2012)
applied to our setting:
Step 1: For each of the above logistic regression working models, fit it using maxi-
mum likelihood estimation using participants who satisfy the corresponding
condition. Specifically, the first model is fit using the participants with CY =
CL = 1, A = a, S = s; the second uses participants with CL = 1, A = a, S = s;
the third uses participants with A = a, S = s; and the fourth uses partici-
pants with S = s. Let ˆP denote the predicted probability corresponding to
each model fit above, e.g.,
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Step 2: Using only participants with A = a, S = s, CL = CY = 1, fit the logistic
regression model (called the updated model) m (L,W, ✏Y ) for P (Y = 1|CY =
1, L, CL = 1, A = a,W, S = s) with single covariate
n
ˆP (CY = 1 | L,CL = 1, A = a,W, S = s) ˆP (CL = 1 | A = a,W, S = s) ˆP (A = a | W,S = s)
o 1
,
and using the logit of ˆP(Y = 1|CY = 1, L, CL = 1, A = a,W, S = s) from the
step 1 as offset in the linear part of the model m. Denote the fitted regression
coefficient as ✏̂Y and the predicted values based on this updated model fit
(which includes the offset) by m (L,W, ✏̂Y ).
Step 3: Define the new variable H = m (L,W, ✏̂Y ) for each participant with CL =
1, A = a, S = s. Fit the initial logistic regression model m0init (W,  init) for
E (H | CL = 1, A = a,W, S = s) using participants with CL = 1, A = a, S = s.
Next, analogous to step 2, fit the logistic regression model m0 (W, ✏H) for
E (H | CL = 1, A = a,W, S = s) using this same set of participants, but with
single covariate
n
ˆP (CL = 1 | A = a,W, S = s) ˆP (A = a | W,S = s)
o 1
and us-
ing as offset logit of the predicted values from the initial model fit m0init. De-
note the fitted regression coefficient as ✏̂H , and the predicted values based on
this model fit (which includes the offset) by m0 (W, ✏̂H).
Step 4: Let n denote the number of enrolled participants from subpopulation S = s.





(Wi, ✏̂H), where Wi is the baseline
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variable for individual i, and the summation is over all enrolled participants
from subpopulation S = s. This completes the TMLE algorithm.
Above, all logistic regression model fits use the R function glm, which imple-
ments maximum likelihood estimation. In step 3, even though H may not take
integer values, it always takes values in the interval [0, 1], and the quasibinomial
glm family in R can be used to obtain a model fit.
Following the above algorithm of computing TMLE estimator, the subpopula-
tion s average treatment effect  s is estimated by applying the above estimation
algorithm to obtain estimates of P (Y = 1|A = a, S = s) for each a 2 {1, 0} and
then taking the difference between the former and the latter. The estimator of the
average treatment effect for a composite population ˜Sj is obtained analogously by
replacing the condition S = s by S 2 ˜Sj above, and using all participants in the
composite population ˜Sj .
In Section (4.9.1), we referred to a version of the above TMLE estimator that
uses the known quantities P (A|W,S) = 1/2 and the known fractions of total par-
ticipants i 2 {1, . . . , N} who have C(t)i,k = 1, i.e., the fraction N
(t)
s,k/N , rather than
fitting models for these. This involves replacing each occurrence of ˆP(A|W,S),
ˆP(CL|A,W, S), and ˆP(CY |L,CL, A,W, S) by the corresponding known quantity in
steps 2-4. The reason for using estimates of these known quantities is that, as
shown by van der Laan and Gruber (2012), this either improves or leaves un-
changed the asymptotic precision of the resulting estimator.
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We assumed that the only cause of missing data was administrative censor-
ing due to some participants not yet having their final outcomes observed. It is
straightforward to incorporate additional right censoring due to loss to follow-up,
under the assumption of censoring at random, i.e., the sequential randomization
assumption in (van der Laan and Gruber, 2012) stating that censoring is condi-
tionally independent of the potential outcomes given the past observed data. The
TMLE that we used already includes working models for the censoring variables
C
(t)
i,k conditional on a participant’s data collected before time t. The TMLE could
be applied unchanged, or the working models could be expanded to include addi-
tional terms if deemed necessary to explain loss to follow-up. Consistency of this
TMLE (and any locally efficient estimator for this problem) under the above as-
sumption requires that these working models are correctly specified. As described,
e.g., by Lu and Tsiatis (2011), the unadjusted estimator is generally not consistent
under the above assumption if censoring is informative, i.e., dropout is associated
with the final outcome for reasons that can be attributed to variables such as side-
effects measured after randomization. Using an adjusted estimator not only can
improve precision but also leads to consistency under weaker assumptions than
the unadjusted estimator.
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4.9.3 Covariance Matrix ⌃
In our simulations, for computational feasibility, we precomputed an approxi-
mation to the covariance matrix ⌃, which we treated as known. This computation
was based on Monte Carlo simulation, where we first generated 50,000 simulated
trials with no early stopping so that the maximum number of participants were
enrolled; in each simulated trial, the estimator and corresponding Wald statistic
at each stage for each population were computed; the empirical covariance matrix
of the 50,000 sets of statistics {Zj,k}jJ,kK was used to approximate ⌃. Next, the
algorithm in Section 4.5 was used to generate the efficacy boundaries uj,k.
In practice, the covariance matrix ⌃ can be approximated by the nonparametric
bootstrap using the data collected up through the current stage. Just as in the error-
spending approach for standard, group sequential designs, it is only necessary to
know (or approximate) the covariance of the statistics up through the current stage,
in order to determine the thresholds uj,k for that stage. For the analysis at the end of
stage k, we resample with replacement from all participants who have completed
the trial to construct B replicated data sets X⇤1, . . . , X⇤B , as described below. For
each replicated data set X⇤b, the sequence of stagewise estimators ˆ j,1, . . . , ˆ j,k and
corresponding Wald statistics Zj,1, . . . , Zj,k are computed for each population j 
J . We then compute the empirical covariance matrix of the set of Wald statistics
over the B replicated data sets, which is a consistent estimator ˆ⌃(k) of ⌃ restricted
to the statistics at or before stage k. This estimator is used to construct the efficacy
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boundaries uj,k for each j  J based on (4.1).
For a given set of information levels Ij,k, let ns,k denote the number of par-
ticipants from subpopulation s who would have final outcomes observed dur-





k=1 nk, and n = {ns,k : s = 1, . . . ,m; k = 1, . . . , K}.
We next describe how each replicated data set X⇤b is constructed at the stage
k analysis for the unadjusted estimator. First, for each stage k0  k and sub-
population s, ns,k0 replicated participants are constructed with full data vector
(S = s,W,A, L(1), . . . , L(T ), Y ), by drawing with replacement from the set of all
subpopulation s participants who have complete data observed, i.e., all partici-
pants i enrolled in any stage at or before k such that Si = s and C
(T+1)
i,k = 1. Every
subpopulation will have some such participants since each subpopulation s is en-
rolled in stage 1 and the first stage interim analysis occurs after ns,1 > 0 participants
have final outcomes Y observed. We use the pooled set (over all stages k0  k) of
subpopulation s participants with Y observed to draw replicated participants for
each stage; this takes advantage of all outcome data accrued on subpopulation s.
Implicit in this approach is the assumption of no change in the population distribu-
tion over time, which follows from the assumptions in Section 4.3; the assumption
of no changes in the population distribution over time is typically needed even
for standard, group sequential designs in order for hypothesis tests to be valid.
This completes the description of how each X⇤b is constructed; it is then used as
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described above to estimate ⌃ restricted to the statistics at or before stage k. The
construction of X⇤b for the adjusted estimator is similar to that for the unadjusted
estimator, except that pipeline participants are included.
Updates to the estimate of ⌃ based on data accrued at stage k may change the
corresponding estimates of the probabilities on the left side of (4.1). This issue oc-
curs for the error spending approach in standard, group sequential designs as well,
as discussed for example by Scharfstein et al. (1997, Section 4.2). To address this
issue, we recommend that a modified version of the algorithm in (4.1) be applied
in which cumulative probabilities are used, i.e., at each interim analysis k  K, for













In the above equation, the values of uj0,k0 for stages k0 < k are those computed
at stage k0 based on the estimator ˆ⌃k0 that was available at that stage. The above
algorithm is equivalent to using (4.1) if ⌃ is known, but may differ when using
estimates of ⌃ updated after each stage. The above algorithm compensates, to a
degree, for early estimates of ⌃ that led to setting efficacy boundaries uj,k0 too low,
by setting current stage boundaries higher (and vice versa).
In principle, it is possible that updated estimates of ⌃ could lead to no solu-
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tion being possible for (4.15), which is similar to the case of nonmonotonicity of
estimated information times in a standard, group sequential design using error
spending approach (Scharfstein et al., 1997, Section 4.2). If this were to occur, we
make a similar recommendation as Scharfstein et al. (1997) not to reject any new
null hypotheses and to continue to the next stage if further enrollment is indicated
under the enrollment rule rk.
4.9.4 Construction of Data Generating Distribution in
Section 4.6.2
In order to conduct a simulation study, we need a population to sample from.
The 100 participants from the original MISTIE II data is a good candidate. How-
ever, although treatments were randomly assigned in the MISTIE Phase II trial,
conditioning on the 100 participants, treatments are correlated to baseline covari-
ates. In fact, for any baseline covariates, W , randomly chosen from the baseline
covariates of the 100 participants, the corresponding treatment assignment is de-
terministic. To make treatment assignment independent of baseline covariates, we
augment the data with a hypothetical twin for each participant. A participant has
the same subpopulation membership and baseline covariates as his twin, but op-
posite treatment assignment.
When setting the short-term and final outcomes of the newly added twins,
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there are two issues we should be specially wary of. First, to make the treatment
effects realistic, the treatment effects in the augmented data should be comparable
to those in the original MISTIE Phase II data. Secondly, since the semiparametric
estimator leverages baseline covariates and short-term outcomes in estimating the
mean final outcomes, the predictability of the final outcomes from the baseline co-
variates and short-term outcomes should be reasonable, in order not to exaggerate
or underestimate the improvement of the semiparametric estimator.
Since at 30 and 90 days of treatment, patients with mRS  3 are rare, we let
the short-term outcomes, L(1) and L(2), be the indicators of mRS no larger than 4
at 30 and 90 days of treatment, respectively. We generate the outcomes of the new
added twins as follows. We first fit logistic regression models for L(1) on (W,A), for
L(2) on (L(1),W,A), and for Y on (L(2), L(1),W,A), using the original MISTIE Phase
II data. Then, preliminary short-term and final outcomes of the newly added twins
are predicted based on these logistic regression models by truncating the success
probabilities at 0.5. Next, to calibrate the treatment effects, for every newly added
twin, we reset his final outcome to be Y = A with probability 0.03. The resetting
probability 0.03 is numerically solved using binary search, so that the treatment
effect of the augmented data is enlarged to match the original data.
Next, we focus on calibrating the predictability of the generated final outcome.
Since the semiparametric estimator also involves fitting generalized linear models
to predict the final outcomes, care should be taken to avoid over fitting. We assume
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that in the phase of data analysis, only part of (W,L(1), L(2)) are available. In detail,




, L(1)), while (W
3
, L(2)) are missing. In the following, we




) and L = L(1) for notational convenience. A good benchmark
on the extent to which the semiparametric estimator may leverage (W,L) in pre-
dicting the mean final outcomes are the relative efficiencies against the unadjusted
estimator under the original MISTIE Phase II data. To eliminate the correlation
between A and (W,L), we reset A by a Bernoulli random variable, B(0.5), exoge-
nously in the original MISTIE Phase II data, and then apply the semiparametric
estimator and the unadjusted estimator in five stages, assuming 1,000 overall sam-
ple size and equal increments between stages. The relative efficiencies are obtained
by taking the ratio of the variances in estimating treatment effects. Then, under the
augmented data, let pa = P (Y = 1|Y ⇠ Qa) be the baseline success rate of treat-
ment arm a. For every newly added twin, with probability 0.164, we reset his final
outcome by a Bernoulli random variable B(pa). We note that this resetting step
doesn’t change the baseline success rates in each treatment arm, and thus doesn’t
change the treatment effect. However, it weakens the dependence between Y and
(W,L). The resetting probability 0.164 is chosen so that, when treatment label A is
reset by a Bernoulli random variable, B(0.5), the relative efficiencies of the adjusted
estimator against the unadjusted estimator using the augmented data mimic those
using the original MISTIE Phase II data.
Ideally, we would assign each participant to two subpopulation groups based
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on their IVH measure. However, this IVH measure is not available in the MISTIE
II data set. Hence, for simulation purposes we randomly assign subpopulation
information for each participant in our augmented data. When simulating trials
under Scenario (b), we reassign the treatment A by Bernoulli(0.5) random variable
for subpopulation 2 so that it has no treatment effect; when simulating trials un-
der Scenario (c), we reassign the treatment A by Bernoulli(0.5) random variable
for both the subpopulations. Note that since the subpopulation is for simulation
purposes - to distinguish Scenario (a) and (b), and to demonstrate the advantage
of adaptive enrichment design, its being merely a label suffices these ends. How-
ever, the baseline variable distribution is the same between two subpopulations -
whether this is practically desired depends on the nature of a real trial.
The above data generating mechanism provides a hypothetical overall popula-
tion of 200 participants, of which 100 come from the original MISTIE Phase II data
and consist of fully measured D = (W,A,L, Y ), and the rest are hypothetical twins
consisting of fully measured (W,A) but random (L, Y ). At stages k certain num-
ber participants of each subpopulation are sampled from the overall population,
according to Table 4.1.
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Individuals differ in how they respond to a given treatment, and characteriz-
ing such variability in treatment response is an imperative aim in personalized
medicine. We propose a general method to model treatment response heterogene-
ity, through identification of treatment-covariate interactions honoring different
1This Chapter 5 is adapted from the working paper “Yu Du, Ravi Varadhan. Lasso Estimation of
Hierarchical Interactions for Analyzing Heterogeneous Treatment Effect.”
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hierarchy conditions. We construct a single-step l
1
norm penalty procedure that
maintains the hierarchical structure of interactions in a sense that the treatment-
covariate interaction term is included in the model only when either of the covari-
ate or the covariate and the treatment both have non-zero main effects. We explore
several parameterization schemes with different constraints added to Lasso that
enforce the hierarchical interaction restriction. We solve the resulting constrained
optimization problem using a spectral projected gradient method. We compare
our methods to the unstructured Lasso using simulation studies covering a va-
riety of scenarios for treatment-covariate interactions. The simulations show that
our methods yield more parsimonious models and outperform unstructured Lasso
in terms of prediction performance, and in terms of the ability to correctly iden-
tify non-zero treatment covariate interactions. The superior performance of our
methods are also corroborated by an application on a large randomized clinical
trial data investigating a drug for treating congestive heart failure (N=2,569). Our
methods can be applied to continuous, binary and time to event outcome, provid-
ing a well-suited approach with sufficient flexibility in terms of parametrization
for doing secondary analysis in clinical trials to analyze heterogeneity treatment
effect.
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5.1 Background
Individuals differ in how they respond to a given treatment, and characterizing
such variability in treatment response is an important aim when practicing per-
sonalized medicine. This heterogeneity in treatment response is well recognized
in clinical practice. Hence any summary from a clinical trial, such as the overall
treatment effect, is not directly relevant for treating individual patients (Rothwell,
1995; Bailey, 1994; Kent and Hayward, 2007). A new treatment might only benefit
a sub-population of the patients with certain characteristics, while it shows no ben-
efit to others. Accurate evaluations of this heterogeneity attributable to the vari-
ation in baseline patient characteristics provides many potential benefits in terms
of facilitating the decision-making in appropriately targeting existing therapies to
the individuals. Thus, the investigation of patient heterogeneity in treatment re-
sponse becomes an imperative, which answers the question of what characteristics
of the patients are associated with a benefit from the studied treatment. One of
the current approaches for assessing treatment response heterogeneity is to find
predictive factors for the treatment, which are covariates predictive of treatment
response. In Epidemiology such variables are called effect modifiers, namely, the
treatment effect will vary across individuals for different values of these variables.
Predictive factors are often derived from prognostic factors, the variables impos-
ing an impact on the outcome in the absence of the treatment. Often, there are
numerous prognostic factors, and to find which ones are predictive of treatment
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response remains an important task.
There is a robust literature addressing the estimation of heterogeneity of treat-
ment effect including e.g., Jiang et al. (2007), Zhou et al. (2008), Barker et al. (2009),
Freidlin et al. (2010), Lee et al. (2010), Kim et al. (2011), Cai et al. (2011), Lai et al.
(2014), Xu et al. (2014), Ohwada and Morita (2016), Spencer et al. (2016), Henderson
et al. (2016). A common strategy for studying the treatment response heterogene-
ity in clinical trial is subgroup analysis (Rothwell, 2005), which explores how treat-
ment effect varies across subgroups defined by one variable at a time. Therefore,
the subgroup analysis ignores the joint effect of the covariates on treatment effect.
Hence, it may fail to identify significant treatment covariate interactions, especially
when the number of variables is fairly large, which is often the case in clinical trial
studies. Another common approach would be to pre-specify all the prognostic co-
variates and fit a model with all treatment-covariate interactions. This is termed as
unstructured interaction model (Kovalchik et al., 2013). However, this approach
has two important limitations. The variables need to be pre-specified, and the
model may include interactions that are not actually present.
Kovalchik et al. (2013) proposed a parsimonious approach, extending the work
of Follmann and Proschan (1999), to use proportional interactions model to inves-
tigate treatment response heterogeneity in a randomized controlled clinical trial.
This overcomes the limitation of subgroup analysis by jointly considering the ef-
fect modification of various variables, however, it still has difficulty in dealing
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with fairly large number of candidate effect modifiers. Another limitation is that
of model misspecification when the underlying treatment-covariate interactions
are not proportional to the main effects.
We propose a general method in this chapter that overcomes the limitations
of Kovalchik et al. (2013), to assess heterogeneity of treatment response in clinical
trials setting. Our work differs in two aspects: (1) We relax the “proportional”
constraint, allowing more flexibility in estimating treatment covariate interactions;
(2) the methods are able to automatically screen a large number of potential effect
modifiers, with desirable properties of low false-positives and false-negatives to
correctly capture the significant interactions.
Our work is also inspired by the work of Bien et al. (2013), which modifies
Lasso (Tibshirani, 1996) to estimate a sparse interaction model, considering the
complete list of two-way interactions. One important constraint Bien et al. (2013)
has employed is the interaction hierarchy restriction that an interaction term can
only be included in the model when one or both of the associated variables are
retained in the model. Our proposed methods make use of this principle, which is
considered very practical, as Cox (1984) once stressed that “Large component main
effects are more likely to lead to appreciable interactions than small components.
Also, the interactions corresponding to larger main effects may be in some sense
of more practical importance.“
Our work differs from Bien et al. (2013) in two ways. First, we focus on treatment-
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covariate interactions in the context of randomized clinical trials, whereas Bien
et al. (2013) examines all two-way interactions in a context different than evaluat-
ing treatment effect heterogeneity. Second, we propose four different ways to in-
corporate hierarchical constraints, two of which enforce the hierarchy constraints
in a direct manner. Thus, our work provides a new and potentially useful frame-
work for identifying predictive variables for heterogeneous treatment response.
Given a large set of p covariates from a randomized clinical trial, we select
and estimate a subset of candidate effect modifiers that are predictive of treatment
response. Our modeling approach is fully parametric and provides a clear inter-
pretation of how individual baseline characteristics affect treatment response. The
primary outcome we consider in this chapter is time-to-event, although our pro-
posed methods are easily adapted to other types of endpoints, e.g., continuous
or binary. In Section 5.2, we introduce the notation, interaction hierarchy restric-
tion, and the parametric modeling assumption. We construct a single-step l
1
norm
penalty procedure that maintains the hierarchical structure of interactions. We
study four parameterization schemes with different hierarchy constraints added
to Lasso. The formulated constrained optimization problems are solved by using
the spectral projected gradient method. We examine the performance of our pro-
posed methods with simulation studies in Section 5.3 in the presence of interaction
hierarchy or non-hierarchical interactions and compare with Lasso (unstructured).
In Section 5.4, we apply our method to the Studies of Left Ventricular Dysfunc-
149
CHAPTER 5. PHASE III SECONDARY ANALYSIS
tion Treatment (SOLVD-T) trial, a two-arm placebo-controlled randomized clini-
cal trial investigating the efficacy of enalapril, the angiotensin-converting-enzyme
inhibitor, to reduce the hazard of death or hospitalization among patients with
chronic heart failure (The-SOLVD-Investigators, 1991). We provide a discussion in
Section 5.5 of the proposed methods, and discuss future extensions of this work.
5.2 Method
5.2.1 Notations and Assumptions
In this chapter, we target the time-to-event (TTE) outcome, where we use T to
denote the event time, and C, the censoring time. The non-informative censoring
is assumed throughout. The observed outcome is represented by a vector (X, ),
X = min (T,C), and   = I(T  C), where I(T  C) is the indicator variable tak-
ing value 1 if T  C. We are dealing with the context of a parallel-arm clinical
trial, so let A be the treatment indicator, where A = 1 means assignment to the
treatment arm while A = 0 means assignment to the control arm. Let Z be the




, . . . , Zp)
0. Thus, the
complete observed data for subject i is denoted by the vector Di = (Xi, i, Ai, Zi),
i = 1, 2, . . . , n, assuming that there are n observations in total. Aiming to capture
the treatment covariate interactions, we assume the following multivariate Cox
150
CHAPTER 5. PHASE III SECONDARY ANALYSIS
proportional hazards model (Cox, 1972) to relate the TTE outcome to the subject’s
treatment assignment, p candidate prognostic factors as well as p candidate inter-
action terms:
 (t|Ai, Zi) =  0(t) exp ( AAi +  Z 0Zi +  0AiZi), (5.1)
where  
0
(t) represents baseline hazard at time t for any subject i drawn from the
overall population,  (t|Ai, Zi) gives the hazard function at time t conditioned on
the subject i treatment assignment and his / her candidate prognostic factors (can-
didate effect modifiers). In this Cox model (5.1),  A acts as the main effect of treat-
ment, interpreted as the log hazard ratio comparing treatment to control, while
 Z = ( Z1 ,  Z2 , . . . ,  Zp)
0 is a p element vector denoting the prognostic effect of Z,




, . . . ,  p)
0 is also a p element vector showing the treatment covariate
interaction effect. Any non-zero  j, j = 1, 2, . . . , p in the vector   identifies an effect
modification between the treatment A and the corresponding prognostic factor Zj
in a sense that treatment effect depends on the factor Zj , causing the heterogeneity
in treatment effect across subjects in the population. The advantage of assuming a
fully parametric model incorporating pairwise interactions between treatment and
covariates is that we can provide a clear interpretation of how individual baseline
characteristics affect treatment response. For example, for the prognostic factor Zj ,
 j > 0 indicates a heterogeneity in a direction that the treatment becomes less effi-
cacious for higher values of Zj while  j < 0 implies a stronger treatment response
when Zj increases. Let us use ✓ to represent the vector of all the parameters, such
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that ✓ = ( A,  Z 0,  0)0. Here we use the TTE outcome as an illustration of the meth-
ods, however, the optimization problems we shall discuss can be easily adapted to
a broader class of linear models, in addition to the Cox model (5.1), including the
generalized linear models, where the primary outcome can either be continuous
or binary.
5.2.2 Parameterization Schemes and Optimization Prob-
lems
Interaction hierarchy restriction states that an interaction term is only allowed
into the model if one or both of the corresponding variables are marginally impor-
tant, namely, the variable(s) has non-zero main effect in the model. Various names
have been called for such restriction by Chipman (1996), Nelder (1977) and Peixoto
(1987) among others, for example, “heredity" and “marginality". We adapt the def-
inition to the clinical setting in the context of a parallel-arm clinical trial, with the
goal to capture treatment covariate interactions as precisely as possible. Therefore,
we define a hierarchical structure for treatment covariate interaction such that for
j = 1, 2, . . . , p
 j 6= 0 =) at least  Zj 6= 0. (5.2)
We make direct use of this hierarchy in the parameterization schemes that will
152
CHAPTER 5. PHASE III SECONDARY ANALYSIS
follow. Traditionally, the parameter vector ✓ is estimated by minimizing over ✓
without any constraints the negative log partial likelihood (namely maximizing






















It is often the case that there are only a handful of estimates out of many that
have non-zero effects in the model, corresponding to a sparse structure. To ad-
dress this, Lasso is a widely applied technique proposed by Tibshirani (1996) that
employs model selection and estimation at the same time. This is accomplished by
imposing an l
1








where   acts as the penalty parameter, balancing the tradeoff between fitting to
the training data and the enforcement of a sparsity coefficients structure. The less
the value of   is, the more sparse the estimates of the parameter vector ✓ will be.
We build interaction hierarchy into the optimization problem (5.3) by proposing
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four parameterization schemes as constraints to extend Lasso.
















, . . . , ⇣p)
0 is a p element vector. The added constraint  j =
 A ⇤  Zj ⇤ ⇣j enforces “strong hierarchy” as defined by Bien et al. (2013), since
it is straightforward to note that if for any particular j,  ̂j 6= 0, then both the
treatment effect and the prognostic effect of Zj have significant (non-zero)
estimates, ˆ A 6= 0 and ˆ Zj 6= 0.
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This scheme serves as a weaker version of scheme 1 since it guarantees only
that ˆ Zj 6= 0 if  ̂j 6= 0, lifting the imposing of  A on the parameterization of
 . Our intention is that a relaxation of the constraint on   would bring more
robustness to the estimation of the parameters, which we shall explore in the
simulation study. Note that Parameterization scheme 1 and 2 still maintain
the convexity of the constraints inherited from Lasso, though they both in-
crease the non-linearity of the optimization problem. Given the non-linear
nature of the partial likelihood function and that there is no closed-from so-
lution for Lasso, the increased non-linearity is computationally tractable and
not undesirable to solve.












Instead of parameterizing the interaction coefficients  , we impose the in-
equality on   to enforce the hierarchical interaction restriction in scheme 3.
Note that if | ̂j| > 0, so are |ˆ A| and |ˆ Zj |.
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Scheme 4 is adapted from the added constraint in Bien et al. (2013) to fit the
clinical setting, dealing only with the treatment covariate interactions. This
imposes a stronger penalization on the interaction parameters   so that a
more sparse structure of interaction coefficient estimates shall be produced
than scheme 3. Notice that the condition in scheme 3, | j|  | A|, for any j,
j = 1, 2, . . . , p, is replaced in scheme 4 by the constraint on the norm of the




j | j|  | A|, resulting in a bigger penalty.
All the above four parameterization schemes we propose are modifications of
Lasso (Tibshirani, 1996) that guarantee to produce models satisfying interaction
hierarchy restriction.
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5.2.3 Algorithm to Solve the Optimization Problems
Despite the enforcement of the interaction hierarchy restriction, the optimiza-
tion problems with scheme 3 and scheme 4 listed in Section 5.2.2 are not convex,
thus undesirable to solve. We thus implement simple convex relaxation of the
problems by substituting each of the variable with two of the components such
that for each j = 1, 2, . . . , p,
 j =  
+




    Zj , (5.9)
 A =  
+
A     A , (5.10)
| j| =  +j +   j , (5.11)




| A| =  +A +   A , (5.13)
where  +j   0,   j   0,  +Zj   0,  
 
Zj






,   A are not defined to be the positive parts and negative parts of the
variables since we do not add the constraints  +j  
 
j = 0,  
+
Zj





which makes the problem convex and tractable to solve. Another consequence out
of this is to make the constraints less restrictive because for example, it is possible
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have a larger bound. This convex relaxation still guarantees interaction hierarchy,
as proved in Bien et al. (2013). For scheme 1 and scheme 2, it is an advantage that
the added constraints do not alter the convexity of the problem, though a potential
disadvantage is that it increases the nonlinearity of the problem, however, this
is not a major issue computationally since the objective function, the partial log-
likelihood, is already nonlinear.
We applied the spectral projected gradient (SPG) method, proposed by Birgin
et al. (2000), to solve the optimization problems in Section 5.2.2. As its name sug-
gests, the SPG method incorporates the spectral gradient scheme (Raydan, 1997)
to greatly improve the effectiveness of the gradient projection method (Bertsekas,
1976 and references therein). As pointed out in Birgin et al. (2014), the SPG method
has been applied in wide areas of statistics, becoming an ideal tool for large-scale
convex constrained optimization problems. The general SPG algorithm used in
this chapter is listed in Table 5.1, where ✓ denotes the vector of all the parameters in
the model as defined in Section 3.2.2, however, for scheme 1 and 2 in Section 5.2.2,
✓ = ( A,  Z
0, ⇣ 0)0, due to the parameterization of  .
The computation of the step length ↵k and the spectral step length  k are given
in details in Birgin et al. (2014). An implementation of the SPG method is readily
available in R (R Core Team, 2016), within the BB package written by Varadhan
and Gilbert (2009). The function spg() in the BB package provides 3 different op-
tions for spectral step lengths: 1) the step length used in Birgin et al. (2000); 2) the
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Input:
l(✓), the negative log partial likelihood of survival data;
rl(✓), the gradient function of l(✓);
 
0
, the initial value of the spectral step length;
P
⌦
(), the projection function into the convex set ⌦ of the constraints;
✓
0
2 ⌦, the initial value of ✓;
✏, the value of tolerance.
Goal:
find the minimizer ˆ✓ of l(✓) subject to ˆ✓ 2 ⌦.
Algorithm:
at the kth iteration, k   1,
while not convergent, e.g., kP
⌦
(✓k  rl(✓k))  ✓kk1 > ✏,
do:
compute the search direction dk = P⌦ (✓k    krl(✓k))  ✓k,
compute the step length ↵k,
compute ✓k+1 = ✓k + ↵kdk,
compute spectral step length  k+1.
Table 5.1: Algorithm for SPG method
step length proposed in Barzilai and Borwein (1988); 3) the step length proposed by
Varadhan and Roland (2008). We used the function spg() with the third choice of
spectral step length, as recommended by Varadhan and Gilbert (2009), to carry out
the method of SPG, solving the convex constrained optimization problems in Sec-
tion 5.2.2. Using the function spg() requires us to provide the computation for l(✓),
the negative log partial likelihood of survival data; rl(✓), the gradient function of
l(✓); and P
⌦
(), the function to project any arbitrary point into the feasible convex
set ⌦ of the constraints. These are straightforward to derive and code for the four
parameterization schemes and the optimization problems listed in Section 5.2.2.
Once all these arguments are provided, the function returns the minimizer ˆ✓ of
the function l(✓), and any non-zero  ̂j reveals a significant interaction between the
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treatment and the prognostic factor Zj . A complete list of codes solving the pro-
posed optimization problems can be found on the author’s Github account.
There are also other methods to solve these convex constrained optimization
problems, for example, a sequential quadratic programming algorithm written by
Kraft (1988), among others. We explored that sequential quadratic programming
method in the simulation study and it produces very similar results and perfor-
mance to SPG method. The focus of the chapter is the proposal of the four parame-
terization schemes that extend Lasso and build the interaction hierarchy restriction
into the model for the clinical setting, dealing with the identification of the treat-
ment covariate interactions out of many candidate effect modifiers. Though this
chapter does not aim to find the most efficient method for solving these convex
constrained optimization problems, it remains an open area for future work.
5.3 Simulation
5.3.1 Simulation Setup
In this section, we conduct several simulations to study the leverage of the
interaction hierarchy restriction in the context of four parameterizations listed in
Section 5.2.2. A hundred clinical trials are simulated such that each trial assigns
n = 500 patients to treatment and control arm with 1:1 randomization ratio. Each
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trial comes with p = 50 potential prognostic factors, thus, 50 candidate treatment
covariate interactions are expected. We let 25 prognostic factors out of 50 have
significant impact on the outcome (i.e., with non-zero coefficients). We set 5 treat-
ment covariate interaction coefficients to be non-zero. The primary outcome is
time-to-event (TTE) survival endpoint, generated by exponential distribution as-
suming the proportional hazard model (5.1), whereas the censoring time is gen-
erated from an independent exponential distribution. The simulation study aims
to evaluate the performance of these methods for identifying non-zero treatment
covariate interactions in the presence of hierarchical interaction and non such inter-
action hierarchy. Therefore, we mainly consider two scenarios for the underlying
data generating distribution:
(A) Hierarchical interaction is enforced,
 j 6= 0 )  Zj 6= 0 and  A 6= 0,
(B) No interaction hierarchy restriction.
5.3.2 Simulation Evaluation and Results
Not only we assess the performance when the fundamental assumption about
the interaction hierarchy is satisfied, but we also consider the case where it is mis-
specified to evaluate the model’s sensitivity to this assumption. Lasso, unmod-
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ified, serves as a basis of comparison since this is a simple and straightforward
approach most commonly used by statisticians for parameter regularization and
identification of a sparse structure of the coefficients. The evaluation of perfor-
mance is twofold: (1) prediction performance and (2) the ability of models to cor-
rectly recover the non-zero treatment covariate interactions. In the assessment of
prediction performance, we choose to use the concordance index, as shown by
Harrell et al. (1996) and Pencina and D’Agostino (2004). The concordance index
is a common metric to evaluate the risk prediction for TTE outcome, and if a pair
of comparable subjects are drawn randomly from the population, it represents the
probability that the subject with higher predicted risk would experience the event
before the other one. For each of the methods, the penalization parameter   should
be set so that the model can be estimated. We apply 10 fold cross validation on
each 500 subjects simulated trial in search of the   that corresponds to the highest
concordance index using the out-of-sample risk predictions for these 500 subjects.
Accompanying each simulated trial is an invisible trial where we generate another
10000 subjects data under the same mechanism, serving as the validation set and
we apply each determined model to this validation set to compute a concordance
index as the assessment of prediction performance for each method. We repeat this
process 100 times and summarize the results in Figure 5.1 for scenario (A) and (B).
Figure 5.1a displays the performance in risk prediction via the boxplots of con-
cordance index for each of the methods in scenario (A) where the hierarchical in-
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Figure 5.1: The comparison in risk prediction using concordance index.
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teraction restriction is enforced in the data generating distribution while that for
scenario (B) is represented in Figure 5.1b. We can clearly see that in both scenar-
ios all these methods have comparable risk prediction accuracy, and on average
(median), all the four parameterizations listed in Section 5.2.2 that incorporate in-
teraction hierarchy have greater concordance index than Lasso, though Parame-
terization scheme 4 (5.7) is highly left skewed in scenario (A). This gives us the
reassurance for the proposed methods since even in scenario (B) where the truth
has no interaction hierarchy, our proposed methods can still rival Lasso in terms
of risk prediction.
The main advantage of the proposed methods lies in the ability to correctly re-
cover the significant, namely non-zero, treatment covariate interactions. To demon-
strate this ability, we assess the sensitivity and the specificity of each model for the
identification of treatment covariate interaction terms, and in addition, we also en-
gineered a global metric of performance, called Global Interaction Recovery Cost
(GIRC), to provide a single metric combining the sensitivity and specificity. Once
the model is determined using cross validation, the parameter estimates are ac-
quired and it is straightforward to compute the sensitivity and the specificity re-
garding the interaction terms. Figure 5.2 shows the boxplots of the sensitivity (Fig-
ure 5.2a) and the specificity (Figure 5.2b) for each method regarding the identifi-
cation of treatment covariate interactions in scenario (A). As shown in Figure 5.2a,
the sensitivity of recovering non-zero interactions for Parameterization scheme 3
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(5.6) is comparable to Lasso while that of the other parameterizations (5.4), (5.5)
and (5.7) lies below Lasso. However, remember that the simulation sets up only
5 non-zero treatment covariate interactions, and the difference between the pro-
posed methods and Lasso in averaged sensitivity amounts to only one term differ-
ence. That means on average, Lasso can recover 4 out of 5 non-zero interactions,
the same as Parameterization scheme 3 (5.6) while the other parameterizations are
also able to identify 3 out of 5. When it comes to the specificity of the interaction
terms as displayed in Figure 5.2b, that is where the advantage of these methods
is appreciated, especially when we are faced with numerous unknowingly false
effect modifiers in practice, as in this simulation. Apart from Parameterization
scheme 3 (5.6) which shows only a little improvement over Lasso, all others have
at least around 15% greater specificity than Lasso, that amounts to 15%⇤(50 5) ⇡ 7
more terms correctly labeled as no effect modification. Thus, the treatment covari-
ate interactions identified by the proposed methods are more likely to be the true
effect modifiers than those given by Lasso. This is what happens when the hierar-
chical interaction restriction is satisfied in truth. Figure 5.3 exhibits the correspond-
ing performance of each method in the sensitivity (Figure 5.3a) and the specificity
(Figure 5.3b) for scenario (B) where the truth has no such interaction hierarchy in
place. Each method has about the same averaged sensitivity, while for specificity
there is still some little improvement for Parameterizations (5.4), (5.5) and (5.6)
over Lasso on average, except a huge difference, 20%, favoring Parameterization
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scheme 4 (5.7).
5.3.3 Global Metric of Performance
We propose a global metric of performance, Global Interaction Recovery Cost
(GIRC), summarizing the sensitivity and specificity of the models for the identifi-
cation of treatment covariate interaction terms. The sensitivity encodes the avoid-
ing of false negative interaction terms while the specificity does the same for false
positive interaction terms. Let NFP and NFN denote the number of false positive
and false negative treatment covariate interaction terms, respectively. We use N
to represent the total number of candidate interaction terms. Two types of error
are associated with the false positive and false negative interaction terms, error of
commission and error of omission. The error of commission is committed when
the irrelevant interactions are included in the model (false positive) while the er-
ror of omission is committed when the relevant interactions are excluded from the




be the cost associated with committing the
error of commission per included irrelevant interaction term and committing the





are constants that may reflect monetary cost, time cost, resource
cost, and etc., for the two types of error. The Global Interaction Recovery Cost
166
CHAPTER 5. PHASE III SECONDARY ANALYSIS

























Figure 5.2: The ability to recover non-zero interactions in scenario (A).
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Figure 5.3: The ability to recover non-zero interactions in scenario (B).
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= 1. Therefore, GIRC is
a global metric of performance, combining the sensitivity and the specificity and
informing the combined cost of recovering non-zero interaction terms. The greater
ability of capturing the significant treatment covariate interactions is warranted by




= 0.5 where the two types of error
incur the same amount of cost per term, we compute the average GIRC for each of
the methods in scenario (A) and (B), which are summarized in Table 5.2.
Table 5.2: The average Global Interaction Recovery Cost (GIRC) of the identifica-
tion of treatment covariate interactions for each method in scenario (A) and (B).






P1 P2 P3 P4 Lasso
Scenario (A) 0.05 0.06 0.09 0.02 0.10
Scenario (B) 0.12 0.12 0.12 0.04 0.13
GIRC, as computed in this simulation study, demonstrates the superior perfor-
mance of our proposed methods against Lasso, especially in truth where there is
interaction hierarchy in place, and the ratio of GIRC comparing Lasso to our pro-
posed methods ranges from 1.1 – 5. Remember we assume that two types of error




= 0.5, however, in practice, the two types of cost are very
likely to differ. Intuitively, committing error of commission should be more costly
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in that the resulting false positive treatment covariate interactions shall give rise to
unnecessary external validation trial, a waste of resources, and misguide the treat-
ment recommendation that might bring harm to the targeted patients. Therefore,




. As we see in Figure 5.2b and Figure 5.3b, the ad-
vantage of using our proposed methods are mainly channeled through the greater
specificity compared to Lasso, i.e., the fewer false positive interaction terms. Ta-
ble 5.3 shows the average GIRC when the cost of committing error of commission




. The maximum ratio of
GIRC comparing Lasso to our methods rises up from 5 to 13. Hence, we believe
that in practice, our proposed methods are even more advantageous over Lasso.
Table 5.3: The average Global Interaction Recovery Cost (GIRC) of the identifica-
tion of treatment covariate interactions for each method in scenario (A) and (B).






P1 P2 P3 P4 Lasso
Scenario (A) 0.05 0.07 0.11 0.01 0.13
Scenario (B) 0.15 0.15 0.15 0.05 0.16
5.4 Data Application
5.4.1 Data Description
We evaluated our proposed methods on a completed, placebo-controlled, ran-
domized trial (SOLVD-T) that tested the efficacy of an experimental drug, enalapril,
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the angiotensin-converting-enzyme inhibitor, for treating chronic heart failure pa-
tients (The-SOLVD-Investigators, 1991). 1284 patients were assigned randomly to
the control arm while 1285 to the treatment arm. The primary outcome of the
trial is a TTE endpoint, the time to hospitalization or death. We assumed non-
informative censoring, and around 47% of the outcome were censored. There are
23 candidate effect modifiers, including baseline age, gender, New York Heart As-
sociation (NYHA) function status, sodium level, creatinine level, etc. The goal of
our proposed methods for this study is to select a subset of these candidates that
are predicted to have non-zero interactions with treatment, and to provide the esti-
mates. Missing values in the dataset are approached by imputation, where Missing
at Random (MAR) are assumed. For example, if Z
1
has missing values, we regress
Z
1
on the observed values of all other covariates Z
2
, . . . , Zp so that the missing
values are filled by the predictive value from the regression. This imputation is
carried out one variable at a time.
5.4.2 Direct Application
We applied our proposed methods as well as Lasso to the SOLVD-T trial, and
provide a treatment covariate interaction recovery map in Figure 5.4. Each column
represents a method while each row shows a candidate effect modifiers. A com-
plete list of description of these variables is given in the Appendix. The black area
indicates which candidates are included in each model, whereas the blank area
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shows no treatment covariate interaction. It is clearly seen that 6, 5, 13, 7 and 11
variables were predicted to influence the patient’s response to treatment respec-
tively by the four parameterization methods (5.4), (5.5), (5.6), and (5.7) and Lasso.
Among our findings, left ventricular ejection fraction, “lvef”, was found by all five
methods to significantly modify the effect of enalapril on the survival outcome,
with greater beneficial effect seen at the lower values of ejection fraction. Similar
findings are also reported in the study of heterogeneous treatment response using
the same trial data (Henderson et al., 2017). We are unable to assess the sensitivity
/ specificity of the methods in this real trial since the true effect modifiers are un-
known, but it serves a good purpose to illustrate the use of our methodology for a
real data application.
5.4.3 Extended Real Data-based Simulation
Despite the inability to evaluate the sensitivity / specificity on this real data,
we instead engineered a design to assess a "partial specificity" of these methods.
We create m noise variables that have no association at all with the response on
top of the original data, and fit each method on this expanded dataset. This "par-
tial specificity" is thus defined to be the percentage of the noise variables that are
correctly identified by the method as having no interaction with the treatment, i.e.,
zero treatment covariate interaction. We set m = 25 and repeat the procedure 100
times. A summary of the average "partial specificity" for each method is provided
172






























Figure 5.4: Treatment covariate interaction recovery map for the proposed meth-
ods and the Lasso.
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in Table 5.4. An improvement regarding this partial specificity can be seen for all
our proposed methods over Lasso. Lasso has the lowest value 62.6%, which says
that for 100 added noise variables that are completely independent from the re-
sponse, Lasso would falsely label around 100   63 = 37 as the effect modifiers,
predictive of the response. Surprisingly, Parameterization scheme 1 (5.4) and 2
(5.5) nearly reject all the noise variables, with close to 100% partial specificity. It is
interesting to note that when the true data generating distribution is unknown, as
in this real trial, Parameterization scheme 1 (5.4) and 2 (5.5) seem more robust to
the model parametric assumptions than the other methods.
Table 5.4: The mean partial specificity of the identification of treatment covari-
ate interactions for each method based on the SOLVD-T trial. P1, P2, P3 and P4
represents Parameterization 1, 2, 3 and 4 respectively.
P1 P2 P3 P4 Lasso
Mean 99.2% 99.5% 65.8% 79.5% 62.6%
5.5 Remarks
Understanding how patients respond differently to treatment is key to trans-
lating clinical trial findings into decision makings for individuals regarding treat-
ment recommendation. Prediction models for outcome prognosis are common in
clinical research, however, models that predict treatment response heterogeneity
in terms of individual baseline characteristics are much less common. Such mod-
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els can be useful for answering the question of which treatment is better for a
given individual. We provide a general prediction method to assess treatment
response heterogeneity by adding novel, convex constraints to Lasso that honor
the interaction hierarchy restriction. We give a clear interpretation on how indi-
vidual characteristics affect treatment response by modeling pairwise interactions
between treatment and covariates. We further extend the work of Kovalchik et al.
(2013) by relaxing the constraint that the treatment covariate interactions are pro-
portional to the main effects. Our proposed methods are able to automatically
screen a larger number of candidate effect modifiers with the aid of parameter reg-
ularization inherited in Lasso, aiming to capture those with non-zero treatment
covariate interactions as precisely as possible. The simulation study in Section 5.3
and the real data example shown in Section 5.4 demonstrate superior performance
of our proposed methods against Lasso regarding the accuracy of risk prediction
as well as the ability to correctly identify the non-zero interactions. In terms of
choosing a parameterization scheme in practice, we recommend to use Parame-
terization scheme 1 (5.4) and 2 (5.5) as default choices because they exhibit the
best performance in the real data application on SOLVD-T trial, where the true
underlying data generating distribution remains unknown. However, in the case
where the model parametric assumption can well approximate the true data gen-
erating distribution, e.g., as backed up by scientific theory, if there is a strong be-
lief that the truth incorporates interaction hierarchy, all our proposed schemes are
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desirable to use, though Parameterization scheme 4 (5.7) has a trade-off between
unstable performance in risk prediction and the great ability to capture non-zero
interactions (as shown by lowest GIRC). While in this case if the interaction hierar-
chy cannot be trusted, we suggest to use Parameterization scheme 4 (5.7) instead,
which shows greater prediction accuracy and more precise identification of treat-
ment effect modification over Lasso and the other proposed methods in scenario
(B). Despite the focus of this chapter on TTE outcome, our methods can easily be
adapted to other types of endpoints, for example, continuous or binary. All the
users need to do is to change the objective function that needs to be optimized, for
example, use instead the likelihood function for Gaussian distribution or Binomial
distribution while the proposed constraints stay unchanged.
There are some limitations with applying our proposed methods for the analy-
sis of treatment response heterogeneity and these limitations of course open room
for future extension and improvement. First of all, the chapter focuses on the pre-
diction side rather than inference, and that is because it is difficult to draw infer-
ences on Lasso type of problem and very few approaches are available for this pur-
pose. It would remain an area of future research to incorporate the inference, e.g.,
confidence intervals of the parameters, into the proposed prediction model with
interaction hierarchy restriction. Nonetheless, our methods are well-suited for
treatment covariate interaction selection purpose. Secondly, our proposed meth-
ods are built upon (semi)parametric model assumptions, such as the Cox model
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(5.1). Vaughan et al. (2017) presents a stagewise estimation with generalized esti-
mating equations to select interactions for the clustered data. The merit of using
generalized estimating equations are twofold: (1) it does not require a paramet-
ric model assumption, and (2) it allows for the analysis of longitudinal/clustered
data. It is possible to adapt our proposed methods with their stagewise procedure,
thus relaxing the parametric model assumption, which is also likely to be more
computationally efficient than the SPG method. Various methods exist to solve the
constrained optimization problem, and one of the future work would be to find
the ones with the highest computational efficiency. Since inference is not our fo-
cus, our proposed prediction methods lie in the category of exploratory analysis,
and the significant effect modifiers found by the methods should be externally and
independently validated in future studies.
Nonetheless, we suggest to incorporate our proposed methods into the sec-
ondary analyses of clinical trial, particularly Phase III trials, to make assessment of
heterogeneity in patient’s response to the experimental treatment. An R package
is under development for implementation of the methods proposed here.
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5.6 Appendix
5.6.1 Description of the Variables of the SOLVD-T Trial
Here we describe the 23 variables of the patients used as the candidate effect
modifiers in the SOLVD-T trial. "age" is the patient’s age at baseline, continu-
ous; "gend" is patient’s gender, binary, where 0 means female and 1 means male;
"smoke" is a categorical variable, encoding patient’s smoking history (0 = Never,
1 = Former and 2 = Current); "diabet" is an indicator of diabetes at baseline (1 =
diabetes while 0 not); "lvef" is the baseline ejection fraction, continuous; "himi"
is the history of myocardial infarction (1 = Yes, 0 = No); "nyha" is the New York
Heart Association functional status at baseline, integer from 1 to 4 in the order of
increasing risk; "depedema" is an indicator of whether or not the patient has de-
pendent edema at baseline (1 = Yes, 0 = No); "crackles" is an indicator of whether
or not the patient has crackles at baseline (1 = Yes, 0 = No); "pulmedema" is an
indicator of whether or not the patient has pulmonary edema at baseline (1 = Yes,
0 = No); "avsys" is the baseline systolic blood pressure, continuous; "avdia" is the
baseline diastolic blood pressure, continuous; "beat" is the baseline heartbeat, con-
tinuous; "anydiurbl" related to any use of a diuretic at baseline (1 = Yes, 0 = No);
"creatinine", "hemoglobin", "lymphocyte" are three continuous clinical measures at
baseline from the blood work; "weightkg" is the weight of the patient at baseline
in kilograms; "copd" is an indicator of the chronic obstructive pulmonary disease
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at baseline (1 = Yes, 0 = No); "histk" is history of any stroke at baseline (1 = Yes, 0
= No); "hlth" is self-rated health at baseline, integers from 1 to 5; "iadldiff" is any
difficulty in performing instrumental activities of daily living, e.g., paying bills,




In this dissertation, I developed four novel statistical methods and applica-
tions in Chapter 2 to 5 for a series of clinical trials, ranging from Phase I stud-
ies to Phase III studies that are used to determine whether a new experimental
treatment/drug/device can go to the market or not. Chapter 2 presents a novel
dose-finding design in Phase I studies, that jointly models an efficacy outcome
and the toxicity data with multiple types over multiple treatment cycles. The ex-
tensive simulations conducted showed a high probability of finding the optimal
doses and good overdose control. The design provides a relaxation of the tradi-
tional Phase I dose-finding methods that use only the binary toxicity data from
the first treatment cycle and assume a monotone increasing relationship between
dose and efficacy. It is very likely in practice that the experimental agent has an
unknown relationship with dose, which should be explored during the study. As
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a future work, I continue collaborating with Mayo Clinic on an extension of this
work that incorporates Bayesian interval design and a novel construction of utility
function that would drive the dose-finding algorithm.
Chapter 3 proposes and evaluates a two-stage, Phase II, adaptive clinical trial
design. Its goal is to determine whether future Phase III (confirmatory) trials
should be conducted, and if so, which population should be enrolled. The pop-
ulation selected for Phase III enrollment is defined in terms of a disease severity
score measured at baseline. The design and analysis is optimized in a decision the-
ory framework. The use of decision theory to guide development of an adaptive
design (which I do here) is discussed in a guidance document on adaptive designs
for medical devices by the Food and Drug Administration (FDA, 2010), who state
“Adaptive designs that rely on anticipated regret can decrease the uncertainty in
studies and make them much more predictable.“ One of the future works is to
continue exploring the use of decision theory framework in improving the design.
In Chapter 4, I provide a general framework for adaptive enrichment designs
in Phase III studies with delayed outcome, leveraging information in baseline vari-
ables and short-term outcomes to improve precision by using semiparametric, lo-
cally efficient estimators at each interim analysis. Through simulations of a real
trial, I showed a substantial reduction in sample size needed/expected to con-
duct the trial, yet with comparable power, bias, variance and mean squared er-
ror against the standard estimator/design. It is an area of future work to apply
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the advanced methods shown to have enhanced efficiency, e.g., the estimators of
Lu and Tsiatis (2011); Rotnitzky et al. (2012); Gruber and van der Laan (2012), in
the context of adaptive enrichment designs, leveraging baseline information and
short-term outcomes.
A novel prediction method for treatment response heterogeneity is proposed
in Chapter 5, as a secondary analysis in Phase III studies. The objective of the pro-
posed methods is to select a subset of the pool of potential effect modifiers that
have interactions with treatment and provide the estimates. The goal is achieved
by adding convex constraints to Lasso that honor interaction hierarchy and a sparse
coefficient structure. The simulation study in Section 5.3 and the real data example
shown in Section 5.4 demonstrated superior performance of our proposed meth-
ods against Lasso regarding the accuracy of risk prediction as well as the ability to
correctly identify the non-zero interactions. It is an area of future work to adapt our
proposed methods with the stagewise procedure, as proposed in Vaughan et al.
(2017), in order to relax the parametric model assumption.
Another interesting area to work on in future is the seamless trial design (e.g.,
Hampson and Jennison (2015)), which requires a complete protocol to be specified
at the outset. This not only saves time in between trials, but also has a great po-
tential to improve power of the trial, by recycling the trial participants information
during the decision-making process. This potentially leads to huge savings in con-
ducting the trial and a faster process to move a molecule to regulatory approval.
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